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Abstract  
Despite progress that has been made in the treatment of obesity, the epidemic continues to rise 
worldwide. While pharmacological treatment of obesity may be effective, medications may have 
significant side effects and can be potentially fatal. This review will provide significant evidence 
to  substantiate  the  existence  of  Reward  Deficiency  Syndrome  in  Obesity  and  the  role  of 
catecholaminergic pathways in aberrant substance seeking behavior, in particular cravings for 
carbohydrates. The genetic basis for generalized craving behavior will be established.  Evidence 
to  support  the  augmentation  of  precursor  amino  acid  therapy  and  enkephalinase,  MOA  and 
COMT  inhibition  leading  to  enhanced  levels  of  neurotransmitters:  serotonin,  enkephalins, 
GABA and dopamine/norepinephrine as well increasing insulin sensitivity (affecting dopamine 
neuronal synthesis regulation) through the use of certain neurometabolic optimizers will also be 
provided. This review article cites many published studies to support a conceptual paradigm shift Functional Foods in Health and Disease: 9:310-378                                                                         Page 311 of 378 
 
 
towards the use of this proposed nutrigenomic formula.  The analysis and research preceding this 
formulation is outlined. This formulation has a generalized anti-craving effect and can inhibit 
carbohydrate bingeing, inducing significant healthy fat loss and prevention of relapse. This is the 
first time that components of this formula have been combined, at the dosage levels indicated 
with the goal of promoting successful and sustainable body recomposition. We are encouraging 
other  laboratories  to  further  evaluate  Neuroadtagen  Amino-Acid  Therapy 
(NAAT)/Nurometabolic  optimizers  as  a  putative  anti-obesity  complex  in  larger  controlled 
blinded studies and await interpretation of must these needed studies.  
 
Keywords: NAAT, Dopamine, Genes, Polymorphisms, Obesity, Craving Behavior, Overeating, 
Reward Deficiency Syndome, Nutrigenomics.  
 
 
Background 
It is well-known that there is indeed an obesity epidemic worldwide. To alter this trend, new 
strategies and programs for weight maintenance as well as weight reduction must become a high 
public health priority. Our take on this, is that programs which promote the “just say no policy” 
will be doomed to fail. We must first begin to understand how the brain controls eating behavior 
and what are the genetic antecedents to abnormal “sugar cravings”. In this rather large review we 
have  attempted  to  provide  a  coherent  detailed  account  accompanied  with  many  data  driven 
references to carefully frame these new but important concepts.  
 
“Weight loss,” “weight gain” and “weight management” are the most common terms used to 
express changes in body composition, particularly regarding fat mass. However, this review will 
present evidence showing that the focus on “weight” as the main criteria for measurment is in 
contradiction to the natural sequence of processes in recompositional metabolism. Given that fat 
is the lightest of pertinent macro molecules and more importantly, fat is usually the last to go in 
the body recomposition process talking about “weight loss” creates inappropriate expectations 
and  does  not  provide  an  accurate  perspective  for  evaluating  healthy  changes  in  body 
composition. Fat metabolism is influenced by many factors from genetics to lifestyle and the 
efficiency of energy metabolism. Existing “weight loss” tactics for the most part have failed to 
provide successful means to achieve sustainable healthy body composition and improve healthy 
fat loss. Commercialized “weight loss” programs, even medically supervised versions, do not 
consider  the  “bi-phasic”  [1]  nature  of  genetically  regulated  set  point  “defense  response” 
mechanisms that mandate preservation of body fat stores against famine and survival threats 
simulated by aggressive weight loss tactics during phase 1. Further, existing tactics place an 
erroneous emphasis on caloric intake to the exclusion of considering nutrient quality and density 
of those calories, a factor far more important to metabolic competence than calories alone. This 
review provides support for a novel body recomposition and healthy body mass management 
technology.  A  unique  formula  and  method  to  safely  and  naturally  induce  effective  body 
recomposition and achieve healthy body mass management objectives is presented. This novel 
technology contrasts with existing tactics to manipulate body composition in that it is based on 
the fact that sufficient nutrition (as opposed to just calories) is required to fund a wide range of Functional Foods in Health and Disease: 9:310-378                                                                         Page 312 of 378 
 
 
factors involved in achieving healthy and efficient metabolic function. This technology combines 
synergistic nutraceutical ingredients necessary to simultaneously address symbiotic mechanisms 
that promote healthy metabolism in the energy management system, stress and inflammation 
management system, the pleasure/food craving management system (controlled by the brain), the 
immune management system and the neuroendocrine system. Importantly, these five systems are 
homeostatic  and  intimately  interactive  and  interdependent  in  ensuring  optimal  metabolic 
function.  This  novel  nutraceutical  technology  optimizes  genetically  programmed  energy 
expenditure  and  storage  functions,  without  inducing  “Yo  Yo”  rebound  weight  gain 
consequences. In contrast to conventional short term expectations, “weight loss” might not be 
expected since the need to improve the health of the cellular energy producing apparatus might 
first result in increased muscle density and weight “gain” that is needed to promote healthy and 
permissible fat oxidation and loss. In fact, a more normal and expectable sequence of events 
might include initial water weight loss, increased muscle density and weight (muscle is heavier 
than fat and water) followed by permissible fat loss, which could take many months to achieve. 
Such a sequence could and has  contributed to disappointment with short term “weight loss” 
results and abandonment of more intelligent programs that would lead to sustainable fat loss 
useing the healthy body recomposition dynamic. 
Various minerals have been shown to be important in funding events leading up to and 
promoting healthy carbohydrate metabolism, insulin function, energy production, fat oxidation, 
serotonin release and availability in the brain, blood lipid metabolism and improving the success 
of fat loss and body composition management efforts.  
 
Figure 1 Nutrigenomics of Neuradaptogen and Amino-Acid-Therapy (NAAT)
 ™ as a putative 
anti-obesity complex. 
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Based  on  the  premise  of  this  review,  the  novel  nutraceutical  technology  presented  herein 
provides ample evidence that the term “weight loss” is a misnomer. This term “weight loss” (or 
any terms using the “weight” language reference) is deliberately misused herein to emphasize the 
point of how conventional tactics (and language) contribute to erroneous, but unquestionably 
accepted, dogma. Current “weight loss” tactics, for the most part, are based on inducing calorie 
intake  deprivation  and  artificially  stimulate,  deprive  or  inhibit  the  body’s  genetically 
programmed energy expenditure, storage, regulatory and management processes (see table 1).  
 
Table 1 Current “weight loss” tactics  
Central  Nervous  System  Stimulants  (CNSS) that  artificially  stimulate  the  rate  of  calorie 
burning (Basal Metabolic Rate [BMR]). 
Appetite Suppressants 
Fat Blockers 
Starch Blockers 
Diuretics (Water Pills) 
Low Calorie Diets 
Low Food Diets 
Meal Replacement Programs (Diet Shakes, bars, etc.) 
High Protein Diets 
High Carbohydrate Diets 
Low/No Carbohydrate Diets 
Low Fat Diets 
Pre-Meal Fiber/Water “Fill-You-Up” Programs 
Fruit and Fruit juice “Rapid “weight loss”” Programs 
Over Night “weight loss” Programs 
Vegetable Soup Diet Programs 
Liposuction 
Radical Digestive Tract Surgeries 
Acupuncture 
Laxatives 
 
Many of these tactics are used individually or in combination to achieve rapid “weight loss” 
results.  As stated, the primary goal of these tactics is “weight loss” and/or image enhancement.  
These objectives are usually pursued without regard for or knowledge of the impact on health, 
the bodys’ natural genetically mandated homeostatic response to such tactics, or the fact that 
depriving the body of resources essential to maintain health is counterproductive.  Essentially, 
these types of tactics simulate the circumstances of a famine and induce genetically programmed 
energy conservation responses. In addition, at some point in the energy conservation sequela, 
increased  appetite  can  result.  Alarmingly,  many  of  these  tactics  are  approved,  administered 
and/or  supervised  by  medical  or  health  professionals.    While  initially  appearing  to  promote 
“weight loss” (phase 1), such tactics are destined to fail as gene-induced recalibration of energy 
management and storage instructions homeostatically adjusts to the artificially imposed influence 
of  such  tactics,  generally  by  lowering  the  basal  metabolic  rate,  increasing  energy  storage 
requirements  and  promoting  increased  fat  retention  (phase  2)  [1,  2].  Chronic  and  repeated 
attempts to lose weight with such tactics are referred to as the yo-yo weight gain rebound effect.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 314 of 378 
 
 
This  phenomenon  is  responsible  for  ever-increasing  frustration,  anxiety  and  a  sense  of 
helplessness caused by the out-of-control “weight loss”/gain juggernaut. 
Ultimately, obesity is an energy-balance and nutrient deficiency-induced famine disorder 
characterized by a survival gene induced increase in fat storage, lowering of the Basal Metabolic 
Rate (to conserve energy) and increase in appetite. Following circumstances when a simulated 
famine  is  induced,  certain  genes,  programmed  to  resist  loss  of  body  fat,  prevail  [3].  This 
programmed genetic predisposition is responsible for down-regulating the resting metabolic rate 
(RMR) in response to dietary and caloric restriction, which is significantly disrupted following 
rapid  “weight  loss” regimens,  like those tactics  indicated  above. Over-consumption of food, 
especially  nutritionally  deficient  high  calorie  food  (excess  energy  intake),  is  a  normal 
consequence contributing to weight gain and obesity. A resistance to the hormone leptin also 
characterizes  common  obesity.  Insulin  has  been  shown  to  increase  leptin  secretion  by  25%. 
Ample evidence demonstrates that insulin resistance is also a primary contributor to obesity, 
suggesting  that  insulin  resistance  induced  hyperinsulinemia  can  provoke  leptin  resistant 
hyperleptinemia  with  a  consequential  increase  in  fat  synthesis  and  storage  in  adipocytes, 
characteristic sequela of Syndrome X or Metabolic Syndrome. Further, adipocytes from fatter 
animals secrete more leptin and a correlation between intracellular ATP concentration and the 
rate of leptin secretion appears to exist. As such, leptin concentration correlates positively with 
percent body fat. A low resting metabolic rate for a given body size and composition, a low rate 
of fat oxidation, and low levels of physical activity are risk factors for weight gain and common 
traits of obese individuals. It has been shown that a decrease in body weight as fat mass and fat 
free mass is accompanied by a greater decrease in resting energy expenditure and fat oxidation 
[4, 5, 6]. 
Effective fat loss and body recomposition strategies addressing the energy management 
pathways  should  simultaneously  improve  insulin,  serotonin  and  fat  oxidation  metabolism; 
potentiate  a  healthy  increase  in  resting  metabolic  rate  and  energy  expenditure;  and  blunt 
excessive appetite cravings, given proper adequate nutrient and energy intake. The technology of 
the present invention replenishes the nutritional needs of at least five  important systems, which 
are essential to healthy weight management as follows: 1. The biochemical mechanisms involved 
in  nutrition  and  energy  management  regulating  intake,  expenditure  and  storage  controls  and 
feedback; 2. Attenuation of the effects of chronic stress and inflammation (which overburden the 
endocrine system and can cause things like excessive cortisol production) reducing fat storage; 
3.The pleasure seeking needs and reward circuitry of the brain, influencing psychological and 
emotional need-induced food cravings; 4. Promotion and support of healthy immune system 
function (involved in catalyzing survival response to metabolic threats; and 5. Supporting and 
maintaining  optimal  health  of  the  neuroendrocrine  system  through  which  the  majority  of 
metabolic signaling is processed.  Nutritional and gene expression deficiencies in the Reward 
neurochemical pathway limit the brain’s reward resources (specific neurotransmitters) and are 
responsible  for  a  condition  called  “Reward  Deficiency  Syndrome,  (RDS)”  which  causes 
excessive cravings [7]. 
The Reward Deficiency Syndrome (RDS) results from a dysfunction in the Brain Reward 
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Receptor Gene as well as other dopaminergic genes (D1, D3, D4, D5). Dopamine is a very 
powerful neurotransmitter in the brain, which controls feelings of well-being. This sense of well-
being is produced through the interaction of dopamine and neurotransmitters such as serotonin, 
the  opioids,  and  other  powerful  brain  chemicals.  Low  serotonin  levels  are  associated  with 
depression. High levels of the opioids (the brain's opium) are associated with a sense of well-
being. The complex interactions of these powerful neurotransmitters, ultimately regulating the 
Dopaminergic Activity in the Reward Center of the Brain, have been termed by Blum et al., "The 
Brain Reward Cascade" (See Figure 2 for anatomy) [8]. 
In individuals possessing an abnormality in the DRD2 Dopamine Receptor Gene, the 
brain  lacks  enough  Dopamine  receptor  sites  to  use  the  normal  amount  of  Dopamine  in  the 
Reward Center of the brain and thus reduces the function of Dopamine in this area of the brain. 
Individuals possessing the variant in the Dopamine Receptor Gene tend to be serious cocaine 
abusers, may have unhealthy appetites that can lead to obesity or overeating.   
The  overall  effect  is  inadequate  Dopaminergic  Activity  in  the  Reward  Center  of  the 
Brain. This defect drives individuals to engage in activities, which will increase brain Dopamine 
function.  Consuming  large  quantities  of  alcohol  or  carbohydrates  (carbohydrate  bingeing) 
stimulate  the  brain’s  production  of  and  utilization  of  Dopamine.  So  too  does  the  intake  of 
crack/cocaine and the abuse of nicotine. Also, it has been found that the genetic abnormality is 
associated with aggressive behavior, which also stimulates the brain’s use of Dopamine. 
 
Figure 2 Anatomy of the Meso-limbic system of the brain reward site. 
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The Reward Deficiency Syndrome involves a form of sensory deprivation of the brain's 
reward  or  pleasure  mechanisms.  The  Reward  Deficiency  Syndrome  can  be  manifested  in 
relatively mild  or severe forms  that follow as  a consequence of  an individual's  biochemical 
inability to derive reward from ordinary, everyday activities. We believe that we have discovered 
at least one genetic aberration that leads to an alteration in the reward pathways of the brain. It is 
a variant form of the gene for the dopamine D2 receptor, called the A1 allele. This genetic variant 
also  is  associated  with  a  spectrum  of  impulsive,  compulsive,  and  addictive  behaviors.  The 
concept of the Reward Deficiency Syndrome unites those disorders and may explain how simple 
genetic anomalies give rise to complex aberrant behavior (See Figure 3, The Reward Deficiency 
Syndrome). 
 
Evidence for the existence of RDS in Substance Use Disorder: 
In 1990, Blum and colleagues, using the Taq1 polymorphism of the dopamine D2 receptor gene 
locus  (DRD2),  for  the  first  time  reported  a  strong  association  between  a  virulent  form  of 
alcoholism and the minor allele (A1) of the Drd2 gene in this population [8,9]. Other more recent 
studies further support an association of the A1 allelic form of the DRD2 gene with substance 
abuse vulnerability and other compulsive behaviors [10, 11, 12, 13, 14,15]. This association 
serves as the cornerstone of the biogenetic disease model and could ultimately lead us to better 
diagnosis  and targeted treatment  [16]. A complete review of this  work can be  found in  the 
Journal of Psychoactive Drugs [17]. 
 
Figure 3: The Reward Defiency Syndrome.  
 
 
This treaties will highlight the importance of a new concept, which provides a clearer 
understanding of impulsive, addictive, and compulsive behaviors. It is our notion that the real 
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nonacceptable)  behavior,  derives  from  an  individual’s  genetic  makeup  at  birth.  This 
predisposition due to multiple gene combinations and polymorphisms is expressed differently 
based  on  numerous  environmental  elements  including  family,  friends,  educational  status, 
economical position, environmental pollutants, and availability of psychoactive drugs including 
food. We believe the core of predisposition to these behaviors is a set of genes, which promote a 
feeling of well–being via neurotransmitter interaction at the “reward site” of the brain (located in 
the meso-limbic system), leading to normal dopamine release. We also subscribe to the notion 
that at least one major gene, the dopamine D2 receptor gene, is responsible for the synthesis of 
dopamine D2 receptors. And further depending on the genotype (allelic form A1 versus A2), the 
dopamine D2 receptor gene dictates the number of these receptors at post-junctional sites.         
A  low  number  of  dopamine  D2  receptors  suggest  a  hypodopaminergic  function,  as 
described by Eliot Gardner in a series of published works [18, 19]. When there is a paucity of 
dopamine receptors the person will be more prone to seek any substance (including glucose) or 
behavior that stimulates the dopaminergic system as a form of self-healing. In this regard we 
know that substances such as alcohol, cocaine, heroin, nicotine and glucose, as well as a number 
of behaviors like gambling and sex, preferentially release dopamine at the n. accumbens (the 
reward  site).  Understanding  this  preamble  allows  us  to  introduce  the  concept  of  reward 
deficiency syndrome into the field of addictive behavior, which will serve as a model to explain 
the commonality of a number of seemingly diverse addictions based on shared genetics and 
neurochemistry. In this regard, most recently, Qing–Shan Yan reported that ethanol, at a peak 
concentration  within  five  to  10  minutes  after  interparenteral  administration,  significantly 
increased both extracellular dopamine and serotonin in the n. accumbens, supporting the role of 
these two neurotransmitters in the reinforcing properties of ethanol [20]. Moreover, Honkanen 
and associates also found low basal dopamine release in alcohol accepting (AA) compared to 
alcohol  non-accepting  (ANA)  rats,  showing  that  dopamine  plays  a  role  in  high  alcohol 
preference of AA rats [21].  
One important study from Nora Volkow’s group further provides support for the role of 
the dopamine D2 receptor gene in alcohol intake in rats. Utilizing a cDNA construct of the 
dopamine D2 receptor gene implanted into the n. accumbens of rats, they found that following a 
four-day treatment, the dopamine D2 receptors increased to 150% above pretreatment level and 
alcohol drinking was reduced by 50%. After a period of eight (8) days, the D2 receptor density 
returned  to  pretreatment  level  and  so  did  alcohol  drinking.  Twenty–four  days  later,  second 
injections of the same construct caused a similar increase in density with a two–fold decrease in 
drinking [22]. The same group has now confirmed this work in mice.  
We will now turn our attention to the pharmacologic and genetic aspects of the inter 
relationship  between  Obesity,  carbohydrate  bingeing,  glucose  receptor  sensitivity  and 
dopamine.The intent of this work is to share with the scientifically informed, interested reader 
the basic scientific evidence which explains why people overeat and become overweight in a 
society where “thin is in”. In order to accomplish this goal we first must consider the relationship 
between  eating  behavior  and  “brain  chemistry”  and  the  interaction  of  both  genetic  and 
environmental elements. 
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Weight gain: A prehistoric look 
In consideration of the ability of our bodies to gain weight, we must review a few simple facts. 
Without our ability to gain weight, we as humans would have never survived. Ironically, whereas 
today the quantity of food is plentiful (although quality of nutrition is questionable), our goal is 
to turn away from food. In contrast, in the time of our prehistoric ancestors, the hunter-gatherers 
did not have a plentiful food supply. For example, when pristine sources of nutrient-rich berries 
and roots were in season and when wild animals were not hibernating, our ancestors ate well and 
“they fattened up”. However, when these foods were not available, they relied on the stored fat 
to see them through the lean times. 
To help us understand the importance of weight gain, two biological functions assisted 
our prehistoric ancestors as they struggled to survive this perpetual cycle known as “feast” and 
“famine”. When there is an abundant supply of pristine quality food, our bodies efficiently store 
fat, and during times of a lack of food, our metabolism slows down. Scientists believe that 
abundant food induced efficient fat storage in our ancestors and when there was less fat their 
metabolism slowed to adjust to the smaller quantities programmed to adapt their metabolic rates 
to food intake. Those who survived were “blessed” with "fat-storage” genes, while those who 
lacked these genes perished. This suggests that the survivors passed their “thrifty” genes on to 
future generations-to you and me. Within the realm of modern times these ancient genes evolved 
over thousands of years and ultimately forced our bodies to store energy from nutrient-deficient 
concentrated sugars, processed carbohydrates, and adulterated fats to survive the famine that 
chronic intake of these types of low quality “foods” simulate [3].  
Today we are faced with an obesity epidemic, which contributes to an estimated 300,000 
deaths in people who die prematurely from this disease. In fact, obesity is a contributing risk 
factor for four of the seven leading causes of death. The Center for Disease Control has stated 
that Obesity is the number one health risk, greater than a lifetime of smoking, drinking and 
poverty  [23].  Obesity  in  the  United  States  is  doubling  every  five  years  and  the  Institute  of 
Medicine has declared war on the nation’s “obesity epidemic”. 
To make sense out of all of this, we must understand that in today’s modern world, no 
longer do we struggle through periods with very little food. Instead, we live in a perpetual calorie 
rich  nutrient  deficient  food  feast  with  a  fast-food  chain  virtually  around  the  corner  for  all 
Americans. This means that our bodies always are on “store mode”; except when we go on "low-
fat diets”, our brain loses control and there is an overwhelming call to “eat”. Thus, in all of us, 
there is a rebound effect, which reacts by quickly regaining the lost weight in preparation for the 
next food shortage, just as it did for our prehistoric ancestors. 
An article in Obesity Research 1996 sums up the problem; 
“[The]  modern  western  lifestyle  appears  to  provide  the  social  and  environmental 
conditions  that  favor  maximum  expression  of  underlying  individual  genetic  differences  in 
susceptibility to becoming overweight.”[3] 
This is an important view because we now know that in today’s society, with its highly 
processed foods, chemicals and pollution, with regard to metabolic effects, the body’s instinct is 
to prepare for and defend against famine, but there is even a more important facet to the genetic 
propensity to gain excess weight and it does not reside in genes which control fat storage, and/or Functional Foods in Health and Disease: 9:310-378                                                                         Page 319 of 378 
 
 
resting metabolic rates. Instead it is in the genes, which control our desire “To Binge or Not to 
Binge” [24]. These genes are termed “reward genes”. 
 
The biology of reward: 
The pleasure and reward system in the brain was discovered by accident in 1954. The American 
psychologist James Olds was studying the rat brain's alerting process, when he mistakenly placed 
the electrodes in a part of the limbic system, a group of structures deep within the brain that 
generally are believed to play a role in emotions [25]. When the brain was wired so the animal 
could stimulate this area by pressing a lever, Olds found that the rats would press the lever 
almost nonstop, as much as 5,000 times an hour. The animals would stimulate themselves to the 
exclusion  of  everything  else  except  sleep.  They  would  even  endure  tremendous  pain  and 
hardship for an opportunity to press the lever. Olds clearly had found an area in the limbic 
system that provided a powerful reward for these animals. 
Research on human subjects revealed the electrical stimulation of some areas of the brain 
(medial hypothalamus,  which is  in  the limbic  system) produced a  feeling of quasi-orgasmic 
sexual arousal [25]. If certain other areas of the brain were stimulated, an individual experienced 
a  type  of  light-headedness  that  banished  negative  thoughts.  These  discoveries  demonstrated 
pleasure is a distinct neurological function that is linked to a complex reward and reinforcement 
system [26]. 
It is useful to think of the brain's reward system as a cascade in which one reaction 
triggers another. At the level of individual neurons, the reward cascade is catalyzed by a number 
of neurotransmitters [27]. Each neurotransmitter binds to certain types of receptors and serves a 
specific function. The binding of the neurotransmitter to a receptor on a neuron, like a key in a 
lock, triggers a reaction that is part of the cascade. Disruption of these intercellular cascades 
results in one form or another of the Reward Deficiency Syndrome. 
 
The Cascade Theory of Reward: A blueprint for mapping obesity genes: 
During the past four decades, considerable attention has been devoted to the investigation of 
neurochemical and neuroanatomical systems underlying chemical dependency. The research on 
the neuropharmacological basis of dependence (on alcohol, opiates, cocaine and glucose) points 
to the involvement of common biochemical  mechanisms  [28, 29]. It  appears as  if  a  limbic-
accumbens-pallidal  circuit  is  the  critical  substrate  for  the  expression  of  drug  reward  [30]. 
However, while each substance of abuse appears to act on this circuit at a different step, the end 
result is the same, the release of dopamine the primary chemical messenger of reward at such 
reinforcement sites as the nucleus accumbens and the hippocampus [31]. 
 In a normal person, neurotransmitters (the messengers of the brain) work together in a 
pattern of stimulation or inhibition, the effects spreading downward from complex stimuli to 
complex patterns of response like a cascade, leading to feelings of well-being: the ultimate 
reward (Cascade Theory of Reward) [27,28,33]. Although the neurotransmitter system is too 
complex and still not completely understood, the main central reward areas in the human brain's 
meso-limbic system are summarized in figure 4a and 4b. 
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Figure 4a. Neurotransmitter Relations in the Reward Cascade 
 
K.Blum (with J. Payne) Alcohol and the Addictive Brain. The Free Press, with permission p199 
[276] 
 
In the reward areas the following interactions take place [29,32]: 
Serotonin (1) in the hypothalamus (I) indirectly activates opiate receptors (2) and causes the 
release of enkephalins, in the ventral tegmental region A10 (II). The enkephalins inhibit the 
firing of GABA (3) which originates in the substantia nigra A9 region (III); 
GABA's normal role, acting through GABA B receptors (4), is to inhibit and control the amount 
of  dopamine  (5)  released  at  the  ventral  tegmental  regions  (II)  for  action  at  the  nucleus 
accumbens (IV). When the dopamine is released in the nucleus accumbens it activates dopamine 
D2 receptors (6), a key reward site [there are at least five dopamine receptors, including D2]. This 
release also is regulated by enkephalins (7) acting through GABA (8). The supply of enkephalins 
is controlled by the amount of the neuropeptidases (9) which destroy them. 
Dopamine also may be released into the amygdala (V). From the amygdala, dopamine (10) 
reaches the hippocampus (IV) and the CA, cluster cells (VII) stimulates dopamine D2 receptors 
(11), another reward site. 
Norepinephrine involves an alternate pathway (12) in the locus of ceruleus A6 (VIII) whose 
fibers project into the hippocampus at a reward area centering around cluster cells which have 
not  been  precisely  identified,  but  which  have  been  designed  a  CAx  (IX).  When  GABA  A Functional Foods in Health and Disease: 9:310-378                                                                         Page 321 of 378 
 
 
receptors (13) in the hippocampus are stimulated, they cause the release of norepinephrine (14) 
at the CAx site (Figure 4b). 
Figure 4b Neurotransmitter Relations in the Reward Cascade 
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It is to be noted that the glucose receptor (GR) in the  hypothalamus is intrically involved and 
"links" the serotonergic system with opioid peptides leading to the ultimate release of dopamine 
at the n. accumbens. 
  In  the  "cascade  theory  of  reward",  these  interactions  may  be  viewed  as  activities  of 
subsystems of a larger system, taking place simultaneously or in sequence, merging in cascade 
fashion toward anxiety, anger, low self-esteem, or other "bad feelings" or toward craving for a 
substance that will make these bad feelings go away, for example sugar (Cascade Theory for 
Carbohydrate  Bingeing).  Certainly,  many  overweight  individuals  also  cross  abuse  other 
psychoactive substances (e.g. alcohol, cocaine, and nicotine) [27]. 
  Alcohol activates the norepinephrine fibers of the mesolimbic circuitry through a cascade 
of events, including the interaction of serotonin, opioid peptides, and dopamine. In a more direct 
fashion,  through  the  subsequent  formation  of  the  neuroamine  condensation  products  TIQs, 
alcohol may either interact with opioid receptors or directly with dopaminergic systems [33, 27]. 
In fact we sowed the important relationship between dopaminergic activation through our novel 
natural agonist SYN (a KB220 variant) and the narcotic antagonist Naltrexone[34]. Functional Foods in Health and Disease: 9:310-378                                                                         Page 322 of 378 
 
 
In the  cascade theory of carbohydrate bingeing, genetic anomalies, long-continued stress,  or 
long-term abuse of sugar can lead to a self-sustaining pattern of abnormal craving behavior in 
both animals and humans. Animal model support for the cascade theory can be derived from a 
series of experiments carried out by T.K. Li et al. [35-40] upon their substance-preferring (P) 
[seek carbohydrates, alcohol, opiates, etc.] and nonpreferring (NP) rat lines. They found that P 
rats have the following neurochemical profile: 
  lower serotonin neurons in the hypothalamus; 
  higher levels of enkephalin in the hypothalamus (due to a lower release); 
  more GABA neurons in the nucleus accumbens; 
  reduced dopamine supply at the nucleus accumbens; 
  reduced densities of dopamine D2 receptors in the meso-limbic areas. 
This suggests a four-part cascade sequence leading to a reduction of net dopamine release in a 
key reward area. This was further confirmed when it was found that administering substances 
which increase the serotonin supply at the synapse, or by stimulating dopamine D2 receptors 
directly,  craving  behavior  could  be  reduced  [39].  Specifically,  D2  receptor  agonists  reduce 
alcohol intake in high alcohol preferring rats whereas D2 dopamine receptor antagonists increase 
alcohol drinking in these inbred animals [41]. 
  In thinking about the causes of obesity and possible ways in which traditional and non-
traditional treatments might be improved, we must turn our attention to “neurotransmitters” and 
the  enzymes  that  control  them.  We  now  know  as  discussed  above,  there  are  at  least  four 
important neurochemical systems involved in the natural process of "reward” or the achievement 
of  pleasurable  states;  serotonin,  opioids,  GABA,  and  catecholamines.  Consideration  of  the 
various neurotransmitters and their individual effects on macro-selection of food is important if 
we want to understand the root causes of overeating (see figure 4). 
 
Figure 5. Schematic of Brain reward Cascade: Normal and abnormal representation.  
 
Figure 5(A) Represents the normal physiologic state of the neurotransmitter interaction at the 
mesolimbic  region  of  the  brain.  Briefly,  serotonin  in  the  hypothalamus  stimulates  neuronal 
projections of methionine enkephalin in the hypothalamus that, in turn, inhibits the release of 
GABA  in  the  substania  nigra,  thereby  allowing  for  the  normal  amount  of  Dopamine  to  be 
released at the Nucleus Accumbens (NAc); reward site of the brain. 
Figure  5  (B)  Represents  hypodopaminergic  function  of  the mesolimbic region  of  the 
brain.  The  hypodopaminergic  state  is  due  to  gene  polymorphisms  as  well  as  environmental Functional Foods in Health and Disease: 9:310-378                                                                         Page 323 of 378 
 
 
elements, including both stress and neurotoxicity from aberrant abuse of psychoactive drugs (i.e. 
alcohol, heroin, cocaine etc) and genetic variables.  
  The  genetic  variables  include  serotonergic  genes  (serotonergic  receptors  [5HT2a]; 
serotonin  transporter  5HTlPR);  endorphinergic  genes  (the  mu  OPRM1  gene;  proenkephalin 
(PENK); PENK polymorphic 3' UTR dinucleotide (CA) repeats}; GABergic genes (GABRB3); 
and dopaminergic genes (including ANKKI Taq A; DRD2 C957T, DRD4 7R, COMT Val/met 
substitution,  MAO-A  uVNTR,  and  SLC6A3  9  or  10R).  Any  of  these  genetic  and  or 
environmental impairments could result in reduced release of dopamine and or reduced number 
of dopaminergic receptors [42].  
 
Neurotransmitters and obesity: Animal studies  
The  literature  on  eating  is  very  complex.  The  same  chemical  element  or  neurotransmitter 
commonly  will  have  different  effects  when  administered  in  low  doses  versus  high  doses, 
centrally versus peripherally, in short-term versus non-predisposed, in overweight versus normal 
weight versus anorectic animals, as function of paradigm, and so on. Detailed reviews have been 
published previously [4, 5, 6, 43, 44]. 
 
Eating-stimulatory neurotransmitters 
The  eating-stimulatory  neurotransmitters  include  the  catecholamine  norepinephrine,  acting 
through  noradrenergic  receptors,  GABA,  and  three  classes  of  neuro-peptides  the  opioids 
(endorphins, enkephalins, and dynorphins); the pancreatic polypeptides (neuro-peptide Y and 
YY),  and  galanin.  These  substances,  when  administered  directly  into  the  rat  hypothalamus, 
potentiate eating in satiated animals [45]. 
  Furthermore,  chronic  administration  of  certain  monoamines  (norepinephrine  [NE])  and 
neuropeptides significantly alter daily food intake and weight gain [46, 47].  
  The eating-inhibitory neurotransmitters in the brain include the monoamines, dopamine, 
serotonin, and gut-brain peptides cholecytokinin-8 (CCK-8), neurotensin, calcitonin, glucogen, 
and corticotropin-releasing factor [48-54]. 
  The effects of these neurotransmitters on eating are characterized primarily by a specific 
change in macro-nutrient selection, rather than an increase or decrease in total food intake. Many 
peptides,  including  CCK-8,  bomesin,  calcitonin,  corticotropin-releasing  factor,  neurotensin, 
somatostatin, glucagon, and methionine-enkephalin have selective inhibitory actions on macro-
nutrients  [55,  56].  Leibowitz  and  associates  [57-59]  reported  that  medial  para-ventricular 
nucleus (PVN) injections of NE in the rat induce a selective increase in carbohydrate ingestion 
with little or no change in fat and suppression of protein intake. Carbohydrate-craving behavior 
is observed consistently with chronic stimulation of NE and neuropeptide Y [49,60]. With regard 
to the all important monoamine Dopamine (released at the reward center), mixed effects have 
been observed with regard to the selective actions on macro-nutrient intake [51,61].  
  In contrast, serotonin, in the medial hypothalamus, may selectively suppress carbohydrate 
intake, while sparing protein intake [51,62,63]. Direct serotonergic agonists (e.g., quipazine), 
indirect serotonergic agonists (e.g., d-fenfluramine), or selective inhibitors of serotonin uptake 
into serotonergic neurons  (e.g., fluoxine) decrease food ingestion in  animal studies  [64-  67] Functional Foods in Health and Disease: 9:310-378                                                                         Page 324 of 378 
 
 
reported that d-fenfluramine (Redux
R) reduced the consumption of a sucrose solution in non-
deprived  rats.  Leander  demonstrated  that  fluoxitine  suppresses  the  ingestion  of  saccharin 
solutions in normal rats [68]. A similar finding was true for alcohol intake in preferring rat lines 
(animals genetically bred to prefer alcohol over water [69]. All the above indicates that direct 
and indirect serotonergic agonists depress a feeding response activated by sweet taste.  
 
Opioid peptides and macro-nutrient selection 
Current evidence suggests that the pharmacology of the opioidergic system on eating behaviors 
is very complex and it would therefore be difficult to a ascribe a generalized role, particularly in 
view of different effects observed with specific opioid peptides on macro-nutrient selection.  
In support of the above observation, both increases in food intake [70-72] as well as decreases in 
food intake [73,74] have been observed under a variety of experimental conditions. In short-term 
experiments, administration of agonists, centrally or peripherally, results in feeding increases.  
  The  results  have  been  far  more  complicated  than  expected.  In  general,  chronic 
administration  of  antagonists  has  been  disappointing.  Naltrexone  caused  some  reduction  in 
binge-eating in bulimics; however, it produced weight gain in anorexic patients [75]. Shimomura 
et al. observed increased food intake with chronic naloxone treatment and decreased food intake 
with chronic morphine [76]. Dhatt et al. had similar observations with chronic administration 
[55].  These  observations  suggest  that  while  in  acute  situations  opioid  agonists  increase  and 
antagonists decrease food intake, in chronic situations opposite effects prevail. In this regard, it 
is noteworthy that the opioid peptides, as well as opiates acting through mu, delta, and kappa 
receptors, augment ingestion of fat and protein, while actually suppressing the relative proportion 
of carbohydrates ingested [56,62,76].Tepperman and Hirst showed that upon inducing neonatal 
reduction  of  endorphins,  rats  become  overweight.  Compared  with  control  animals,  these 
overweight rats chose a greater percentage of their daily calories as carbohydrates and lower 
percentages as fat and protein [77].   
 
Inhibitors of Enkephalinase(s) and craving behavior  
As stated earlier, although it is known that opiates and/or opioids reportedly increase food intake 
in animals and humans, some papers suggest the opposite-suppression of food intake, especially 
when one considers macro selection of food sources (i.e., sugar/carbohydrates) [62,70,75,76,78-
80]. Moreover, Broekkamp et al. reported that infusion of enkephalin into the ventral tegmental 
A10 area of the brain induces a short-term latency behavioral stimulant effect reminiscent of 
effects produced by stimulation of the meso-limbic dopamine pathway; this effect is blocked by 
pretreatment of the opiate receptor antagonist naloxone [81]. This takes on importance in terms 
of feeding behavior, as feeding has been shown to increase dopamine levels in various brain 
structures such as the posterior hypothalamus, the nucleus accumbens, and the amygdala.  
  It is well known that dopamine in sufficient concentration can inhibit food intake [82]. 
Gilman and Lichtigfeld proposed as an appropriate therapeutic for carbohydrate bingeing (i.e., 
bulimia) a selective D2 agonist such as bromocriprtine [or natural released dopamine], providing 
D2 occupancy [83]. In this regard, using a push-pull cannula technique, Chesselet et al. were able 
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which suggests regulation by delta receptor stimulation [84]. Indeed Kelotorphan (an inhibitor of 
the opioid peptide degrading enzyme) may protect against possible CCK-8 degradation by brain 
peptidiases. This important satiety neuropeptide is co-localized with dopamine in the nucleus 
accumbens, and there is a close interaction between CCK-8, dopamine, and endogenous opioid 
peptides (like enkephalins) [85].  
  The  opioid  peptides  are  involved  not  only  in  macro-nutrient  intake,  but  have  been 
implicated in substance seeking [86- 88], as well as brain self-stimulation behavior [89,90]. In 
essence, there are a substantial number of animal experiments which support not only the “Brain 
Reward Cascade" but the subsequent sequale induced by a defected reward cascade leading to a 
number of addictive, compulsive and impulsive behaviors-defined as the "Reward Deficiency 
Syndrome”[91].  
  In  this  regard,  Blum  et  al.  reversed  alcohol-seeking  behavior  in  genetically  preferring 
C57Bl/6J mice with the chronic administration of an enkephalinase inhibitor [87]. In other work 
by George et al, they concluded that a relative lack of enkephalin peptides trans-synaptically, 
possibly resulting from enhanced enkephalin degradation, may contribute to increased alcohol 
consumption in C57Bl/6J mice [92]. Moreover, others showed that intracranial self-stimulation 
by  rats  was  reduced  by  nucleus  accumbens  microinjections  of  kelatrophan,  a  potent 
enkephalinase  inhibitor.  In  terms  of  food  intake,  Riviere  and  Bueno  reported  that  central 
injections of the enkephalinase inhibitor, thiorphan, also reduced daily food intake in sheep [93]. 
These  results  suggest  that  human  carbohydrate  bingeing  might  be  critically  mediated  by 
differences in patterns of endogenous peptides. 
 
 D2 Receptors and animal models:  
Hamdi  et  al.  studied  the  specific  binding  of  [3H]  YM  –09151-2  to  investigate  the  possible 
differences in age-associated changes in striatal D2 dopamine receptor properties in genetically 
obese  (fa/fa)  Zucker  rats  and  their  lean  littermates.  The  maximal  binding  sites  of  D2DA 
receptors were found to decline with age in both obese and lean rats: the rate of decline in 
receptor Bmax was slightly higher in lean than obese rats. However, the Bmax of D2DA receptor 
in 6-, 12- and 18-month old obese rats was significantly lower compared to the age matched lean 
rats. The very important interpretation by the authors further supports the role of dopamine in 
obesity. According to the authors, their data indicate that obesity decreases the number of striatal 
D2DA receptors without affecting the rate at which receptor number decreases with age [94].  
Hypothalamic  neuropeptide  Y  (NPY)  and  corticotropin  –  releasing  hormone  (CRH) 
influence  feeding  and  levels  of  plasma  glucose,  insulin,  free  fatty  acids,  and  triglycerides. 
Treatment of genetically obese, ob/ob mice, with D1/D2 agonists normalizes hyperphagia, body 
weight gain, hyperglycemia, and hyperlipidemia. Bina and associates examined whether levels of 
NPY and CRH immunoreactivity in discrete hypothalamic nuclei are altered in ob/ob mice, and 
whether  dopaminergic  treatment  reverses  this  alteration  [95].  Such  dopaminergic  treatment, 
while  normalizing  body  weight  gain  and  hyperglycemia,  also  significantly  reduced  elevated 
brain levels of NPY and CRH. These findings suggest that dopaminergic D1 /D2 coactivation 
may  improve  hyperphagia,  hyperglycemia,  and  obesity  in  the  ob/ob  mouse,  in  part  by 
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revealed  that  injection  of  NPY  anti-sense  unto  brain  could  modify  the  anorectic  action  of 
repeated  S1/S2  agonists,  indicating  the  involvement  of  NPY.  Taken  together  the  present 
knowledge suggests that both subtypes of D1 and D2 receptors and cerebral NPY are involved in 
the anorectic action of the dopamine releasing agent amphetamine [96].       
Scislowski  and  associates  reported  that  a  two  week  treatment  with  SKF  38393  (a 
dopamine D1 receptor agonists) plus bromocryptine (a D2 agonist) [BC] acted synergistically to 
normalize overeating, body fat, hyperglycemia and hyperlipidaemia in ob/ob mice. In a more 
recent study they found that the BC/SKF treatment also increased serum dehydroepiandrosterone 
(DHEA)  sulfate  concentrations,  an  inhibitor  of  body  fat  store  accumulation.  The  authors 
conclude  that  their  findings  demonstrate  that  dopaminergic  treatment  not  only  normalizes 
overeating  (hyperphagia)  of  ob/ob  mice,  but  also  redirects  several  metabolic  and  endocrine 
activities, independent of its effects on feeding to improve the obese –diabetic syndrome in ob/ob 
mice [97, 98]. 
Long term administration of the antipsychotic drugs known to block D2 receptors such as 
sulpiride,  haloperodol,  etc  increased  body  weight  in  rats.  This  effect  was  found  to  be  sex 
dependent that is, while female rats were prone to gain weight, male rats did not. In a study 
conducted by Baptista et al. a linear relationship between dose of sulpiride and body weight gain 
was found. Also sulpiride increased caloric intake, and both actions were counteracted by the 
specific D2 agonist bromocriptine. These results confirm that antipsychotic drugs affect feeding 
and body weight and suggest that hyperphagia and body weight gain might be mediated by 
blockade of dopamine D2 type receptors [99]. More recently, Freeman et al. studied the effect of 
glucose on anti-psychotic drug-induced changes in dopamine neuronal activity and suggested 
that caloric intake may influence antipsychotic drug-induced changes in the population activity 
of  midbrain  dopaminergoc  neurons.  In  fact,  glucose  significantly  reduced  the  number  of 
spontaneously active A9 and A10 dopaminergic cells per track in control rats, but significantly 
attenuated the chronic haloperidol- and clozapine –induced reductions in dopaminergic cells per 
track [100].   For a review of animal models of food addiction see Blum et al. [101].                                             
 
Brain hypodopaminergic function and the self-healing process 
Since deficits have been found in neurotransmitter functions underlying craving behavior, and 
since these deficits may be alleviated by facilitated dopamine release consequent to the use of 
drugs, nicotine, alcohol, and food, the studies mentioned above indicate enkephalinase inhibition 
may similarly compensate for neurotransmitter imbalance (i.e., opioids, thereby attenuating 
craving behavior). 
  In an attempt to understand that carbohydrate craving is a subset of generalized craving 
behavior  (“Reward  Deficiency  Syndrome“),  due  to  hypodopaminergic  function  (an  impaired 
“reward cascade"), scientists believe individuals self-heal through biochemical (licit or non-ilicit) 
attempts to alleviate the low dopaminergic brain activity via drug-receptor activation (alcohol, 
heroin, cocaine, and glucose). It is conjectured this will subsitute for the lack of reward and yield 
a temporary sense of well-being. In order to help explain this so called self-healing process, it is 
germane  that  the  reinforcing  properties  of  many  drugs  of  abuse  may  be  mediated  through 
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dopamine  system.  In  this  regard,  glucose,  opiates,  nicotine,  cocaine,  tetrahydracannabinol 
(THC), and ethanol have been shown to directly or indirectly enhance release or block re-uptake 
of dopamine in at least one of the primary terminal sites for the limbic dopamine neurons, the 
nucleus accumbens [31,102-104].  
  A number of studies of genetically bred animal models support the D2 dopamine receptor 
involvement in substance-seeking behavior due to lower D2 receptor sites in preferring compared 
to  non-preferring  animals  [38,105,106-108].One  inference  from  these  observations  is  that 
ethanol intake, as well as the self-administration of other substances (i.e., glucose), might be 
altered by manipulation of dopamine receptors. Of interest is that further confirmation of the 
“Reward  Deficiency  Syndrome"  in  generalized  substance-behavior  involving  slow  dopamine 
release in the nucleus accumbens in polysubstance seeking Lewis animals has been observed 
recently by Gardner (1997)[17, 18].  
 
Reward Deficiency Syndrome: Human studies  
Human support for the Reward Deficiency Syndrome can be derived from a series of clinical 
trials with neuronutrients (precursor amino acid loading technique and enkephalinase inhibition) 
indicating :  
 reduced alcohol and cocaine craving 
  reduced stress rates 
  reduction of leaving treatment against medical advice (AMA) 
  facilitated recovery  
  reduced relapse rates 
  reduction in carbohydrate bingeing 
  loss of body weight 
  prevention of weight regain 
  reduction of glucose craving 
  enhancement of insulin sensitivity 
  reduction of cholesterol 
 enhancement of memory and focus 
 
There are a number of studies using precursor amino-acids and enkephalinase inhibition which 
have been shown to affect various aspects of RDS [109- 119, 23] [see Table 1 and below]. 
  Most recently, the notion of dopamine as the "final common pathway" for a number of 
diverse drugs of abuse such as cocaine, morphine, and alcohol [as well as glucose] is supported 
by Ortiz and associates at Yale University School of Medicine and the University of Connecticut 
Health Services Center. This support demonstrates that chronic treatment of cocaine, morphine, 
or  alcohol  similarly  results  in  several  biochemical  adaptations  in  the  meso-limbic  dopamine 
system, which may "underlie prominent changes in the structural and functional properties of the 
neuronal pathway" related to the above. [120,121]. 
  The brain reward cascade schematic (Figure 3), since then, became the blueprint for the 
search for “reward genes”. We propose that the Reward Deficiency Syndrome gives rise to a 
wide  range  of  disorders  that  can  be  classified  as  impulsive-addictive-compulsive  diseases. Functional Foods in Health and Disease: 9:310-378                                                                         Page 328 of 378 
 
 
Impulsive diseases include attention deficit disorder and Tourette's Disorder. Addictive diseases 
include  substance-seeking  behavior  involving  alcohol,  drugs,  nicotine,  and  most  importantly 
food. Compulsive diseases include pathological gambling and excessive sexual activity. In terms 
of personality disorders it includes conduct disorder, oppositional defiant disorder, antisocial 
personality  disorder,  schizoid/avoidant  behavior,  violent  aggressive  behaviors  (See  Figure  1) 
[122-125]. 
 
Compulsive Bingeing Dopamine & Other Genes  
Obesity is a disease that comes in many forms. Once thought to be primarily environmental, it 
now is considered to have both genetic and environmental components. In a Swedish adoption 
study, for example, the weight of the adult adoptees was strongly related to the BMI of the 
biological parents and to the BMI of the adoptive parents. Other studies of adoptees and twins 
suggest heredity is an important contributor to the development of obesity, whereas childhood 
environment has little or no influence. Moreover, the distribution of fat around the body also has 
been  found  to  have  heritable  elements.  The  inheritance  of  subcutaneous  fat  distribution  is 
genetically separable from  body fat  stored in  other compartments  (among the viscera in  the 
abdomen, for example). It has been suggested there is evidence for both single and multiple gene 
anomalies [126]. In fact according to our laboratory, in conjunction with David Comings of the 
City of Hope National Medical Center, at least twelve different genes have been associated with 
obesity providing a 33 per cent contribution to the overall variance.  
  Given the complex array of metabolic systems that contribute to overeating and obesity, it 
is not surprising that a number of neurochemical defects have been implicated. Indeed at least 
three  such  genes  have  been  found:  one  associated  with  cholesterol  production,  one  with  fat 
transport and one related to insulin production [126]. Other genes include human chromosome 2, 
uncoupling protein 2 and the APO-D genes. The ob gene and its product the leptin protein have 
also been implicated in regulating long-term eating behavior [127]. Another protein, glucagon-
like  peptide  1(GLP-1)  has  been  found  to  be  involved  in  the  regulation  of  short-term  eating 
behavior [128]. The regulation between leptin and GLP-1 is not known. The ob gene may be 
involved in the animal’s selection of fat. But perhaps not in the ingestion of carbohydrates, 
which  appears  to  be  regulated  by  the  dopaminergic  system.  It  may  be  that  the  ob  gene  is 
functionally linked to the opioid peptodergic system involved in reward.  
  Whatever the relation between these systems the complexity of compulsive eating disorders 
suggests that more than one defective gene is involved. Indeed, the relation between compulsive 
overeating and drug and alcohol addiction is well documented [129, 130, 91]. Neurochemical 
studies show that pleasure-seeking behavior is a common denominator of addiction to alcohol, 
drugs, and carbohydrates [8]. 
  Variants of the dopamine D2 receptor gene appear to be risk factors in obesity. The A1 
allele  was  present  in  45  percent  of  overweight  subjects  as  compared  to  19  percent  of  non-
overweight subjects [131]. Furthermore, the A1 allele was not associated with a number of other 
metabolic  and  cardiovascular  risks,  including  elevated  levels  of  cholesterol,  and  high  blood 
pressure. In contrast, when the subject’s profile included factors such as parental obesity, a later 
onset of obesity and carbohydrate preference, the prevalence of the A1 allele rose to 85 percent.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 329 of 378 
 
 
  There also is an increased prevalence of the A1 allele in overweight subjects who have 
severe alcohol and drug dependence [91]. When obesity, alcoholism, and drug addiction were 
found in a patient, the incidence of the A1 allele rose to 82 percent. In contrast, the allele had an 
incidence of zero percent in non-overweight patients who also were not substance abusers and 
did not have a family history of substance abuse. In an unpublished study Blum and associates 
also found the A1 allele of the dopamine D2 receptor gene significantly contributes to percent 
body fat in morbidly overweight subjects. The percent contribution was found to be as much as 
45.9 percent  of the overall variance, when  compared  with  “super" controls (highly  assessed 
controls-no “reward deficiency" behaviors). Additionally, Comings et al (1996) found that the 
Dopamine D2 receptor A1 allele also associated with overweight young females [132]. Both the 
ob and the Dopamine D2 receptor gene are additive in contributing to the overall variance of 
obesity (22 per cent in young females).  Thus, the presence of the dopamine D2 receptor gene 
variants increase the risk of obesity and related behaviors along with other polymorphic genes, 
some of which have not as yet been identified. In order to investigate the prevalence of the 
Taq1A1 allele of the dopamine receptor gene in obesity with and without comorbid SUD, a total 
of 40 patients, from an outpatient clinic were studied. In this sample with a mean BMI of 32, the 
A1 allele of the DRD2 gene was present in 52% of these obese subjects. Furthermore, it was 
found that in the 23 obese subjects possessing comorbid SUD, the prevalence of the DRD2 A1 
allele was present in 73.9% of the obese subjects compared to only 23.5 % in obese subjects 
without comorbid SUD.  
  Moreover,  when  they  assessed  severity  of  substance  usage  (alcoholism,  cocaine 
dependence, etc.) increasing severity of drug use increased the prevalence of the Taq1 DRD2 A1 
allele: where 66.7% of less severe probands possessed the A1 allele compared to 82% of the 
most severe cases. Linear trend analyses showed that increasing use of drugs was positively and 
significantly associated with A1 allelic classification.        
 
Dopaminergic genes and obesity  
In a study by F. Yasuna from Japan, personality is a behavioral pattern, which differs among 
individuals. E. Kretchmer (see Yasuna) categorized personality variants according to the concept 
of fundamental body types. Several lines of evidence suggest that the central dopamine system 
may underlie the regulation of weight and personality trait. In this study, the authors examined 
the dopamine D2 receptor (D2R) binding together with body mass index (BMI) and personality 
trait  on  the  temperament  and  character  inventory  in  16  subjects.  The  data  demonstrates  a 
significant relation among the D2R binding in the amygdala, BMI and personality trait of harm 
avoidance (this is in agreement with other work by Blum et al. showing significant association 
with D2RA1 variants and harm avoidance). The authors conclude that variation of dopaminergic 
activity in the amygdala underlies the personality variants related to body type [133].  
  In  a  study  by  Jenkinson  and  associates,  the  association  of  the  dopamine  D2  receptor 
polymorphisms Ser311cys and Taq1A with obesity or type diabetes mellitus in Pima Indians was 
evaluated. They found that heterozygotes at the Ser311CysDRD2 polymorphism had a higher 
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  Moreover, the atypical antipsychotics have been shown to have superior efficacy compared 
with  typical  antipsychotics  such  as  haloperidol,  particularly  in  the  treatment  of  negative 
symptoms of schizophrenia. However, following clinical use, marked bodyweight gain has been 
frequently  observed  with  some  of  the  atypical  antipychotic  drugs.  A  careful  review  of  the 
literature from 1966- 2000, revealed that relative receptor affinities of the atypical antipsychotics 
for 5-HT2 and dopamine D2 receptors appear to be most robust correlate of body weight gain. 
This  makes  sense  because  if  one  blocks  dopaminergic  sites  at  the  receptor  it  will  increase 
carbohydrate  bingeing.  Wetterling  suggests  that  if  obesity  is  a  problem  in  a  patient  other 
modalities must be considered for the long term treatment [135].  
  In a study, G.N. Thomas evaluated the potential relationship between blood pressure and 
obesity  and  dopamine  D2  receptor  Taq1  polymorphism.  Pharmacological  data  suggest  that 
obesity and blood pressure (BP) may be modulated through the dopamine D2 receptor (DR2R), 
which may represent and underlying mechanism that links these conditions. Thomas et al. found 
that the A1 was decreased in hypertensives compared with controls. In the combined population, 
systolic,  diastolic,  and  mean  arterial  BP’s  were  lower  in  subjects  with  the  A1A1  genotype 
relative to the A2A2 genotype. However, the DRD2A1 allele frequency increased with increased 
markers of “gynoidal” or peripheral subcutaneous obesity [136].  
 
Brain dopamine receptors and obesity risk  
Moreover,  dopamine  plays  a  major  in  the  regulation  of  appetite  and  growth  hormone. 
Dopaminergic agonists are known to suppress appetite and dopamine D2 receptor antagonists 
enhance it. Comings found that DRD2 polymorphisms significantly associated with high BMI as 
well as height [137].  
  In another study, Wang and associates found that striatal dopamine D2 receptor availability 
was significantly lower in ten obese individuals than in lean controls. The availability of the D2 
receptors was decreased in obese individuals in proportion to their BMI. Dopamine modulates 
motivation and reward circuits and hence dopamine deficiency in obese subjects may perpetuate 
pathological eating as a means to compensate for decreased activation of these circuits. The 
authors conclude that strategies aimed at improving dopamine function may be beneficial in the 
treatment of obese individuals [138].  
 
Other dopaminergic reward gene risk taking behavior and overeating 
Although we believe the gene for the D2 receptor plays a critical role in Reward Deficiency 
Syndrome  behaviors,  other  dopaminergic  receptor  genes  (such  as  the  dopamine  transporter 
genes,  dopamine-beta-hydroxylase  genes  and  the  D3  and  D4  dopaminergic  receptor  genes) 
undoubtedly are involved in the different manifestations of the syndrome, but, for example, both 
the dopaminergic transporter and the dopamine-beta-hydroxylase genes are not associated with 
obesity.  It  is  noteworthy,  that  some  have  suggested  one  type  of  overeating  might  reside  in 
individuals  who  are  high-risk  takers  and  switch  their  addictive  risk  taking  dopamine-linked 
neuronal release to carbohydrate bingeing. This is not surprising in light of recent molecular 
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  George Koob and Associates from Scripts Institute in La Jolla, California found evidence 
for the D3 locus and suggested it as a primary site of cocaine effects [31]. The exact effect of 
cocaine is unknown regarding gene expression; however, we do know that D2 receptors are 
decreased by chronic cocaine administration and this may induce severe cocaine craving and 
possibly cocaine dreams [139] and the dopamine D2 receptor gene has been associated with 
severe cocaine addicts [14]. The likelihood of carrying the A1 allele increases as the number of 
risk  factors  increases  among  cocaine-dependent  people.  Three  risk  factors  are  especially 
significant: parental alcoholism and drug abuse, the potency of the cocaine used by the addict 
and early childhood deviant behavior, such as conduct disorder. 
  Most recently scientists from Israel and the National Institutes of Mental Health confirmed 
a genetic variation of the dopamine D4 receptor gene to associate with novelty (or sensation) 
seekers.  Both  of  these  studies  set  out  to  test  the  hypothesis  advanced  by  Cloninger  of 
Washington University that novelty seeking behavior is affected by the way brain cells process 
dopamine. Epstein and his colleagues at the Herzog Memorial Hospital in Jerusalem found this 
association  in  124  unrelated  Israeli  subjects.  Specifically  he  found  that  subjects  who  scored 
highest  on  novelty  seeking  tended  to  be  compulsive,  exploratory,  fickle,  excitable,  quick 
tempered,  and  extravagant.  They  were  much  more  likely  to  have  the  longer  version  of  the 
receptor gene than other subjects. Subjects with the shorter version of the gene scored lower and 
tended  to  be  reflective,  rigid,  loyal,  stoic,  slow  tempered,  and  frugal.  In  the  second  study 
conducted by Benjamin of the laboratory of clinical science, National Institute of Mental Health 
found similar results in his sample of 315 American subjects, most of them male siblings and 
other family members [140, 141]. The D2 receptor gene and the D4 receptor gene are fairly close 
in gene homology and may have similar physiological functions. 
  In an unpublished work scientists at UCLA found an association between the DRD2 A1 
allele  and  agitation  marked  by  impulsivity,  excitability,  "hot  temper".  These  subjects  were 
classified as "sensation seekers." The recent work of Benjamin and Epstein provide additional 
confirmation  of  the  relationship  between  the  Reward  Deficiency  Syndrome  behaviors 
characterized by Blum and associates and the dopaminergic system. Additionally Benjamin and 
Epstein  provide  support  of  the  earlier  work  of  Susan  George  and  associates  (1993)  at  the 
University  of  Toronto  who  found  a  strong  association  between  the  D4  gene  variance  and 
alcoholism and nicotine dependence again showing the interchangeable nature of this syndrome 
[13]. Therefore adding another element to the “binge or not to binge?“ equation. 
  In this regard, Poston et al. carried out an association study of the D4 dopamine receptor 
and  obesity  risk.  Many  genes  have  been  identified  that  may  play  a  role  in  increasing 
susceptibility to obesity. Reduced dopamine function appears to play a role in dysfunctional 
eating patterns and may predispose some individuals to obesity. The long version of the D4 
dopamine  receptor  gene  (D4DR)  has  been  shown  to  alter  receptor  function  and  reduce 
intracellular response to dopamine. It also has been associated with novelty-seeking – related 
personality  traits  that  are  found  with  greater  frequency  in  obese  individuals.  Poston  and 
associates  examined  the  association  between  the  D4DR  and  obesity  in  115  obese  patients 
participating  in  a  weight  management  program.  They  constructed  four  models  of  increased 
obesity that included combinations of traditional risk factors (i.e. history of obesity, parental Functional Foods in Health and Disease: 9:310-378                                                                         Page 332 of 378 
 
 
obesity, a body mass index > 40) and novelty elevations on the Karolinska Scales of Personality. 
There was a significant increase in the frequency of the D4DR long alleles in individuals defined 
as high risktaking using the combination of novelty –seeking – related personality traits, severe 
obesity ( i.e. BMI > 40), and any other traditional risk factor, but not with the traditional risk 
factors alone. These preliminary data suggest a potential role for the DR4D gene in increasing 
obesity susceptibility [142]. 
 
What  is  the  neuronal  inter-relationship  between  glucose  and  dopamine  release 
mechanisms: Are there close ties? 
To  understand  the  important  relationship  between  dopamine  and  glucose,  it  is  of  utmost 
importance to realize that in the meso-limbisc system the glucose receptor is in close proximity 
with the enkephalinergic neurons. There are also other important connections in the substania 
nigra (SN), tuberoinfundibular neurons, globus pallidus, and other important brain regions.  
  It  is  well  known  that  glucose  modulates  SN  dopamine  neuronal  activity  and  GABA 
terminal transmitter release by the actions of an ATP-sensitive potassium channel. In a study by 
Levin et al. the effect, on striatal dopamine release, of altering SN glucose levels was assessed by 
placing microdialysis probes into both the SN and striatum of male rats. During 50 mM glucose 
infusion,  striatal  DA  efflux  increased  transiently  by  50%  and  returned  to  baseline  after  60 
minutes. Moreover, efflux increased by a further 30% when GABA (A) antagonist bicuculline 
was added. Furthermore, at basal glucose levels, nigral bicuculline alone raised striatal dopamine 
efflux by 31% suggesting the well-known tonic GABA inhibitory input to the DA neurons. Thus 
striatal dopamine release is affected by changing SN glucose levels. According to Levin and 
associates, this response may reflect the known effect of glucose on K(ATP) channel activity on 
both SN Dopamine  neurons and GABA axon terminals in the SN. These interactions could 
provide a mechanism whereby glucose modulates motor activity involved in food intake [143]. 
  Koshimura  et  al.  found  that  long  –term  incubation  with  high  concentration  of  glucose 
increased the capacity of calcium uptake to enhance depolarization-induced dopamine release 
from Pheochromocytoma –12 cells. These data taken together suggest that a high concentration 
of glucose induced activation of the calcium channel to stimulate dopamine release from P12 
cells [144].  
  Bello  et  al.  found  that  restricted  feeding  with  scheduled  sucrose  access  results  in  an 
upregulation of the rat dopamine transporter in the n. accumbens and ventral tegmental area of 
the brain [145]. Moreover, Lee et al. (1998) found that dopamine can activate B3 adrenoreceptors 
to lower glucose uptake into rat white adipocytes which lack dopaminergic receptors [146]. It is 
of interest that intrastriatal injection of D1 and D2 dopamine agonists affects glucose utilization in 
both the direct and indirect pathways of the rat basal ganglia [147]. Moreover, dopamine receptor 
antagonism can influence fat intake in rats dependent upon dosage and time after treatment. In 
this regard, both D1and D2 receptor co-activation significantly reduced body weight, body fat, 
food consumption and serim concentrations of glucose, triglycerides, free fatty acid and insulin 
while increasing protein mass [99]. Furthermore, studies on blood glucose found blood glucose 
concentrations  to  be  significantly  correlated  with  cerebrospinal  fluid  concentrations  if  the 
dopamine metabolite, homovanillic acid [148]. Functional Foods in Health and Disease: 9:310-378                                                                         Page 333 of 378 
 
 
  With regard to the concept that within the RDS concept genetic commonality exist between 
a number of dopaminergic activating substances such as alcohol and opiates and possibly even 
glucose, evidence now exists that intermittent, excessive sugar intake causes endogenous opioid 
dependence.  In  rats,  repeated,  excessive  intake  of  sugar  created  a  state  in  which  an  opioid 
antagonist  caused  behavioral  and  neurochemical  signs  of  opioid  withdrawal.  The  indices  of 
anxiety  and  DA/Ach  imbalance  were  qualitatively  similar  to  withdrawal  from  morphine  or 
nicotine, suggesting that rats have become sugar-dependent [149]. In terms of understanding the 
brain reward cascade, there is evidence that serotonergic activation may also influence dopamine 
D2 receptor function. This is important when we consider the so called “sweet tooth” which has 
been associated with serotonin predominantly. Therefore the work by Kogan et al. confirms that 
the  drug  DR4004,  a  putative  5-HT7  receptor  antagonist,  also  has  functional  activity  at  the 
dopamine D2 receptor [150]. It is of interest that neuroanatomical data suggest a potentially 
interactive role between accumbens acetylcholine and dopamine. There is evidence that nucleous 
accumbens.  Acetylcholine  is  apparently  related  to  neural  processes  underlying  not  only 
psychostimulant  reward  but  also  natural  consummatory  behavior  i.e.  feeding.  In  this  regard, 
Hajnal et al. found that accumbens cholinergic interneurons play a role in the regulation of body 
weight and metabolism. In this context both stress and the role of dopamine play an important 
part in the Ach response [151].               
  It  is  well  known  well  known  that  pharmacologic  doses  of  the  glucose  analogue,  2-
deoxyglucose (2DG) cause acute glucoprivation and are associated with enhanced dopamine 
turnover in preclinical studies. In fact, lines of evidence indicate that a variety of metabolic 
stressors, including acute glucose deprivation are associated with dopamine release. Using PET 
Adler et al. found that 2DG administration enhanced synaptic dopamine concentrations [152]. 
The  administration  of  2DG  is  associated  with  significant  striatal  dopamine  release  even  in 
healthy volunteers. These data are important because it further closely ties glucose levels to 
dopaminergic  activity.  Moreover,  there  is  even  a  relationship  between  insulin  levels  and 
dopamine release in the tuberonfundibular neurons. The insulin effect is dependent on CA++ 
ions,  protein  kinase  C  Na  (+)  –  H  +  exchange  system.  Additionally  when  there  is  lowered 
glucose in the brain leading to cerebral global transient ischemia, monamine release especially 
dopamine is inhibited. In this regard, Trugman et al. showed D1 antagonists lowered glucose 
utilization  by  24-28%  in  the  globus  pallidus,  entopeduncular  nucleus,  subthalmic  nucleus, 
substania nigra, and even the motor cortex, suggesting that stimulation of the D1 receptor by 
endogenous dopamine contributes to basal metabolism in these regions [153]. In contrast both 
D1 and D2 agonists increase glucose utilization. These results suggest that feeding behavior is 
tied into the stimulation of both D1 and D2 receptors and provides metabolic evidence for the 
importance  of  D1  and  D2  functional  linkage  in  the  brain,  which  relates  to  hyperphagia  or 
overeating.   
  The direct effect of dopamine on glucose release from primary cultured rat hepatocytes 
were studied in Japan by Shiroyama et al. [154]. In this regard, dopamine is known to induce 
hyperglycemia in both animals and man. The authors investigated whether dopamine has any 
direct effect on glucose release from hepatocytes through the glcogenlytic and/or gluconeogenic 
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glucose release. The notion, increasing glucose release from tissue would reduce cravings for 
glucose  and  carbohydrates.  Glycogen  –rich  and  gluconeogenic  –depleted  hepatocytes  were 
prepared  in  order  to  study  glycogenolytic  and  gluconeogenic  –depleted  glucose  release, 
respectively.  Dopamine  caused  release  of  glucose  which  was  inhibited  by  the  beta  blocker 
propranolol. The authors conclude that dopamine has a direct effect on heptocytes, increasing 
glucose  release  via  both  glycogenolytic  and  gluconeogenic  pathways  and  mediated  by  beta 
adrenergic receptors.   
 
Other obesity genes  
Twin and family studies suggest that genetic factors potentially influence energy and nutrient 
intake. In this regard, the Heritage Group utilizing a genome-wide scan for dietary energy and 
nutrient intakes have determined that in whites, the strongest evidence of linkage appeared for 
dietary energy and nutrient intakes on chromosomes Ip21.2 and 20q14.1. The linkage evidence 
on  chromosomes  20  related  to  total  energy  intake  rather  than  to  the  intake  of  specific 
macronutrients.  In  blacks,  promising  linkages  for  macronutient  intakes  occurred  on 
chromosomes 12q23-q24.21, Oq32.1, and 7q11.1. Several potential candidate genes are encoded 
in and around the linkage regions on chromosomes Op21.2, 12q14.1 and 20q13.13 [155].  
 
Pharmacologic  mechanisms of the drug Meridia: Comparison to proposed KB220 anti-
craving formula. 
Meridia is an approved FDA drug for “weight loss” and weight management. The major effect of 
this drug is an anti-craving action derived from its effect to inhibit the reuptake of serotonin 
(5HT), dopamine (DA) and norepinephrine (NE). This inhibition of neurotransmitter reuptake 
results in  an increase in the length of time 5HT, DA, and NE are available to act in the synaptic 
junction,  and  ultimately  in  an  amplification  of  the  neurotransmitter  effects  to  reduce  sugar 
/glucose cravings.  
  In its simplest form, the ingredients in the patented composition proposed for anti-craving 
effects mirrors the Meridia mechanism and should produce similar anti-craving effects. In this 
section we will point out the potential of the ingredients in the proposed formula, based on a 
large body of neurochemical evidence concerning precursor amino-acids; the role of chromium 
as a tryptophan enhancing substance; D-amino acid inhibition of enkephalinase; Rhodiola as a 
suspected inhibitor of catechol-O-methyl transferase (COMT) as well as Synephrine, a substance 
that can minic some of the effects of catecholamines. Thus it is anticipated that since the same 
three  neurotransmitters  affected  by  Meridia®  (sibutramine)  could  potentially  be  affected  by 
certain ingredients, it should produce similar effects. It could be hypothesized that by increasing 
precursor (i.e. phenylalanine, tyrosine, and chromium and or 5-hydroxytryptophane or any other 
neurotransmitter  enhancer  even  via  transport  blockers)  intake  and  inhibiting  enzymatic 
degradation  by  COMT,  greater  levels  of  5HT,  DA  would  be  available  at  the  synapse.  The 
availability of the synapse is also increased since the D-phenylalnine causes preferential release 
of dopamine via opioid peptide breakdown inhibition. Thus the sum total effect is very much like 
Meridia and the following information will assure the scientific potential of this novel natural 
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  Most  recently,  Balcioglu  and  Wurtman  measured  the  effects  of  sibutramine  given 
intravenously, on brain dopamine and serotonin flux intostriatal and hypothalamic dialysates of 
freely moving rats. While low doses of the drug had no effect, higher doses increased both 
serotonin  and  dopamine  concentrations  in  the  striatal  and  hypotalmic  brain  regions.  These 
findings further support the neurochemical effects of sibutramine, and suggest that the drug’s 
anti-obesity action may result from changes it produces in brain dopamine as well as serotonin 
metabolism [156]. The importance here is that it provides further support for the KB220 variant 
formula and both serotonergic and dopaminergic anti-obesity actions.    
 
There are known limitations which will be addressed: 
 
  Competition for uptake of precursors across the blood brain barrier 
 
While it is well known that the ability of phenylalanine, tyrosine and tryptophan to penetrate the 
blood brain barrier is mediated by a shared active transport system, it is also well known that the 
use of Chromium could significantly assist in enhancing or concentrating blood tryptophan into 
the brain  by its  effect  on insulin  release and subsequent  enhance  glucose utulization  due to 
increase  glucose  receptor  sensitivity  [61].  In  addition,    glucose  has  the  concurent  effect  of 
increasing muscle absorption of large amino acids like leucine, valine and isomeric forms, into 
muscle (see below). This all works in concert to help tryptophan cross into the brain and there 
increase serotonin synthesis. This is the exact reason for the inclusion of chromium at a dose of 
1000 mcg’s rather than the usual lower dosage of between 200-400mcgs. Moreover, even if this 
was  not  effective  to  increase  the  synthesis  of  serotonin,  with  the  formula  it  could  bypass 
serotonin and work through its enkephalinase activity of D-phenylalanine. This would cause 
dopamine release via its inhibition of SN GABA. In Earlier work by Wurtman’s group, they 
showed that by reducing blood glucose the brain will concentrate up to 33% more blood borne 
tryptophan  [157].  Furthermore,  it  is  well  known  that  if  you  reduce  typtophan  levels  in  the 
hypothalamus  you  will  reduce  brain  serotonin  levels  and  its  neuronal  release.  Conversely, 
elevating  tissue  tryptophan  levels  (accomplished  by  adding  natural  5-hydroxytryptophan  or 
chromium) could increase both serotonin levels and serotonin release. According to Schaechter 
and Wurtman, these observations demonstrate for the first time that both precursor –dependent 
elevations and reductions in brain serotonin levels produce proportionate changes in serotonin 
release, and the magnitude of the tryptophan effect is unrelated to neuronal firing frequency, 
suggesting the importance of precursor administration to increase serotonin levels. In essence, 
the data support the hypothesis that serotonin release is proportionate to intracellular serotonin 
levels [157]. 
 
   Nutrient –Dependent Control Of Brain Catecholamine Synthesis & Release  
 
While brain serotonin synthesis is affected by availability of tryptophan or 5-hydroxytryptophan 
under  control  conditions,  precursor  dependency  of  catecholamine  synthesis  in  the  brain  is 
coupled  to  the  firing  rate  of  the  tyrosine  hydroxylase  containing  neuron.  It  has  been Functional Foods in Health and Disease: 9:310-378                                                                         Page 336 of 378 
 
 
demonstrated in a number of studies that a supplementation of l-tyrosine does not augment the 
synthesis of catecholamines under resting non-stressed condition, while an enhanced neuronal 
activity will increase the synthesis and release of catecholamines, especially dopamine following 
tyrosine application. Of these physiological stress is the most important, in terms of enhancing 
neuronal  activity.  In  essence  stress  is  mandatory  for  l-tyrosne  administration  to  affect 
catecholamine synthesis. While it is well known research has demonstrated that catecholamines 
such as norepinephrine and dopamine can act as feedback inhibitors of tyrosine hydroxylase, the 
enzyme  that  converts  tyrosine  into  the  immediate  precursor  for  dopamine  or  norepinephrine 
under physiological stress this mechanism is obliterated [158]. The reason for this is that the 
mechanisms  that  couple  catecholaminergic  neuron’s  firing  frequency  to  its  precursor 
responsiveness involve the phosphorylation of the tyrosine hydroxylase enzyme portion [159]. 
This enzyme’s affinity for its cofactor is thereby enhanced and it becomes independent of end - 
product inhibition, yet dependent on the availability of its precursor substrate. In essence under 
stress  l-tyrosine  supplementation  becomes  similar  to  the  l-tryptophan  (5-hydroxytryptophan) 
type of precursor responsiveness.  Moreover, it is important to realize that this enzyme activation 
occurs under enhanced neuronal activity and is calcium – and calmodulin dependent. In addition, 
the phosphorylation of tyrosine hydroxylase can be catalyzed by several protein kinases that 
selectively act on different amino acids of the enzyme protein. The protein kinase enhances the 
enzyme  activity  without  affecting  end-product  inhibition  or  the  affinity  to  tyrosine  or  the 
tetrahydrobiopterin cofactor. In addition, it is well known that a different, cAMP –dependent 
protein kinase can also phosphorylate tyrosine hydroxylae, enhancing the affinity to the cofactor 
(but not to tyrosine) and reducing the regulation by end –product inhibition. In summary, these 
changes allow the enzyme activity to become dependent on the extent to which it is saturated 
with its substrate l-tyrosine. 
 
Stress & obesity 
 The  effect  of  excessive  stress  in  modern  life  can  lead  to  chronic  states  of  fatique  –related 
depression. This is an unfortunate fact yet true that about 80% of all illness can be traced back to 
stress and depression. According to the American Academy of Family Physicians, these factors 
account for about 2/3 of all office visits. 
  The importance here is to understand that it is our position that indeed an obese individual 
or  a  carbohydrate  binger  is  definitely  subject  to  a  stressful  condition  and  therefore  there  is 
increased  neuronal  firing.  There  are  numerous  examples  in  the  literature  to  support  this 
contention. Furthermore, if an obese individual has the DRD2A1 variant, numerous studies have 
shown that resultant low dopamine D2 receptors caused an inability to cope with stress in the 
family and as an individual [160, 131,132].  In this regard, it is known that stress could even 
reduce D2 receptor mRNA message in the substania nigra, the lateral part of the VTA, basal 
ganglia especially in the “reward site” the nucleus accumbens [161].This  work supports  the 
concept that forebrain dopamine systems are involved in mediating the behavioral effects of 
chronic mild stress. It further supports the view that in obese subjects, with chronic mild to 
moderate stress, a compromised number of D2 receptor sites and reduced mRNA message, the 
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tyrosine supplementation as proposed in the formula. Moreover, it is also known that neuronal 
depletion of dopamine could also induce an independent end-product inhibitory state for TOH, 
which will also respond to l-tyrosine supplementation. With a slow release formula, there is 
constant  dopamine  release  because  of  the  effect  of  enhanced  opioidergic  activity  via  D-
phenylalanine on substania nigra GABA neurons.             
       
Treatment: Role of nutrients and pharmacogenomics in obesity and overeating  
In the eating game we must first appreciate the importance of brain neurochemistry and how 
certain nutrients such as amino-acids could effect brain neurotransmitter status and how this 
could  effect  macro-selection.  In  this  regard  we  must  be  cognizant  of  how  a  nutritionally 
unbalanced diet may lead to neurochemical processes that now induce the intake and aberrant 
craving  for,  high  carbohydrate  meals.  The  intake  of  macro  –  and  micronutrients  leads  to 
characteristic changes in the serum concentration of amino –acids, in particular large neutral 
amino acids. The consensus of the literature suggests that changes in the concentration of large 
neutral amino acids lead to parallel changes in their brain concentration that, in turn, specifically 
influence the synthesis of their respective neurotransmitters. 
  While  the  functional  impact  of  these  neurotransmitters  differs  markedly,  the  basic 
metabolic processes are comparable. Most of these substances are metabolized within nerve cells 
from their precursor molecules that have been taken up from the extracellular brain fluid. They 
are stored in intraneuronal vesicles and are released following a depolarization of the neuron. 
They  interact  with  either  pre-or  postsynaptic  receptors  within  the  synaptic  cleft  and  are 
inactivated either through enzymatic degradation or through neuronal uptake.  Central nervous 
system functions clearly depend on those mechanisms that guarantee the stability of precursor 
amino acid concentration. It also follows that a marked reduction in the concentration of these 
amino acids impairs physiological functions that are regulated and /or modulated by a respective 
neurotransmitter. The regulation of the synthesis of metabolic products from large neutral amino 
acids appears to be specific for neurotransmitters such as monamines. It is noteworthy that a 
similar impact on the synthesis of neurohormones (i.e opioid peptides) does not exist, since 
ribosomal protein synthesis does not depend on the fluctuation of amino acid concentrations. It 
may thus be speculated that a coupling of nutrient intake (amino-acid precursors), transmitter 
synthesis, and neuronal function reflects a phylogenetically relevant process. 
  When we consider that there are shared genes and RDS is an encompassing term which 
includes a number of impulsive, compulsive and addictive behaviors, we should not be surprised 
of the vast numbers involved in RDS. We know that at least one-third of the US alone carries the 
DRD2 A1 variant. This has been linked to multiple addictions including carbohydrate bingeing 
and other drugs of abuse (i.e. alcohol, cocaine, nicotine) and its presence at birth predicts future 
problems with food, drugs and certain destructive behaviors at the predictive value of 74% [43].     
  In  the  United  States  alone  there  are  60  million  persons  who  are  at  least  20  percent 
overweight, 18 million alcoholics, 28 million children of alcoholics, six to ten million cocaine 
addicts, 14.9 million who abuse other substances, 25 million people addicted to nicotine, 3.5 
milion school age children with attention-deficit disorder or Tourette Syndrome and about a half 
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neurochemistry will ultimately lead us to a better modality that is potentially without side –
effects.   
  While we believe natural nutritional therapy could offer an important approach to prevent 
as well as treat reward deficit problems, especially as it relates to obesity, there is reason to 
believe a pharmacological approach can not be ignored. In an attempt to show the power of a 
new emerging field of “Pharmacogenomics" we provide the following example.  
  It is tempting to speculate that the pharmacological sensitivity of overeaters to dopaminer-
gic agonists (bromocriptine, bupropion, n-propylnor-apomorphine, phentermine, and dopamine) 
may be determined partly by the individuals D2 genotype. We predict that A1 carriers should be 
more responsive to D2 agonists (including naturaly released dopamine), especially in stimulant-
dependent people. At least one study already has shown that direct microinjection of the D2 
agonist n-propylnor-apomorphine into the rat nucleus accumbens significantly suppresses the 
animals symptoms after withdrawal of opiates  [162]. A double-blind study demonstrates the 
utility of this approach in human subjects [15]. The D2 agonist bromocriptine or a placebo was 
administered to alcoholics who were carriers of the A1 allele (A1/A1 and A1/A2 genotypes) or 
who carried only the A2 allele (A2/A2). The greatest improvement in the reduction of craving and 
anxiety was found among the A1 carriers who were treated with bromocriptine. The attrition rate 
(relapse) was highest among the A1 carriers who were treated with the placebo. It is noteworthy, 
that as expected, dopamine receptor occupancy by a dopamine agonist or by dopamine itself, 
initiates a feedback system that produces more dopamine receptors even in A1 carriers (low 
dopamine receptors) after a period of time. This is supported by the fact that the greatest effect 
occurred after a period of six weeks. In support of this, since 1993, Molinoff and associates using 
transfected  kidney  cells  consistently  showed  that  occupancy  of  D2  receptors  by  dopamine 
agonists over time results in proliferation of dopamine D2 receptors [163, 164]. 
  Similar  evidence  for  the  role  of  genes  in  physiological  response  even  with  nutritional 
supplements has been accomplished with chromium picolinate by Blum et al. [165]. While there 
still is controversy regarding the effects of chromium salts (picolinate and nicotinate) on body 
composition  and  fat  loss  in  general,  recent  unpublished  work  seems  to  support  the  positive 
change in body composition in humans (see Table 2). In consideration of the above study, Chen 
and Blum and others decided to genotype 130 overweight subjects for the dopamine D2 receptor 
gene [166]. The subjects were assessed for scale weight and for percent body fat using dual 
energy X-ray absorptionmetry (DEXA 
R). The subjects were divided into matched placebo and 
chromium picolinate groups (400 μg. per day). The sample was separated into two independent 
groups; those with either an A1/A1 or A1/A2 allele and those with only the A2/A2 pattern. In the 
A2/A2 carriers, the measures of change in fat weight, change in body weight, the percent change 
in weight, and the body weight change in kilograms were all significant, whereas no significance 
was found for any parameter for those subjects possessing a dopamine D2 receptor A1 allele. 
These  results  suggest  the  dopaminergic  system,  specifically  the  density  of  the  D2  receptors, 
confers a significant differential therapeutic effect of chromium picolinate in terms of improved 
body mass and change in body fat. Moreover, we propose for the first time that mixed effects 
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typing  the  patient  via  dopamine  D2  receptor  genotyping  prior  to  treatment  with  not  only 
chromium salts, but with other nutritional supplements as well. 
 
Brain nutrition and behavior 
A detailed account of this subject is treated in the books Alcohol and the Addictive Brain [34], 
and To Binge or Not to Binge? [23]. In short, if genetic anomalies result in neurotransmitter 
imbalance, then how could we help to restore balance? 
  At the functional level, it seems clear that neurotransmitter imbalance may be a problem of 
brain nutrition: more specifically, a deficiency or excess of amino acids. In the healthy body, 
amino acids are in balance; if there is an excess or shortage, distortions of brain function can 
result [167]. 
  As we know the brain cannot synthesize all of the amino acids involved in the formation of 
neurotransmitters; some are derived from food metabolism, and come to the brain via the blood 
supply.  There  are  two  categories  of  amino  acids:  essential  and  nonessential.  There  are  five 
essential amino acids necessary for the manufacture of neurotransmitters, thought to play a role 
in  obesity:  methionine,  leucine,  phenylalanine,  tyrosine,  and  trytophan  (see  above  for  more 
detail). Among the nonessential amino acids  manufactured in  the body, Glutamine probably 
plays a significant role, because it is involved in the manufacture of GABA. Two forms of amino 
acids are found in nature. The amino acids in the brain that make up the neurotransmitters, and 
the  enzymes  that  regulate  them,  are  all  derived  from  the  L-form.  The  D-form  (as  in  D-
phenylalanine) is found in a few microorganisms and in multi-cellular organisms like frog skin. 
 
Single Versus Multiple Amino acid Neuronutrients  
  First,  although  a  single  amino  acid  may  be  involved  in  the  formation  of  a  given 
neurotransmitter, it does not act alone. It needs the help of co-factors such as vitamins and 
minerals before the formation can take place. For example, vitamin B6 (in the alcoholic, 
pyridoxal –5-phosphae form is required) is needed for the manufacture of dopamine.  
  Second, obesity is the result of a complex disorder that involves processes taking place in 
the neuron, at the synapse, and at receptors. 
  Third, we cannot determine (until we use DNA tests) the specific defect that is producing a 
particular part of the problem. Therefore, in the effort to offset neurotransmitter deficits, it is 
not feasible to depend on single amino acids. This is why we include both serotonergic and 
dopaminergic precursors. 
  Fourth, an odd characteristic of the blood/brain barrier actually makes treatment easier. 
Most overweight individuals have compounded stress and may have comorbid addictions 
like  alcohol,  smoking,  and  other  drugs;  it  is  known  that  all  of  these  weaken  the  barrier 
facilitating the passage of restorative substances such as amino acids into the brain. This is 
particular important when you consider large neutral amino carrier system and competition of 
tryptophan,  phenylalanine  and  tyrosine.  It  is  equally  important  when  you  consider,  as 
mentioned  earlier,  that  the  rate-limiting  enzyme  Tyrosine  Hydroxylase  works  best  under 
stressful conditions and the precursor tyrosine will indeed be converted to dopamine and will 
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  Fifth, it is well known that the degradation of catecholamines by COMT plays a role, albeit 
only  partial,  in  clearing  these  neurotransmitters  from  synaptic  cleft.  Dopamine, 
norepinephrine  and  serotonin  reuptake  into  nerve  terminals  via  membrane  transporter  is 
thought to play a more significant role [158].  
      However, it is our position that any enhancement of the neurotransmitters in the synapse 
is positive. In this regard, the effects of synephrine on norepinephrine receptors [168] plus 
the  central  nervous  system  effects  of  Rhodiola  rosea  [169,  170]  could  contribute  to  a 
sibutramine/D-fenfluromine–like effect. The amount of Rhodiola rosea recommended in the 
prposed formula herein  is 240 mg per day (based on a 3% extract standardized to rosavin) 
which is  somewhat higher than the recommended dose  for use of  Rhodiola rosea  as  an 
antidepressant (200mg/day, [171], see below). Moreover, the proposed formula may also 
contain synephrine, derived from citrus aurantium (6% synephrine) at a daily dose of 50mg. 
This amounts to only 6 mg per day. While this is less than normal recommended dose as s 
sympathiomimetic agent, when it is combined with caffeine thermogenesis could be achieved 
without the stimulatory effects seen with much higher doses (104mg/day).  
 
Studies  showing  anti-craving  efficacy  of  precursor  amino-acids  and  Enkephalinase 
inhibitor activity  
  It is our contention that with the  proposed formula as designed for anti-craving, synergistic 
outcomes for other comorbid addictions might be observed since the ingredients are included 
that could act through several different mechanisms ( see above) to enhance the activity of 
the neurotransmitters. 
  In  a  number  of  experiments  we  have  shown  brain  changes  of  enkephalins  using  D-
phenylalanine  (500mg/kg/day  for  18  days)  and  or  its  metabolite  hydrocinnamic  acid 
(intracerebral ventricular injection of 25 micrograms) in mice [88]. Using the same doses 
these  known  enkephalinase  inhibitors  significantly  reduced  alcohol  preference  in  both 
acceptance and 14 day preference test [17].  
   We have shown in healthy volunteers electrophysiological changes (enhanced memory and 
focus) with the combination of DL-phenylalanine (1500mg/day), L-tyrosine (900mg/day), L-
glutamine (300mg/day), chromium picolinate (360 micrograms /day) and other co-factors 
[117]. 
   Positive effects in alcoholics in an in-patient hospital including lower building up to drink 
scores, required no PRN benzodiazepines (0% vs. 94%), ceased tremoring at 72 hours, had 
no severe depression on the MMPI, in contrast to 245 of control group. The ingredients 
included  Dl-phenylalanine  (2760mg/kg/day),  L-tryptophan  (150mg/day),  L-glutamine 
(150mg/day), and pyridoxal -5-phosphate (30mg/day) [110]. 
   in a double –blind placebo controlled study of polysubstance abusers in an in  -patient 
hospital, the combination of Dl-phenylalanine ( 2760mg/day), L-tryptophan (150mg/day) , L-
glutamine  (150mg/day),  and  pyridoxal-5  –phosphate  (30mg/day),  significantly  reduced 
stress,  improved  physical    and  emotional  scores,  a  six  –fold  reduction  in  AMA  rates, 
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   Utilizing  DL-phenylalanine  (1500mg/day),  L-tyrosine  (900mg/day),  L-glutamine 
(300mg/day), L –tryptophan (400mg/day) and pyridoxal –phosphate (20mg/day)  in inpatient 
treatment of cocaine abusers over a 30 day period compared to controls significantly reduced 
drug hunger and withdrawal against advice rate (AMA), reduced need for benzodiazepines, 
and  facilitated retention in the treatment program [172]. 
   In an outpatient clinic DUI offenders (alcoholics and/or cocaine addicts) were treated with 
a  combination  of  dl-phenylalanine,  L-tyrosine,  L-glutamine,  Chromium,  pyidoxyl-5-
phosphate over a ten-month period. Compared to a vitamin control (only B-complex and 
vitamin c), the experimental group significantly reduced relapse rates and enhanced recovery 
in these DUI outpatient offenders. The retention rates obtained for alcoholics was 87% for 
the experimental group compared to only 47% of the control patients and for cocaine abusers 
the numbers are 80% vs. only 13% [108] . For alcoholics: DL-phenylalanine (2760mg/day), 
L-Glutamine  (150mg/day),  chromium  picolinate  (360  micrograms/day),  pyridoxal  –5-
phosphate; For cocaine abusers: DL-phenylalanine ( 1500mg/day), L-Tyrosine ( 900mg/day), 
L-glutamine ( 300mg/day), pyridoxal –5-phosphate (20mg/day).  
   Utilizing amino acid and enkephalinase inhibitory therapy, J.A. Cold found significant 
improvement  in  both  cocaine  craving  and  withdrawal  symptoms  in  out  patient  cocaine 
addicts  [114].  The  ingredients  included  DL-phenylalanine  (1500mg/day),  L-Tyrosine 
(900mg/day), L-glutamine (300mg/day), and pyridoxal–5-phosphate (20mg/day).  
  With only chromium picolinate it was  found in two double  – blind placebo controlled 
studies  that  doses  of  either  200  mcg  or  400  mcg  resulted  in  a  body  composition 
improvement, loss of body fat, gain in nonfat mass [115,116]; 
  With  DL-phenylalanine  (2700mg/day),  L-tryptophan  (150mg/day),  L-glutamine 
(150mg/day) and pyridoxal –5 phosphate (30mg/day) it was also found that 27 outpatients 
with high carbohydrate bingeing behavior where females were assigned 800 calories total 
intake per day and males were assigned 1,000 to 1,200 calories per day and  all withdrew 
from sugar use attending a supervised diet- controlled treatment program, the supplement  
group  over a 90 day period lost an average of 26.96 pounds compared to the control group ( 
no supplement) lost only 10 pounds. In fact, only 18.2 % of the experimental group relapsed 
(lost less than 15 pounds over the 90 day period)  compared to 80.% in the control group 
[112]; 
   In  another  study  where  the  supplement  contained  dl-phenylalanine  (2760mg/day),  L-
tryptophan  (150mg/day),  L-glutamine  (150mg/day),  pyridoxal  –5  phosphate  (30mg/day), 
chromium Picolinate (200 micrograms/day), and carnitine (60mg/day) over a 2-year period in 
247 obese  patients  the following results were obtained in a dual blind non-randomized open 
trial  utilizing  Centrum  vitamin  as  a  control.  Compared  with  the  Non-Phencal  /  Centrum 
group  the  experimental  Phencal/Centrum  group  showed  a  two-fold  decrease  in  percent 
overweight for both males and females; a 70 % decrease in food cravings for females and a 
63% decrease for males; and a 66% decrease in binge eating for females and a 41 % decrease 
for males. Most importantly, the experimental group regained only 14.7% of the lost weight, 
and multiple regression modeling revealed that with Phencal treatment, morbid obesity and 
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history  of  chemical  dependence  was  most  closely  associated,  although  not  statistically 
significant, with improved results with Phencal [116]. 
  Blum  decided  to  test  the  hypothesis  that  possibly  that,  the  combination  of  a  narcotic 
antagonist  and  amino  acid  therapy  consisting  of  an  enkephalinase  inhibitor  (D-
Phenylalanine)  and  neurotransmitter  precursors  (L-amino  –acids)  to  promote  neuronal 
dopamine release, might enhance compliance in methadone patients rapidly detoxified with 
the narcotic antagonist Trexan®. In this regard, Thanos et al. and associates found increases 
in the dopamine D2 receptors (DRD2 ) via adenoviral vector delivery of the DRD2 gene into 
the nucleus accumbens, significantly  reduced both  ethanol preference  (43%) and alcohol 
intake (64%) of ethanol preferring rats, which recovered as the DRD2, returned to baseline 
levels [21]. This DRD2 overexpression similarly produced significant reductions in ethanol 
non-preferring rats, in both alcohol preference (16%) and alcohol intake (75%). This work 
further suggests that high levels of DRD2 may be protective against alcohol abuse [24, 173]. 
The DRD2 A1 allele has also been shown to associate with heroin addicts in a number of 
studies. In addition, other dopaminergic receptor gene polymorphisms have also associated 
with opioid dependence.  For example, Kotler et al. showed that the 7 repeat allele of the 
DRD4 receptor is significantly overpresented in the opioid dependent cohort and confers a 
relative risk of 2.46 [174]. This has been confirmed by Li et al. for both the 5 and 7 repeat 
alleles in Han Chinese case control sample of heroin addicts [175]. Similarly Duaux et al. 
found  a  significant  association  with  homozygotes  alleles  of  the  DRD3-Bal  1  in  French 
Heroin addicts [176]. A study from NIAAA, provided evidence which strongly suggests that 
DRD2  is  a  susceptibility  gene  for  substance  abusers  across  multiple  populations  [177].  
Moreover, there are a number of studies utilizing amino –acid and enkephalinase inhibition 
therapy showing reduction of alcohol, opiate, cocaine and sugar craving behavior in human 
trials.  Over the last  decade, a new rapid  method to  detoxify either methadone or heroin 
addicts utilizing Trexan
R sparked interest in many treatment centers throughout the United 
States, Canada, as well as many countries on a worldwide basis. In using the combination of 
Trexan
R  and  amino-acids,  results  were  dramatic  in  terms  of  significantly  enhancing 
compliance  to  continue  taking  Trexan®.  The  average  number  of  days  of  compliance 
calculated  on  1,000  patients,  without  amino-acid  therapy,  using  this  rapid  detoxification 
method is only 37 days. In contrast, the 12 subjects tested, receiving both the Trexan® and 
amino-acid therapy was relapse-free or reported taking the combination for an average of 262 
days  (P<0.0001).  Thus  coupling  amino-acid  therapy  and  enkephalinase  inhibition  while 
blocking the delta receptors with a pure narcotic antagonist may be quite promising as a 
novel  method  to  induce  rapid  detox  in  chronic  methadone  patients.  This  may  also  have 
important ramifications in the treatment of both opiate and alcohol dependent individuals, 
especially  as  a  relapse  prevention  tool.  .It  may  also  be  interesting  too  further  test  this 
hypothesis  with  the  sublingual  combination  of  the  partial  opiate  mu  receptor  agonist 
buprenorphrine.  The  ingredients  tested  included  DL-phenylalanine  (2760mg/day),  L-
Glutamine  (150mg/day),  chromium  picolinate  (360  micrograms/day),  pyridoxal  –5-
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  Most recently a study was performed by Julia Ross best selling author of The Diet Cure 
[178], in an outpatient clinic in Mill Valley, California involving amino-acid therapy and 
enkephalinase inhibition based on Blum’s work. At Recovery Systems, Ross has successfully 
utilized this approach to treat a number of RDS behaviors, especially eating disorders. In a 
preliminary evaluation, utilizing the following ingredients tailored made for each client, dl-
phenylalaine, 5-hydroxytryptophan, l-tryptophan, l-tyrosine, l-glutamine, chromium , vitamin 
B6, follow –up interviews  of six randomly selected former eating disordered female clients ( 
three were also chemically dependent), were contracted nine months to three years post – 
treatment  to  evaluate  efficacy  of  combining  targeted  nutritional  elements  (amino-acids, 
vitamins, digestive enzymes, a diet low in  refined carbohydrates but adequate in calories and 
other  nutrients)  with  conventional  counseling,  education,  and  peer  support.  Follow-up 
confirmed significant initial benefits in mood and freedom from compulsive behavior and 
ideation in 100% tested. While one subject relapsed within six months, the remaining five 
subjects all sustained, and in some cases exceeded expectations. Following this preliminary 
evaluation, we also evaluated an additional 100 patients and the data collected revealed 98% 
significant improvement in both mood and reduced craving for not only carbohydrates but 
other abusable substances as well. According to Ross this work further suggests the positive 
potential  of  adding  targeted  nutritional  protocols  to  conventional  treatment  elements  to 
improve outcome in an RDS intransigent population [179]. 
  The following results from a study in Las Vegas at an outpatient clinic has been evaluated 
and presented herein. Relapse rates: Clark County District:-Out of 15 patients only 2 patients 
dropped out, while the other 13 patients remained in the program for 12 months. Therefore, 
the percent relapse for this group is 13.33; County Court(Las Vegas) – Out of 43 patients 11 
patients dropped out, while the other 32 patients remained in the program for 12 months. 
Therefore,  the  percent  relapse  for  this  group  is  23.2.;  Federal  Court  Sustem-  Out  of  10 
patients  only  2  dropped  out,  while  the  other  8  patients  remained  in  the  program  for  12 
months. Therefore, the percent relapse for this group is 20.0.; Self Referral- Out of 8 patients 
none dropped out, thus 8 patients remained in the program for 12 months. Therefore, the 
percent relapse for this group is 0.0. If we calculate the percent relapse of the entire program 
which included a total of 76 patients with a total of 15 patients that dropped out it is a 
remarkable  19.9  %  relapse.  The  majority  of  drop  outs  (11  out  of  15  or  73.3  %)  were 
methamphetamine  abusers.-the  ingredients  include  DL-phenylalanine  (  2700mg/day),  5  –
hydroxytryptophane  (20mg/day),  L-Tyrosine  (  750mg/day),  L-glutamine  (350mg/day), 
Rhodiola  rosea  (  3%  rosavin)  (66mg/day),  Chromium  dinicotinate  glycerate  1000 
micrograms/day), DMAE (40mg/day), Hiperzine A ( 150 micrograms/day). Combination of 
vitamins (C, E, Niacin, Riboflavin, Thiamin, B6 [20% Pyridoxal  –5 phosphate and 80% 
Pyridoxine],  folic  acid,  B12,  Biotin,  Pantothenic  acid,  Calcium,  Magnesium,  Zinc, 
Manganese  and  a  herbal  calming  blend,  focus  blend  or  mood  enhancing  blend.  The 
ingredients  and dosage  was  dependent  on type  of abusers  including diagnosis  of ADHD 
[180].  
We have categorized the various benefits observed by individuals according to the following:  
  Stress Reduction Functional Foods in Health and Disease: 9:310-378                                                                         Page 344 of 378 
 
 
  Enhancement of Sleep 
  Increased Energy Levels 
  Generalized Well –Being 
  Craving Behavior Reduction (sweets/carbs) 
  Mental Focus/Memory 
  Blood Sugar Levels 
  Food Consumption Reduction  
  Loss Of Inches 
  Loss Of Fat  
  Blood Pressure Reduction  
  Improvement of Workout Performance 
  Reduction of drug seeking behavior ( Alcohol, nicotine, cocaine, marijuana, opiates, etc)  
  Reduction of Hyperactivity  
  Reduction of Cholesterol 
 
Fortunately, if a broad menu of amino acids is available in sufficient quantity, the brain appears 
to have the ability to choose from the menu the one or ones needed to manufacture more of the 
neurotransmitter  that  is  deficient.  Based  on  consistent  positive  research  outcomes    and 
technology, the following nutrients are scientifically formulated and have been clinically tested 
for  over  25  years[34]  and  have  relevance  to  the  problem  defined  as  Reward  Deficiency 
Syndrome, more specifically-overeating and carbohydrate bingeing. However, the work to date 
supports a generalized anti-craving claim utilizing a number of important ingredients:.  
  D-Phenylalanine,  to  inhibit  enkephalinase,  the  enzyme  that  metabolizes  or  breakdown 
enkephalins,  thereby  increasing  the  availability  of  enkephalins  and,  presumably,  making 
more dopamine available at the reward sites especially under stressful conditions.  
  L-Phenylalanine, to stimulate the production of dopamine, and/ or increase norepinephrine 
levels in the reward area of the brain. The major problem with this amino acid is that it could 
compete with other amino-acids such as blood borne l- tryptophan and l-tyrosine at the large 
neutral amino –acid brain carrier system [159]. However, other data demonstrates for the first 
time that the synthesis and release responses to some dopaminergic agents may be elicited 
from  synaptosomal  dopamine  which  is  formed  by  the  hydroxylation  of  phenylalanine. 
Amphetamine  and  Cogentin  increased  the  release  of  dopamine  formed  from  14C  –
phenylalanine in rat caudate nucleus synaptosomal preparation and concomitantly stimulated 
the synthesis. Amfoelic acid also caused a net release of that dopamine. In conclusion, the 
results suggest that synaptosomal particles represent a unit capable of synthesizing dopamine 
from l-phenylalanine and that synthesis from this precursor may be under the regulatory 
control of the particles [181].   
  L-glutamine, to increase brain GABA levels at receptors associated with anxiety. Its major 
use is to maintain balance in case of over inhibition by D- phenylalanine.    
  L-5-hydroxytryptophan (or its natural form) – The effect of systemic administration of 
5-hydroxy-l-tryptophan on the release of serotonin in the lateral hypothalamus of the rat in 
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immediate increase of the 5-HT in dialysates, which was long lasting and dose dependent. 
When calcium was omitted from the perfusion medium, thereby limiting exocytosis, levels of 
basal 5-HT were significantly decreased and the 5-HTP– induced response of 5-HT was 
markedly attenuated [182].          
  Pyridoxal-5-phosphate, the active ingredient of vitamin B6 to serve as a co-factor in the 
production  of  neurotransmitters  and  to  enhance  the  gastrointestinal  absorption  of  amino 
acids. 
  Chromium  Salts  (Nicotinate  and  Picolinate),  have  a  number  of  metabolic  effects 
including : increase of insulin sensitivity; reduction of cholesterol; reduction of percent body 
fat;    net  reduction  of  weight;  maintaining  muscle  mass  promoting  lean;  enhancing  body 
composition; promotes brain serotonin  production ( see above) 
  Carnitine (optional ingredient), promotes fat metabolism [183].  
  Calcium, promotes neurotransmitter release based on many studies [182, 159].  
  Rhodiola rosea – Several clinical trials with double –blind placebo controls in Russia 
provide evidence that R. rosea possess positive mood enhancing and anti-stress properties 
with no detectable levels of toxicity.  Generally, R. rosea extract has been shown to have a 
positive influence on the higher nervous system, increasing attention span, memory, strength 
and mobility of the human body, and weight management. It is believed that R. rosea can act 
as  a  COMT  inhibitor  where  brain  levels  of  serotonin  and  dopamine  has  been  observed. 
Studies  by  Saratikov  and  Marina  suggest  that  R.  rosea  can  increase  the  level  of 
neurotransmitters by 30 percent and decrease COMT activity by 60 percent. In the weight 
management  area  there  are  double  –blind  studies  with  regard  to  “weight  loss”  and  fat 
mobilization and central nervous system effects [184-192]. Scientists explain that Rhodiola 
rosea  likely  affects  multiple  body  systems  to  promote  emotional  well-being,  physical 
endurance,  and  mental  sharpness.  Pharmacological  studies  in  vitro  and  in  vivo  have 
demonstrated that Rhodiola rosea stimulates neurotransmitter activity in the Central Nervous 
System  (CNS)  and  may  positively  influence  Serotonin,  Norepinephrine,  Dopamine  and 
Acetylcholine availability in neuropathways that regulate mood. Further laboratory analysis 
has  shown that  Rhodiola Rosea also  enhances  permeability  of the blood-brain  barrier to 
specific  neurotransmitter  precursors  of  Serotonin  and  Dopamine.  Although  the  exact 
mechanism of action is not yet fully understood, clinical and laboratory research indicate that 
Rhodiola rosea may help to promote a healthy neurotransmitter balance and provide positive 
support for a occasional nervousness, nervous tension, and anxiety as well as a depressed 
mood and mild to moderate mood changes caused by everyday stress.  
  Gymnea Syveste (Optional Ingredient) helps to reduce undesirable fat formation by its 
ability to reduce cravings for sweets and control blood sugar levels. A peptide isolated from 
Gymnema, gurmarin, has also been shown to block the sweet taste of glucose and sucrose in 
animals. Gurmarin temporarily binds the sweet and bitter receptors on the tongue, thereby 
blocking the taste sensation and reducing sweet cravings. It is very important to consider a 
recent  study  by  Preuss  et  al  regarding  the  efficacy  of  a  novel,  natural  extract  of  (-) 
hydroxycitric acid  and a combination of niacin-bound chromium and Gymnema sylvetre 
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subjects  for  eight  weeks  the  combination  compared  to  controls  resulted  in  reduction  of 
weight loss, and reduction in BMI.  Food intake was also reduced. The daily dosage of the 
HCA-SX  was  4,667  mg,  ChromeMate  provided  400mcg  of  elemental  chromium  ,  and 
Gymnema sylvetre was 400mg (providing 100mg gymnemic acid) [193]. 
  Passiflora incarnate or passionflower is a name that has been given to several members of 
the genus Passiflora. There are more than 40 species in the genus whose origins are in both 
the  tropical  and  subtropical  regions  of  the  western  hemisphere.  Passionflower  was  first 
brought to Europe from Mexico in the sixteenth century by Spanish conquerors. Its main 
medicinal purpose was that of a calming tea. It is now part of the medicinal herbarium in 
many  countries  throughout  the  world.  Passion  flower’s  long  history  in  herbal  medicine 
includes its use as a treatment for colic, diarrhea, dysentery, menstrual pain, skin eruptions, 
conjunctivitis, hemorrhoids, and myscle spasms. However, the inclusion in NAAT involves 
its central nervous system effects.It is well known that substances that alter meso-limbic 
function will ultimately influence metabolic X syndrome [194-197].  
     One of the problems with this subtropical plant is its identity. While there are a number of 
alkaloids which have been sold under the rubric of Passionflower, the most important and 
consistently effective candidate is Passiflora incarnata. The ethnobotanical database on the 
U.S. Agricultural Research Service’s Web site lists the total alkaloid content P. incarnata as 
100 to 900 ppm and the total flavinoid content as 1.2 –3.9 percent which ahs been further 
tested  by  others  [198].  Twenty  –six  components  fall  into  two  categories:  20  flavonoids 
(including a cyanogenic glycoside and gynocardine) and 6 alkaloids. Some researchers have 
ascribed the sedative effects of p. incarnata ip  indole alkaloids such as Harmane and its 
relatives; harmaline and harmol. However, others have suggested that P. incarnata’s alkaloid 
content is too small to cause this and other CNS effects and that flavonoids-such as apigenin, 
luteolin, or their glycosides-are more likely to account for CNS bioactivity. Most recently, 
scientists  have  isolated a  highly  anxiolytic,  trisubstituted  benzoflavone  moiety  from  a  P. 
incarnata extract. Reports from the literture reveal that this extract has the ability to restore 
libido on aging male rats [199], and those who are addicted to tetrahydrocannibinol [200] to 
restore fertility and libido that has been reduced by alcohol or nicotine use [201], and to 
reduce  the  anxiety  arising  from  alcohol  withdrawal  [202].  There  are  also  double  –blind 
randomized studies which suggest that Passiflora extract is as effective substance for the 
management of generalized anxiety disorder comparative to the drug Oxazepam [203]. There 
is even evidence that Passiflora in a double –blind randomized controlled trial may be an 
effect  adjuvant  in  the  management  of  opiate  withdrawal  of  opiates  [204].  In  addition 
Passoflora  reduced  benzodiazepone  dependence  in  mice  [201].  In  fact,  many 
pharmacological investigations confirm the sedative effects of Passoflora, especially in the P. 
incarnata form [205]. We have formulated NAAT with the knowledge afforded EuroMed 
(source of the fragmented or cut, dried aerial parts of P. incarnata). According to Dhawan et 
al. the separated leaves afford the best possible CNS results, and in fact, the selected of the 
entire aerial parts excluding the flowers may prove to be the optimum approach for pocking 
up the bioactive plant parts of P. incarnata. The importance of standardization of preparations 
of Passoflora has been actively studied especially as it relates to the anxiolytic activity [205].      Functional Foods in Health and Disease: 9:310-378                                                                         Page 347 of 378 
 
 
Why Passoflora in NAAT? 
     In the early 70’s one of us (KB) showed the importance of the brain neurotransmitter 
serotonin as a biological substrate of stress [206]. In fact, induction of stress in rodents was 
attenuated  by  injections  of  the  serotonin  chemical  synthesis  depleator  Para  –Chlora-
Phenylalanine (PCA). Others have also shown the involvement of serotonin and dopamine in 
stress production in both animals and humans. Moreover, work by Blum et. al. also showed 
that amino-acid and enkepkalinase inhibition therapy reduced stress in polysubstance abusers 
as measured in a double –blind –placebo randomized controlled trial in humans using skin 
conductance levels.  These studies  seem  to  dove tail  the work reported  on the anxiolytic 
effects of Passoflora. In fact it is very interesting that at least one phytoconstituent is indeed 
an indole similar to the chemical makeup of serotonin [109, 110].  
 
Combining  KB220  Variants  [NAAT]  with  Neuroadaptagens  and  Neuro-metabolic 
Optimizers 
There are at least four important factors that can effect weight gain; genetics, environment, diet 
composition and lifestlye and family society and culture. In this regard, an individual’s genetic 
code can determine basal metabolic rate, neurotransmitter function, regulatory peptide levels, 
and other variables that may put someone at greater risk of increased, excessive and aberrant fat 
storage. There is another even more important facet to the genetic tendency for aberrant fat 
storage than genes that control fat storage or metabolic rates. This is in the genes that control our 
desire  “to  binge  or  not  to  binge”.  These  are  the  “reward  genes’.  The  understanding  of 
neurochemistry, genetics, metabolic rates and energy expenditure, carbohydrate bingeing, body 
types, lipid anabolism and catabolism, caloric intakes and Syndrome X will provide the basis for 
polygenetic diagnosis and treatment of obesity [194-197].  
 
NAAT
is a unique, patented scientifically advanced product that provides a multi-nutritional 
approach  to  normal  brain  function.  We  are  proposing  herein  that  combining  Synaptose 
(KB220Z) an example of NAAT with other ingredients known to optimize metabolic function 
(SEP711CG) through neurophysiolgical processes will ultimately provide a clinically effective 
novel approach to obesity. 
 
Neurometablic Optimizer (SEP711CG) 
Based  on  consistent  positive  research  outcomes  and  technology,  the  following  nutrients  are 
scientifically formulated (following meticulous ingredient selections and dosage determinations), 
have been clinically tested, and have demonstrated profound efficacy at supporting optimal brain 
health; improving craving management; enhancing energy expenditure, neuroendocrine function, 
memory, focus, and cognition; immune competence; stress reduction; and body composition and 
weight management. 
  Synaptose™  –  A  patented  and  patent-pending  KB220/KB220Z  neuroadaptogen 
nutraceutical complex has 24 clinical studies (at the time of this writing) demonstrating 
its  ability  to  correct  gene  expression;  help  maintain  dopamine  in  the  normal  range, 
promote  optimal  brain  health,  regulate  cravings,  and  support  focus,  cognition,  and 
neurotransmitter  balance;  reduce  the  impact  of  stress;  enhance  energy  regulation, Functional Foods in Health and Disease: 9:310-378                                                                         Page 348 of 378 
 
 
neuroendocrine function, immune competence, and healthy mood; and support a leaner 
body composition and healthy weight management (see below for benefits).. 
  Cognitrim™-  Comprised  of  l-alpha-Acetyl-phosporylcholine  and  is  a  semi-synthetic 
derivative of Lecithin. 
  CurQFen™ – Superior to other curcumin products by up to 125 times, CurQFen is a 
fully  reacted  patent  pending  BR213  Curcuma  galactomannosides  compound  that 
promotes: cognition, healthy cardiac function, immune competence, and a healthy gut; 
reduces  the need to  activate inflammatory cytokines;  helps  maintain blood sugar and 
blood lipid levels within the normal range; and slows the absorption of carbohydrates, 
cholesterol, bile acids, and improves gastric emptying. 
  PhosphoLean™  NOPE2G2  is  a  patented,  advanced,  appetite  regulating  and  weight 
management compound that is clinically proven to help people control binge eating, and 
lower depressed feelings - all keys to successful, long-term weight loss. In a recent study, 
PhosphoLean™  increased  satiety,  decreased  depressive  symptoms,  decreased  binge 
eating  severity,  and  provided  favorable  changes  in  insulin  resistance  and  lipids.  The 
EGCG  polyphenols  in  PhosphoLean
™  NOPE2G2  act  synergistically  via  spathetic 
activation of thermogenesis and increased fat oxidation, thus enhancing the compound’s 
weight management effects. PhosphoLean also significantly improved diet compliance in 
a group of healthy, overweight or obese subjects, as demonstrated by reduced dropout 
rate. 
  SH1028 Choline alphoscerate – After consumption, SH1028 Choline alphoscerate is 
converted to the metabolically active form of choline able to reach cholinergic synaptic 
endings, thus increasing acetylcholine release. Metabolically active choline prevents fat 
deposits in the liver and facilitates the movement of fats into the cells. SH1028 promotes 
significant  improvement  in  cognition,  memory,  and  other  neuro-chemical  and  -
psychological cholinergic-dependent structures and functions, such as parasympathetic 
and  sympathetic  nervous  system  functions,  neuromuscular  junctions,  basal  forebrain 
function (considered to be the major cholinergic output of the central nervous system 
(CNS)), and important for healthy brain stem complexes.  
In addition, acute supplementation augments growth hormone response to, and peak force 
production during, resistance exercise.  
  GlucodOX™  is  a  proprietary  nutraceutical  ingredient  complex  comprised  of  a 
supercritical  Commiphora  mukul  extract  and  a  medium  chain  triglyceride  (MCT)  oil 
composed  of  C8  and  C10  fatty  acids.  GlucodOX™  contains  guggulsterones 
(standardized to 2.0% by HPLC analysis), which have been linked to several mechanisms 
that support lipid metabolism, glucose metabolism and cellular energy.  
GlucodOX™ is a unique blend whose properties are enhanced by MCTs, which can gain 
rapid access to the mitochondria (energy producing organelle in cells). Given their high 
energy density, rapid rate of absorption, and quick metabolic conversion into cellular 
energy, MCTs can be used for fueling physical exertion. 
 
SEP711C3G is designed to:  Functional Foods in Health and Disease: 9:310-378                                                                         Page 349 of 378 
 
 
1.  Improve the efficiency of energy metabolism and fat burning 
2.  Improve tolerance to stress (reduce the impact of stress on the body) 
3.  Promote learning, memory, cognition, healthy brain function, and longevity (anti-aging) 
4.  Support a happier mood 
5.  Promote healthy cravings  
6.  Reduce  the  time  needed  for  and  improve  the  quality  of  satiety  or  the  satisfaction  from 
pleasurable experiences (like eating) 
7.  Improve brain, nerve and glandular (neuro-endocrine) function  
8.  Promote competent immune function 
9.  Promote healthy blood sugar and blood lipid levels within the normal range 
10.  Promote healthy fat loss and weight management. 
 
 
Table  2  SEP711CG:  Proposed  new  set  of  important  ingredients  that  have  never  been 
combined into one anti-obesity product 
Ingredient*  Description  Benefits  Protection 
/patents 
References 
by  claim 
number 
CurQFen™  Novel result of 
curcuminoids 
fully reacted 
with 
galactomannan
s from 
Curcumin and 
Fenugreek. 
 
Provides 13 
times more 
absorption of 
powerful 
curcumninods 
than regular 
95%  
curcuminoid 
supplements. 
 
Delivers and 
maintains a 10-
fold greater 
blood serum 
level 
1.Healthy blood flow 
2.Healthy cardiac 
function 
3. Joint health 
4.Immune 
competence 
5. A healthy gut 
6.Blood sugar 
management 
7.Healthy cell 
structure & function 
8. Reduce the need to 
activate inflammatory 
cytokines 
9.Cognitive 
performance 
10.Hypoglycemic 
effects 
11.Hypolipidemic 
effects 
12.slow down the 
absorption of 
carbohydrates, 
cholesterol, bile acids 
Fully reacted 
patent pending 
BR213 
Curcuma 
galactomannosi
des compound. 
 
LifeGen Inc has 
exclusive to the 
combination 
for “My Secret 
Formula”. 
1.[207] 
2. [208] 
3. [209] 
4. [210] 
5. [211] 
6. [212] 
7.[213], 
[214], [215] 
8. [216] 
9. [217] 
10. [218] 
11. [219] 
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consistency of 
curcuminoids 
(bound with 
galactomannan
s) than regular 
curcuminoid 
supplements.  
 
Provides a 125-
fold increase in 
the 
concentration 
of curcuminoids 
in animal blood 
after 24 hours. 
 
Results in a 
125-fold 
increase in the 
concentration 
of curcuminoids 
in human 
blood. 
 
The Galactose 
to Mannose 
Ratio is 1:1 and 
offers a more 
uniform 
arrangement of 
the monomers 
that prevents 
molecular 
breakage and 
maintains 
stability. 
 
 
and improves gastric 
emptying 
 
GlucodOX™  Gugul + 
Triheptanoin 7 
product (GU-
TC7) 
13.potent inhibitor of 
HMG-CoA reductase 
(beneficial for 
promoting healthy 
GlucodOX™is 
a proprietary 
GU-TC7 extract 
of Commiphora 
13.[221],[2
22] 
14. [223], 
[224] Functional Foods in Health and Disease: 9:310-378                                                                         Page 351 of 378 
 
 
 
The extract is 
standardized 
for its naturally 
occurring 
triheptanoin, a 
triglyceride 
composed of 
three 7-carbon 
fatty acids that 
support 
efficacy, 
bioavailability 
and is known to 
improve energy 
production 
from fatty acid 
oxidation.  
 
cholesterol levels 
within the normal 
range). 
14.. Inhibit 
transformation of 
pre-adipocytes to 
adipocytes (i.e. fat 
cells) and inhibit 
triglyceride storage 
15. Significantly 
promote insulin 
sensitivity in 
adipocytes as 
measured by 
enhanced glucose 
uptake 
16. Increased glucose 
uptake 
17. Stimulate AMPK 
(nutrient/energy 
sensor), which is an 
important target that 
also helps to naturally 
reduce blood sugar 
levels within the 
normal range. 
18. Increase the 
NAD/NADH ratio via 
increased NAD 
19. Healthy glucose 
metabolism 
20. Mitochondrial 
biogenesis (creation of 
new energy-producing 
mitochondria) 
21. Primary energy 
production 
22. Increased 
catabolism 
(breakdown of larger 
molecules into simpler 
molecules thereby 
mukul (Guggul 
GU-TC7). 
 
LifeGen Inc has 
exclusive to the 
combination 
for “My Secret 
Formula”. 
15.[225], 
[226], 
[227], 
[228], [229]  
16. [230], 
[231]. 
[232], 
[233], 
[234], 
[235], 
[236], 
[237], [234] 
17. [238], 
[239], [240] 
18. [241] 
19. [242], 
[243],  
[244] 
20. [245],  
[246], 
[247], [231] 
21. [248], 
[249], 
[250], 
[251], 
[252], [253] 
22. [254], 
[255], [256] 
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releasing 
energy…secondary 
energy production) 
23. Reduced lipid 
production &8. 
Healthy blood lipid 
metabolism 
 
PHOSPHOLEA
N
™ 
NOPE+EGCG 
PhosphoLean
™ 
is a patented, 
natural, 
compound of N-
oleoyl-
phosphatidyl-
ethanolamine 
(NOPE) and 
EGCG, and it 
has been 
clinically 
proven to help 
dieters stay on 
their diets. 
 
Recent research 
has shown that 
OEA, the active 
compound 
liberated from 
PhosphoLean
™, 
binds to a cell 
receptor class 
called 
peroxisome-
proliferator-
activated 
receptor-alpha 
(PPAR-α) 
found in the 
intestinal tract.  
This signal is 
“hard-wired” to 
the brain, 
24. PhosphoLean™ 
significantly improved 
diet compliance in a 
group of healthy, 
overweight or obese 
subjects, as 
demonstrated by drop 
out rate.  It also 
increased satiety, 
decreased depressive 
symptoms, decreased 
binge eating severity, 
and provided 
favorable changes in 
insulin resistance and 
lipids. 
Protected 
under US 
Patent 
Application:  
US 
2010/0179107 
A1; Filed 
September 19, 
2007; 
Publication 
Date, July 15, 
2010.  Pistolesi 
et al.; “N-Acyl-
Phosphatidyl-
Ethanolamines 
And / Or 
Mixtures Of N-
Acyl-
Ethanolamines 
With 
Phosphatidic 
Acids Or 
Lysophosphatid
ic Acids 
 
LifeGen Inc has 
exclusive to the 
combination 
for “My Secret 
Formula”. 
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where appetite 
suppression is 
switched on.  
 
The EGCG 
polyphenols in 
PhosphoLean
™ 
NOPE+EGCG 
act 
synergistically 
with OEA via 
sympathetic 
activation of 
thermogenesis 
and increased 
fat oxidation, 
thus enhancing 
the compound’s 
weight 
management 
effects.   
 
 
 
 
Cognitrim™  l-alpha-Acetyl-
phosporylholine 
is a semi-
synthetic 
derivative of 
Lecithin.  
 
After oral 
administration, 
it is converted 
to 
phosphorylcholi
ne, which is 
ametabolically 
active form of 
choline able to 
reach 
25. Significant 
improvement in 
neuropsychological 
parameters associated 
with dementia.  
 
26. Acute 
supplementation with 
alpha-
glycerylphosphorylch
oline augments 
growth hormone 
response to, and peak 
force production 
during, resistance 
exercise 
 
LifeGen Inc has 
exclusive to the 
combination 
for “My Secret 
Formula”. 
25. [259] 
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cholinergic 
synaptic 
endings, thus 
increasing 
acetylcholine 
and reelase.  L-
Alpha-Acetyl- 
phosporylholine 
contributes to 
anabolic 
processes 
responsible for 
membrane 
phospholipid 
and glycerolipid 
synthesis 
positively 
influencing 
membrane 
fluidity and 
integrity.  
 
 
Benefits and Features 
In  summary,  NAAT
provides  a  unique  combination  of  diet  ingredients  which  include  the 
Synapatamine
TM  composition  and  other  natural  substances  like  potassium  glycerophosphate, 
citrus aurantum, and gymnema sylvestre among others helps normalize the “Reward System” in 
the brain by maintaining normal levels of neurotransmitters involved eating behaviors. When 
normal  neurotransmitter  function  is  maintained  food  intake,  especially  of  carbohydrates  is 
controlled. Potassium glycerophosphate is a compound that helps the body maintain metabolic 
and enhance function and increase energy levels. The product also contains thermogenic and 
energy supporting ingredients that will help one lose weight and increase lean muscle. To review 
of the clinical outcomes of many trials go to the reference Chen et al. [181].    
In terms of craving behavior each neutraceuitical developed will address a specific brain 
dysfunction.  In  this  regard,  NAAT
  has  been  designed  to  significantly  reduce  carbohydrate 
bingeing. The mechanism for this effect involves the pharmacological principal -like treats like. 
In this case, the common release of dopamine at the reward site by glucose is linked to aberrant 
glucose seeking behavior. This compulsive drive for dopamine is affected by the use of the 
patented (US # 6.132.724) Synaptose 
TM composition which works on the brain reward system to 
mimic the action of glucose on nucleus accumbens neurons to release dopamine.  Dopamine 
when released activates dopamine D2 receptors. When these receptors are activated by dopamine 
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in  brain  chemical  functions  underlying  craving  behavior,  and  since  these  deficits  may  be 
alleviated by facilitated dopamine release consequent to the use of substances such as glucose, 
combining amino- acid precursors and enkephalinase inhibition may stimulate the brain’s reward 
system  and  compensate  for  neurotransmitter  imbalance  (thereby  attenuating  glucose  craving 
behavior).  In  an  attempt  to  understand  that  carbohydrate  seeking  behavior,  is  a  subset  of 
generalized  craving  behavior  (  Reward  Deficiency  Syndrome)  due  in  part  to  low  dopamine 
function  (an  impaired  reward  cascade),  scientists  believe  individuals  self-heal  through 
biochemical attempts to alleviate hypodopaminergic activity via glucose - reward site interaction. 
Since the brain is made up of 200 billion cells and these cells require good nutrition, which 
includes minerals, vitamins, trace metals and amino acids, NAAT
 is a special blend with brain 
stabilizing and metabolic properties. It is noteworthy, that since it is known that dopamine D2 
occupancy by dopamine D2 agonists increase D2 receptors, it is the contention that the use of this 
product would induce a constant release of dopamine, to occupy dopamine D2 receptors, and 
ultimately reduce craving behavior due to a genetic deficiency of carrying the Dopamine D2 
Receptor A1 allelle (expression of low D2 receptor number).       
 
Imaging studies: Genes and weight gain.  
We  decided  to  test  the  acute  oral  NAAT
on  reward  circuitry  during  uprotracted  abstinence 
following psychostimulant dependence in ten subjects associated with G & G Holistic Addiction 
Treatment  Center of North Miami Beach, Florida. These subjects  were diagnosed as  having 
severe psychostimulant dependence and have been in recovery for at least two years. As part of 
the inclusion criteria, each patient was urine tested to determine the absence or presence of any 
psychoactive  drug  (illicit).  None  of  the  subjects  tested  showed  a  positive  drug  tested  urine. 
Therefore, they were subsequently admitted to the study.  
We  found  that  a  comparison  of  the  FFT  absolute  Power  (uVSq)  of  alpha  (8-12Hz) 
demonstrated  higher  activity  in  the  NAAT
group  compared  to  the  placebo  group.  Similarly 
observing the FFT absolute Power (uVSq) of low beta (12.0 15hz), the activity is considerably 
larger in the NAAT
group compared to the placebo group. Finally, there was a consistent effect 
of NAAT
on frontal regions when compared to placebo. The p values for group 1 (NAAT
) 
versus Group 2 (Placebo) for a between-group analysis of week 1 and week 2 whereby group 
comparisons utilizing T-tests were performed resulted in significant differences. This study is 
still in progress whereby we are increasing the subject population. 
To date, as observed there are numerous clinical trials showing various recovery benefits 
from  RDS  behaviors  using  NAAT
.  However,  prior  to  the  imaging  studies,  a  measurable 
magnitude  of  effect  and  the  mechanism  of  action  have  been  elusive.  The  results  of  these 
preliminary qEEG studies suggest an interaction of NAAT and meso-limbic activation leading to 
“normalization” of abnormal dopaminergic function in anticipation of patients carrying a number 
of reward gene polymorphisms [261, 100].   
While NAAT
appears to be a D2 natural non-addicting agonist, cautious interpretation 
must  await  future  fMRI  and  PET  scan  analysis  to  determine  chronic  induction  of  D2/D3 
receptors,  especially  in  DRD2  A1  allele  carriers  and  direct  interaction  at  D2  receptor  NAc 
interaction.   Functional Foods in Health and Disease: 9:310-378                                                                         Page 356 of 378 
 
 
Further confirmation and study expansion results of the qEEG analyses and continued 
demonstration that NAAT
 in the oral form leads to activation of the Parietal and Frontal regions 
of the brain, will be important. Moreover, increasing both alpha and low Beta activity will have 
important  clinical  outcomes.  If  confirmed  it  will  suggest  that  NAAT
  “normalizes“  brain 
abnormalities associated with drug dependence (alcohol, heroin and psycho stimulants) induced 
by dopaminergic deficiency by acting as a Dopaminergic receptor agonists during protracted 
abstinence in polydrug abusers. This notion is supported by other studies showing enhanced 
treatment response in only A1 vs. A2 carriers we anticipate, that the greatest effect will have 
occurred with those individuals possessing the DRD2 TAq A1 allele [15,262,263].   
We cautiously suggest that long-term activation of dopaminergic receptors (i.e., DRD2 
receptors)  will  proliferate  D2  receptors,  leading  to  enhanced  "dopamine  sensitivity"  and  an 
increased sense of happiness. Even in carriers of DRD2 A1 allele, in psychostimulant abusers 
this  is  supported  by  numerous  clinical  trials  and  awaits  PET  scanning  results  to  determine 
chronic effects of NAAT
 on numbers of D2 receptors [15]. Positive outcomes will provide 
important  information  that  could  ultimately  lead  to  significant  improvement  of  recovery  for 
victims of RDS having dopamine deficiency [264- 267].  
Our laboratory has now published three papers on utilizing these nutrigenomic principles 
to target certain gene polymorphisms including but not limited to 5HT2a receptors, PPAR –
Gamma, MTHFMR, LEP-OB and DRD2 genes (figure 4)with significant reductions in both 
weight (see figure 5) and BMI (see figure 6) [ 267, 268]. In these studies we also found that there 
was a 2 fold better compliance with carriers of the DRD2 A1 allele compared to carriers of the 
DRD2 A2 allele. (see figure 7) [269].  
 
Figure 6 Happiness gene map as proposed whereby five gene polymorphic genes (circles) were 
utilized for obesity nutrigenomic therapeutic targets. 
 
 
 Functional Foods in Health and Disease: 9:310-378                                                                         Page 357 of 378 
 
 
Figure 7. DNA directed KB220 (LG839 in experiment) reducs weight.Taken from reference 268 
(with permission) 
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Figure 8.  DNA directed KB220 reducs (LG839 in experiment) BMI. Taken from reference 268 
(with permission) 
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Figure 9. Treatment Compliance: Data on DNA directed KB220 (LG839 in experiment). Taken 
from reference 269 (with permission) 
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Conclusion  
While we have attempted to provide a detailed comprehensive account of the need to develop 
nutrigenomic   solutions  to  treat  obesity and especially sugar  craving  behavior, a subtype of 
Reward Deficiency Syndrome, we are cognizant that additional  large randomized  double –
blinded  –placebo  studies  are  needed  to  firmly  confirm  these  novel  ideas  prior  to  any  final 
conclusions  could  be  ascertained.  The  intent  herein  is  to  encourage  our  scientific  peers  to 
consider additional studies utilizing nutrigenomic solutions such as proposed with NAAT [267-
269].  
It is well know that stress induces the preferential release of the circularitory hormone 
cortisol in humans [270]. It is well know that lipolysis is the major activity that is involved in the 
burning of fat in adipose tissue. Ottosson et al. [271] clearly showed that cortisol significantly 
reduced  the  basal  rate  of  lipolysis  (p  <0.01)  and  the  catecholamine  lipoysis  stimulators 
isoprenaline and noradreanline in vitro [270]. Thus, cortisol will increase rather than decrease fat 
burning. In addition, the patogenesis of obesity has been suggested to be intimately linked to the 
catechoalminegic regulation of lipolysis and the function of the sympathetic nervous system. 
Norepinephrine and epinephrine activate lipolysis via B1 and B2 and B3 – adrenoreceptors and 
inhibit it via alpha2 adrenoreceptors, and these neurotransmitters are the most important lipolytic 
substances on vivo [271]. Defects of the catecholamine –induced lipolysis have been observed in 
a number of obese subjects, and polymorphisms of the B2- and B 3 receptors [272, 273].    
By  adding  both  Passoflora  and  KB220BZ  (for  a  detailed  description  see  [180])  a 
combination heretofore never combined we propose a synergistic effect on stress production and 
enhanced catecholamine synthesis. We further believe that these ingredients coupled together Functional Foods in Health and Disease: 9:310-378                                                                         Page 359 of 378 
 
 
would induce a reduction of plasma cortisol on humans. This will indeed then enhance lipolysis 
and increase fat burning.         
In  essence,  this  novel  formulation  will  promote  the  synthesis  of  the  brain  reward 
neurotransmitters like serotonin and catecholamines and through its effect on the natural opioids 
will  by  virtue  of  inhibiting  GABA  cause  a  significant  release  of  dopamine  at  the  nucleus 
accumbens.    This  constant  release  of  possibly  therapeutic  amounts  of  dopamine  (anti-stress 
substance)  occupies  dopamine  D2  receptors,  especially  in  carriers  of  the  A1  allele  (low  D2 
receptors  and  high  glucose  craving),  and  over  time  (possibly  6-8  weeks)  effects  RNA 
transcription  leading  to  a  proliferation  of  D2  receptors,  thereby,  reducing  craving  for 
carbohydrates. Evidence for anorectic actions of dopaminergic stimulators like Amphetamines I 
(ephedra)  have  been  found  to  work  via  activation  of  both  D1  ands  D2  dopamine  receptors 
[40,44]. In addition, elucidation of the composition, characteristics and properties of stabilized (-
) HCA compounds of GcEs is essential to differentiate effective sources from ineffective and 
substantiate  the  actual  active  ingredients  in  such  mineral-based  complexes.  Recent  research 
demonstrates intake of 4500 mg/d of a novel IH464 GcE containing 720 mg of K and 495 mg of 
Ca bound by (-) HCA for 8 weeks, while consuming a 2000 Kcal/d diet, produced safe and 
effective loss of body fat and improved BMI without stimulating the central nervous system. 
Other ingredients as listed in the example will also provide  important benefits  such as anti-
craving,  anti-sress,  enhancement  of  serotonin,  energy  and  metabolism  induction,  appetite 
suppression, starch blocking,  glucose stabilization,  fat burning, and general nutrition. as well as 
neurotransmitter rebalancing. Collateral benefits of lowered food intake and improved serotonin, 
insulin, lipid and leptin metabolism provide valuable evidence that this compound addresses 
multiple pathways in achieving sustainable healthy fat loss and improvements in body mass 
index while averting the consequences of rapid “weight loss” induced by CNS stimulation and/or 
calorie deprivation impacting many obesity genes [274,275]. 
  Through a series of both neurogenetic and clinical experiments it is becoming increasingly 
clear that this novel formulation is the first neuroadaptagen known to activate the brain reward 
circuitry. Ongoing research repeatedly confirms the numerous clinical effects ultimately result in 
significant  benefits  for  victims  having  genetic  antecedents  for  all  addictive,  compulsive  and 
impulsive behaviors. These behaviors are all correctly classified under the rubric of “Reward 
Deficiency Syndrome” (RDS). Preliminary findings in United States using qEGG and China 
using  fMRI  regarding  the  effects  of  oral  NAAT
  in  addicts  on  activation  of  brain  reward 
circuitry provides potentially exciting results. It seems from this preliminary data, utilizing an 
fMRI 2X2 design at resting state, NAAT
  in comparison to placebo shows activation of the 
caudate  brain  region  and  potentially  a  smoothing  out  of  heroin  induced  putamen  abnormal 
connectivity. If further confirmed in the ongoing studies in China coupled with the qEEG results 
showing an increase in alpha and increase in low beta may have important treatment outcomes. 
Cautiously these remarkable results are in progress and must await final analysis. For a very 
recent review on Neuroadaptagen –Amino-Acid Therapy [NAAT
] see Chen et al. [275].  
  Understanding that we have a worldwide epidemic of obesity coupled with substance use 
disorder described under the rubric of Reward Deficiency Syndrome one of us (KB) as early as 
1991 sumerized it up in his book “Alcohol and the Addictive Brain”[276] Functional Foods in Health and Disease: 9:310-378                                                                         Page 360 of 378 
 
 
 
“In the remainder of this century and the early decades of the centeury to come, I think that we 
will  see  neurobiokogy,  neuropharmacology,  biogenetics,  psychiatry,  and  medicine  moving 
forward in close coordination to reduce the devasting behavioral and social costs of faulty brain 
function. My vision of the future is a world in which the chemical and electrical functions of the 
brain are understood; the problem of chemical imbalences as they affect behavior has been 
solved; the role of genetic anomalies in defective brain chemistry is understood; pharmaceutical 
and nutrional intervention as an adjunct to twelve-step programs and professional treatment is 
precise  and  effective;  and  the  technique  of  defective-gene  replacement  has  been  perfected, 
enabling us to break the genetic chain of inherited addiction. In this world, each individual will 
be  able  to  enjoy  the  inborn  legacy  of  reward  and  pleasure  without  having  the  need  for  an 
addictive substance [sugar], without having to pay the price of addiction and pain.”  
 
Competing Interest 
Kenenth Blum, B. William Downs, Margaret A. Madigan, Roger L. Waite all own stock in 
LifeGen,  Inc.  John  Giordano  and  Frank  Fornari  are  partners  of  LifeGen,  Inc.  The  various 
nutriceuticals discussed in this manuscript are based on US and foreign patents issued, awarded 
and pending to Blum et al.These patents have been exclusively licensed to LifeGen, Inc.  There 
are no other conflicts of interest by any other author.  
 
Authors Contributors 
KB wrote the manuscript; AB developed the figures; BWD, RW, JG, MM, ERB, JMD, and TS 
contributed to the writing of the manuscript; JG and SM provided case studies; MAM edited the 
entire manuscript. 
 
Acknowledgements:  
The authors are grateful to the staff of the following entities:  Path Foundation, NY , New York;  
G &G Holistic Addiction Treatment Center, North Miami Beach, Florida; LifeGen, Inc., San 
Diego; and California and ElectronicWaveform Lab, Huntington Beach, California.  
 
References  
1.  Jenkinson C P, Hanson R., Cray K, Wiedrich C, Bogardus C. Baiser, L: Association of dopamine 
D2 receptor polymorphisms Ser311Cys and Taq1 with obesity or type 2 diabetes mellitus in 
Pima Indians. International Journal of Obesity & Related Metabolic Disorders. 2000, 24:1233-
1238. 
2.  Tataranni PA, Baier L, Jenkinson C, Harper I, Del Parigi A, Bogardus C.: A Ser311Cys mutation 
in  the  human  dopamine  receptor  D2  gene  is  associated  with  reduced  energy  expenditure. 
Diabetes. 2001, 50: 901-904. 
3.  Rivera R. and Deutsch R.D.: Your Hidden Food Allergies Are Making You Fat. Prima Health 
(division of Prima Publishing), Rocklin, California; 1998. 
4.  Hoebel BG, Leibowitz SF, and Hernandez L.: Neurochemistry of anorexia and bulimia; In The 
Biology  Of  Feast  And  Famine.  Edited  by  Andereson  GH  and  Kennedy  SH.  San  Diego, 
California, Academic Press; 1992; 21-45.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 361 of 378 
 
 
5.  DeZwaan M and Mitchell JE.: Opiate antagonists and eating behavior in humans: a review. 
Journal of Clinical Pharmacology. 1992, 32:1060-1072. 
6.  Krueger DW: Eating Disorders. In: Substance Abuse: A comprehensive Textbook.  Edited by 
Lowenson, JH, Ruiz P, Milman, RB, Langrod JG. 2 nd
 edition. 1992. Baltimore: Williams and 
Wilkins; 1992; 371-379.  
7.  Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, 
Comings DE.: Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment 
of  impulsive,  addictive,  and  compulsive  behaviors.  Journal  of  Psychoactive  Drugs.  2000, 
32(Suppl: i-iv):1-112.  
8.  Blum  K  and  Kozlowski  GP.:  Ethanol  and  neuromodulator  interactions:  a  cascade  model  of 
reward.  In:  Alcohol  and  Behavior.  Edited  by  Ollat  H.,  Parvez  S.  and  Parvez  H.  Utrecht, 
Netherlands, VSP Press; 1990:131-149. 
9.   Blum K, Noble, EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswaran P, Nogami H, 
Briggs  A.H,  and  Cohn  JB.:  Allelic  association  of  human  dopamine  D2  receptor  gene  in 
alcoholism. Journal of the American Medical Association. 1990, 263: 2055-2060. 
10. Comings  DE,  Gonzalez  N,  Wu  S,  Saucier  G,  Johnson  P,  Verde  R,  MacMurray  JP.: 
Homozygosity  at  the  dopamine  DRD3  receptor  gene  in  cocaine  dependence.  Molecular 
Psychiatry. 1999, 4:484-487. 
11. Hill SY, Zezza N, Wipprecht G, Xu J, Neiswanger K: Linkage studies of D2 and D4 receptor 
genes and alcoholism. American Journal of Medical Genetics. 1999, 88:676-685. 
12. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE.: Dopamine D2 receptor 
gene  variants:  association  and  linkage  studies  in  impulsive-addictive-compulsive  behaviour. 
Pharmacogenetics. 1995, 5:121-141.  
13. George SR, Cheng R, Nguyen T, Israel Y, and O’Dowd BF: Polymorphisms of the D4 dopamine 
receptor alleles in chronic alcoholism. Biochemical and Biophysical Research Communications. 
1993, 196:107-114.  
14. Noble EP, Blum K, Khalsa H, Ritchie T, Montgomery A, Wood RC, Fitch RJ, Ozkaragoz T, 
Sheridan, PJ, Aglin MD. Paredes A, Treiman LJ, Sparkes RS.: Allelic association of the D2 
dopamine receptor gene with cocaine dependence. Drug and Alcohol Dependence. 1993, 33: 
271-285.  
15. Uhl G, Blum K, Noble E, Smith S.: Substance abuse vulnerability and D2 receptor genes. Trends 
in Neurosciences. 1993, 16:83-88.  
16. Lawford BR, Young RM, Rowell J, Qualichefski BH, Fletcher K, Sundulko T,  Ritchie T, Noble 
EP.: Bromocriptine in the treatment of alcoholics with D2 dopamine receptor A 1 allele. Nature 
Medicine. 1995, 1: 337-341.  
17. Bowirrat  A,  Oscar-Berman  M.  Relationship  between  dopaminergic  neurotransmission, 
alcoholism, and Reward Deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet. 2005, 
132B:29-37.  
18. Gardner  EL:  Brain  Reward  Mechanisms.  In:  Substance  Abuse:  A  Comprehensive  Textbook 
.Edited by Lowenson, JH, Ruiz P, Millman RB, Langrod JG. 2 nd
 edition. 1992. Baltimore: 
Williams and Wilkins; 1997, 51-58.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 362 of 378 
 
 
19. Gardner  El.:  Neurobiology  and  genetics  of  addictions:  Implications  of  “Reward  Deficiency 
Syndrome" for therapeutic strategies in chemical dependency. In: Russell Sage Conference on 
Addictions: July 15,
th 1997, Chaired by Jon Elston. 
20. Yan  QS.:  Extracellular  dopamine  and  serotonin  after  ethanol  monitored  with  5-minute 
microdialysis. Alcohol. 1999, 19:1-7. 
21. Honkanen A, Hyytiä P, Korpi ER, Ahtee L.: Effects of morphine on metabolism of dopamine 
and serotonin in brains of alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol. 1999, 
18:3-10.   
22. Thanos PK, Volkow ND, Freimuth P, Umegaki H, Ikari H, Roth G, Ingram DK, Hitzemann R.: 
Overexpression  of  dopamine  D2  receptors  reduces  alcohol  self-administration.  Journal  of 
Neurochemistry. 2001, 78:1094-103. 
23. Reither EN, Olshansky SJ, Yang Y: New Forecasting Methodology Indicates More Disease And 
Earlier  Mortality  Ahead  For  Today's  Younger  Americans.  Health  Affairs  (Millwood).  2011, 
30:1562-1568.  
24. Blum K, Cull, J. G, .Miller M: To Binge or Not to Binge? Psychiatric Genetics Press 1999, San 
Antonio, Texas.  
25. Olds ME, and Olds J: Effects of lesions in medical forebrain bundle on self-stimulation behavior. 
American Journal of Physiology 1969, 217: 1253-1264. 
26. Hall  RD,  Bloom  FE,  Olds  J:  Neuronal  and  neurochemical  substrates  of  reinforcement. 
Neuroscience Research Program Bulletin 1977, 15:131-314. 
27. Blum K, Trachtenberg MC. Alcoholism: scientific basis of a neuropsychogenetic disease. Int J 
Addict. 1988, 23:781-96.  
28. Cloninger CR.: Genetic and environmental factors in the development of alcoholism. Journal of 
Psychiatric Treatment Evaluation 1983, 5:487-496. 
29. Blum K, Briggs AH, Trachtenberg MC.: Ethanol ingestive behavior as a function of central 
neurotransmission. Experientia. 1989, 4:444-452.  
30. Wise RA, and Bozarth MA: Brain reward circuitry: four circuit elements "wired" in apparent 
series. Brain Research Bulletin. 1984, 297:265-273.  
31. Koob GF, Bloom FE.: Cellular and molecular mechanism of drug dependence. Science. 1988, 
242:715-23. 
32. Stein  L, and Belluzzi JD.:  Second messenger,  natural  rewards, and drugs  of abuse.  Clinical 
Neuropharmacology. 1986, 9(Suppl. 4):205-207. 
33. Alvakisinen MN, Saano V, Juvonene H, Huhtikangas A, Gunther J: Binding of beta-carbolines 
and  tetrahydroisoquinolines  by  opiate  receptors  of  the  delta-type.  Acta  Pharmacologica  et 
Toxicologica 1984 , 55: 380-385. 
34. Chen TJ, Blum K, Payte JT, Schoolfield J, Hopper D, Stanford M, Braverman ER. Narcotic 
antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, 
amino-acid precursors and enkephalinase inhibition therapy. Med Hypotheses. 2004, 63:538-48. 
35. Russell V, Lanin MCL, Taljaard, JF.: Effect of ethanol on 
3H-dopamine release in rat nucleus 
accumbens and striatal slices. Neurochemical Research. 1988, 13:487-492.  
36. McBride WJ, Guan XM, Chernet E, Lumeng L, Li TK: Regional serotonin1A receptors in the 
CNS of alcohol-preferring and -nonpreferring rats. Pharmacol Biochem Behav. 1994, 49:7-12. Functional Foods in Health and Disease: 9:310-378                                                                         Page 363 of 378 
 
 
37. Zhou FC, Bledsoe S, Lumeng L, Li TK.: Serotoninergic immuno-stained terminal fibers are 
decreased  in  selected  brain  areas  of  alcohol-preferring  P  rats.  Alcoholism:  Clinical  and 
Experimental Research. 1990, 14: 355. 
38. McBride WJ, Chernet E, Dyr W, Lumeng, L, Li TK.: Densities of dopamine D2 receptors are 
reduced in CNS regions of alcohol preferring P rats. Alcohol. 1990, 10:387-390. 
39. McBride WJ, Chernet E, Russell RN, Wong DT, Guan XM, Lumeng L, Li, TK.: Regional CNS 
densities of monoamine receptors in alcohol-naive alcohol-prteferring P and nonpreferring NP 
rats. Alcohol. 1997, 14:141-148.  
40. Hwang BH, Lumeng L, Wu JY, Li, TK.: Increased number of GABAergic terminals in the 
nucleus  accumbens  is  associated  with  alcohol-preferring  p  rats.  Alcoholism:  Clinical  and 
Experimental Research 1990, 14:503-507. 
41. Dyr W, Mcbride WJ, Lumeng, L, Li T-K. Murphy, JM.: Effects of D1 and D2 dopamine receptor 
agents on ethanol consumption in the high-alcohol-drinking (HAD) line of rats, Alcohol 1993, 
10: 207-212. 
42. Blum K, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, 
Stice  E,  Downs  BW,  Waite  RL,  Madigan  MA,  Kerner  M,  Fornari  F,  Braverman  ER.: 
Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male 
psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2. 
Postgraduate Medicine. 2010 122:214-26. 
43. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG, Comings DE.  The D2 
dopamine receptor gene as a determinant of reward deficiency syndrome.J R Soc Med. 1996, 
89:396-400 
44. Blum WF, Englaro P, Attanasio AM, Kiess W, Rascher W: Human and clinical perspectives on 
leptin. The Proceedings of the Nutritional Society 1998, 57:477-85.  
45. Liebowitz,  SF:  Paraventricular  nucleus:  a  primary  site  mediating  adrenergic  stimulation  of 
feeding and drinking. Psychopharmacology Biochemistry Behavior. 1978, 8:163-175.  
46. Stanley  BG,  Liebowitz  SF:  Neuropeptide  Y  injected  in  the  paraventricular  hypothalmus:  a 
powerful stimulant of feeding behavior. Proceedings of the National Academy Of Science USA. 
1985, 82:3940-3943. 
47. Lichtenstein  SS.,  Marinesccu  C,  Liebowitz  SF.:  Chronic  infusion  of  norepinephrine  and 
clonidine into the hypothalamic paraventricular nucleus. Brain Research Bulletin 1984, 13:591-
595. 
48. Inokuchi A, Domura Y, Nishimura H.: Effect of intracerebro-ventricularly infused glucagon on 
feeding behavior. Physiological Behavior 1984, 33:397-400. 
49. Blundell  JE.:  Problems  and  processes  underlying  the  control  of  food  selection  and  nutrient 
intake. In: Nutrition and the Brain. Edited by Wurtman, RJ. and Wurtman, JD, Raven Press; New 
York,1983:163-222. 
50. Blundell JL.: Serotonin and appetite. Neuropharmacology. 1984, 23:1537-1551. 
51. Blundell JE.: Serotonin manipulations and the structure of feeding behavior.  Appetite. 1986, 
7(Suppl): 39-56. 
52. Bhakthavat-salam  P,  Liebowitz,  SF:  Morphine-elicited  feeding:  diurnal  rhythm  circulating 
corticosterone  and  macronutrient  selection.  Pharmacology,  Biochemistry  and  Behavior  1986, 
24:911-917. Functional Foods in Health and Disease: 9:310-378                                                                         Page 364 of 378 
 
 
53. Young SN. The clinical psychopharmacology of tryptophan. In: Nutrition and the Brain. Food 
Constituents Affecting Normal and Abnormal Behaviors. Edited by Wurtman RJ, Wurtman JJ. 
Raven Press, New York, 1986: 49-88. 
54. Rogers  LL,  Pelton,  RB.:  Glutamine  in  the  treatment  of  alcoholism  :  a  preliminary  report. 
Quarterly Journal Of Studies in Alcohol 1957, 18: 581-587. 
55. Dhatt RK. Rattan AK, Mangat HK. Effect of chronic intracerebroventricular morphine to feeding 
responses in male rats. Physiological Behavior 1988, 43 : 553-557. 
56. Marks-Kaufman R, Kanarch TB: Morphine selectively influences macronutrient intake in the rat. 
Pharmacology Biochemistry and Behavior 1980, 12: 427-430.  
57. Liebowitz SF, Hor L.: Endorphinergic and alpha-noradrenergic systems in the paraventricular 
nucleus: effects on eating behavior. Peptides 1982, 3: 421-428.  
58. Liebowitz SF, Weiss G, Yee F. , Tretter JB: Noradrenergic innervation of the paraventricular 
nucleus specific role in control of carbohydrate ingestion. Brain Reseach Buletin 1985, 14: 561-
567.  
59. Liebowitz SF:  Brain  neurotransmitters and appetite regulation.  Psychopharmacology  Bulletin 
1985, 21: 412-418. 
60. Stanley  BG,  Daniel  DR,  Chin  AS:  Paraventricular  nucleus  injections  of  pepetide  YY  and 
Neuropepetide Y preferentially enhance carbohydrate ingestion. Peptides 1985,  6: 1205-1211. 
61. Liebowitz SF: Brain monoamines and peptides: role in the control of eating behavior. Federation 
Proceedings 1986, 45: 1396-1403.  
62. Shor-Posner  G,  Azr  AP,  Filart  R,  Tempel  D,  Liebowitz  SF:  Morphine-stimulated  feeding 
analysis  of  macronutrient  selection  and  paraventricular  nucleus  lesions.  Pharmacology 
Biochemistry and Behavior 1986, 24: 931-939. 
63. Wurtman  JJ,  Wurtman,  RJ:  Drugs  that  enhance  serotonergic  transmission  diminish  elective 
carbohydrate consumption by rats. Life Sciences 1979, 24: 895-904. 
64. Samanin R, Bendotti C, Candelaresi G, Garattini S.: Specificity of serotonergic involvement in 
the decrease of food intake induced by quipazine in the rat. Life Sciences 1977, 21: 1259-1266. 
65. Garattini S, Caccia S, Mennini T, Consolo S,  Landisky H.: Biochemical pharmacology of the 
anorectic drug fenfluramine: a review. Current Medical Research and Opinion. 1979, 6(suppl. 
1):15-27.  
66. Goudie AJ, Thornton DW, and Wheeler TJ.: Effects of Lilly 110140, a specific inhibitor of 5-
hydroxytryptamine  uptake  on  food  intake  and  on  5-hydroxytryptophan-induced  anorexia, 
evidence for serotonergic inhibition of feeding. Journal of Pharmacy and Pharmacology. 1976, 
28: 318-320. 
67. Borsini  F,  Bendotti  C,  Samanin  R.:  Salbutanol,  d-amphetamine  and  d-fenfluramine  reduce 
sucrose intake in freely fed rats by acting on different neurochemical mechanisms. International 
Journal of Obesity. 1985, 9:277-283.  
68. Leander JD: Fluoxetine suppresses palatability-induced ingestion. Psychopharmacology. 1987, 
91:2885-2887.  
69. Murphy JM, Waller MB, Gatto W, McBride WJ, Lumeng L, Li T-K.: Effects of Fluoxitine on 
the intragastric self administration of ethanol in the alcohol preferring P line of rats. Alcohol. 
1988, 5:283-286.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 365 of 378 
 
 
70. Atkinson RL.:  Familial  subtypes  of childhood hyperactivity.  Journal of Nervous and Mental 
Disease 1987, 171: 362-368.  
71. Bado A, Roze C, Lewin MJM, and Dubrasquet M: Endogenous opioid peptides in the control of 
food intake in cats. Peptides. 1989, 10:967-971. 
72. Gosnell BA, Grace M, Levine AS.: Effects of B-chlonaltrexamine on food intake, body weight 
and opioid-inducing feeding. Life Sciences. 1987, 40:1459-1467. 
73. Morley JE, Levine AS.: Corticotropin releasing factor, grooming and ingestive behavior. Life 
Sciences. 1982, 31: 1459-1464. 
74. Morley JE, Parker S, Levine AS.: Effect of butorphanol tartrate on food and water consumption 
in humans. American Journal of Clinical Nutrition 1985, 42: 1175-1178. 
75. Jonas JM, Gold MS.: The use of opiate antagonists in treating bulimia: a study of low-dose 
versus high-dose Naltrexone. Psychiatry Research 1987, 24: 195-199.  
76. Shimomura. Y, Oku J, Glick Z, Bray, GA.: Opiate receptors, food intake and obesity. Physiology 
and Behavior 1982, 28: 441-445. 
77. Tepperman FS, and Hirst M: Concerning the specificity of the hypothalamic opiate receptor for 
food intake in the rat. Pharmacology Biochemistry and Behavior 1982, 17: 1141-1144. 
78. Bakshi  VP,  Kelly  AE.:  Striatal  regulation  of  morphine-induced  hyperphagia:  An  anatomical 
mapping study. Psychopharmacology. 1993, 111:207-214. 
79. Gosnell BA, Levine AS, Morley JE.: The stimulation of food intake by selective agonists of mu, 
kappa and delta opioid receptors. Life Sciences. 1986, 38:1081-1088.  
80. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA.: Naloxone, an opiate blocker, 
reduces  the  consumption  of  sweet  high-fat  foods  in  obese  and  lean  female  binge  eaters. 
American Journal of Clinical Nutrition 1995, 6:1206-1212. 
81. Broekkamp CLE, Phillips AG, Cools R.: Stimulant effect of enkephalin microinjection into the 
dopaminergic A10 area. Nature. 197, 278:560-562. 
82. Hoebel BG: The psychopharmacology of feeding. In: Handbook of Psychopharmacology Edited 
by Iversen LF, Iversen SD, Snyder SH. New York: Plenum Press. 1977, 1-53. 
83. Gillman  MA,  Lichtigfeld  FJ.:  The  opioids,  dopamine,  cholecystokinin,  and  eating  disorders. 
Clinical Neuropharmacology. 1986, 9:91-97.  
84. Chesselet MF, Chéramy A, Reisine TD, Glowinski J.: Morphine and delta-opiate agonists locally 
stimulate in vivo dopamine release in CA1 caudate nuclei. Nature. 1981, 291: 320-322. 
85. Koob GF.: Drug abuse: Anatomy, Pharmacology and function of reward pathways. Trends in 
Pharmacological. Science. 1992, 13:177-184. 
86. Lynch WC, Burns G.: Enhancement of sucrose intake by the kappa opioid agonists U-50, 4888H 
persists beyond the period of drug exposure. Society of Neuroscience 1987, 13: 878.  
87. Blum K, De Lallo L, Briggs AH, Wallace JE.: Ethanol acceptance as a function of genotype 
amounts of brain (met) enkephalin. Proceedings of the National Academy of science USA. 1983, 
80:6510-6512. 
88. Blum K, Wallace JE, Trachtenberg MC.: Enkephalinase inhibition: regulation of ethanol intake 
in genetically predisposed mice. Alcohol 1987, 4:449-456. Functional Foods in Health and Disease: 9:310-378                                                                         Page 366 of 378 
 
 
89. Banks WA, Kastin, AJ: Inhibition of the brain to blood transport system for enkephalins and 
Tyr-mif-1 in mice addicted or genetically predisposed to drinking ethanol. Alcohol. 1989, 6:53-
57. 
90. Heidbreder C, Roques B, Vanderhaeghen JJ, De Witte, P.: Kelotorphan, a potent enkephalinase 
inhibitor, presents opposite properties when injected intracerebroventricularly or into the nucleus 
accumbens on intracranial self-stimulation. Neurochemistry International. 1988, 12:347-350. 
91. Blum K, Braverman ER, Wood RC, Gill J, Li C, Chen TJH, Taub M, Montggomery AR, Cull 
JG, Sheridan PJ.: Increased prevalence of the Taq1 A1 allele of the dopamine receptor gene in 
obesity with comorbid substance use disorder. Pharmacogenetics. 1996, 6: 297-305.  
92. George SR, Roldan L, Lui A, Naranjo CA.: Endogenous opioids are involved in the genetic 
determined high preference for ethanol  consumption.  Alcoholism,  Clinical  and Experimental 
Research. 1991, 15: 668-672. 
93. Riviere  PJM,  Bueno  L.:  Origin  of  the  stimulation  of  food  intake  by  oral  administration  of 
enkephalinase inhibitors in sheep. Life Sciences 198,. 41: 333-339.  
94. Hamdi A, Porter J, Prasad, C.: Decreased striatal D2 dopamine receptors in obese Zucker rats: 
changes during aging. Brain Research 1992, 589: 338-340.  
95. Cincotta  A.H.,  Tozza  E,  Scislowski  PW.:  Bromocryptine/SKF38393  treatment  ameliorates 
obesity  and  associated  metabolic  dysfunctions  in  obese  (ob/ob)  mice.  Life  Sciences  1997, 
61:951-6, 1997.  
96. Bina KG, Cincotta AH: Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y 
and  corticotropin-releasing  hormone,  body  weight  gain,  and  hyperglycemia  in  ob/ob  mice. 
Neuroendocrinology. 2000, 71:68-78.  
97. Kuo DY.: Further evidence for the mediation of both subtypes of dopamine D1/D2 receptors and 
cerebral  neuropepetide  Y  (NPY)  in  amphetamine  –induced  appetite  suppression.  Behavioral 
Brain Research.  2003, 147: 149-155. 
98. Scislowski  PW,  Tozzo  E,  Zhang  Y,  Phaneuf  S,  Prevelige  R,  Cinocotta  AH.:  Biochemical 
mechanisms  responsible  for  the  attenuation  of  diabetic  and  obese  conditions  in  ob/ob  mice 
treated  with  dopaminergic  agents.  International  Journal  Of  Obesity  &  Related  Metabolic 
Disorders. 1999, 94:425-31.  
99. Baptista T, Parada M,  Hernandez L.: Long term administration of some antipsychotic drugs 
increases  body  weight  and  feeding  in  rats.  Are  D2  receptors  involved?  Pharmacology, 
Biochemistry & Behavior. 1987, 27:399-405.  
100. Freeman AS, Weddige FK, Lipinski JL Jr.: Effect of glucose on antipsychotic drug-induced 
changes in dopamine neuronal activity. European Journal of Pharmacology 2001, 431:43-46.  
101. Blum K, Liu Y, Shriner R, Gold MS.: Reward circuitry dopaminergic activation regulates food 
and drug craving behavior. Cur Pharm Des. 17:1158-67. 
102. Dichiara G, Impereto A: Drugs abused by humans preferentially increase synaptic dopamine 
concentrations in the mesolimbic systems of freely moving rats. Proceedings of the National 
Academy of Science USA. 1988, 84:1413-1416.  
103. Gessa  Gl,  Mutoni,  F,  Coller,  M,  Vargin  L,  Mercer  G:  Low  doses  of  ethanol  activate 
dopaminergic neurons in the ventral tegmental area. Brain Research. 1985, 348:201-203.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 367 of 378 
 
 
104. Tandra G, Pontieri FE, Dichiara G. Cannabinoid and heroin activation of mesolimbic dopamine 
transmission by a common mu1 opioid receptor mechanism. Science. 1997, 276:2048-2050. 
105. Nakajima  S:  Subtypes  of  dopamine  receptors  involved  in  the  mechanism  of  reinforcement. 
Neuroscience Biobehavior Review. 1989, 13:123-128. 
106. Stefanini E, Frau M., Garau MG, Garau B, Fadda F, Gessa, GL.: Alcohol preferring rats have 
fewer dopamine D2 receptors in the limbic system. Alcohol and Alcoholism. 1992, 27:127-130.  
107. Pffer AO, Samson HH.: Haloperidol and opomorphine effects on ethanol reinforcement in free 
feeding rats. Pharmacology Biochemistry Behavior. 1988, 29:343-350. 
108. Boehme, RE and Ciaranello, R.: Dopamine receptor binding in inbred mice: strain differences 
in mesolimbic and nigrostriatal dopamine binding sites. Proceedings of the National Academy of 
Science USA. 1981, 78:3255-3259. 
109. Brown RJ, Blum K, Trachtenberg MC.: Neurodynamics of relapse prevention: A neuronutrient 
approach to outpatient DUI offenders. Journal Psychoactive Drugs. 1990, 22:173-187.  
110. Blum K, Trachtenberg MC, Ramsey J.: Improvement of inpatient treatment of the alcoholic as a 
function  of  neurotrient  restoration:  A  pilot  study.  International  Journal  of  Addiction.  1988, 
23:991-998.  
111. Blum  K,  Trachtenberg  MC,  Elliott  CE,  Dingler  ML,  Sexton  RL,  Samuels  AI,  Cataldie  L.: 
Enkephalinase  inhibition  and  precursor  amino  acid  loading  improves  inpatient  treatment  of 
alcohol and polydrug abusers: Double-blind placebo-controlled study of the nutritional adjunct 
SAAVE. Alcohol. 1988, 5:481-493.  
112. Blum K, Briggs AH, Trachtenberg MC.: Ethanol ingestive behavior as a function of central 
neurotransmission. Experientia. 1989, 45:444-4452.  
113. Blum, K., Trachtenberg MC, Cook, DW.: Neuronutrient effects on weight loss in carbohydrate 
bingers: An open clinical trial. Current Therapeutic Research. 1990, 48: 217-233. 
114. Kaats  G,  Blum  K.:  The  short  –term  therapeutic  efficacy  of  treating  obesity  with  a  plan  of 
improved nutrition and moderate caloric restriction. Curr Ther  Res. 1992, 51:261 
115. Cold JA. NeuRecover-SA in the treatment of cocaine withdrawal and craving: a pilot study. 
Clinical Drug Investigation. 1996, 12:1-7. 
116. Kaats GR, Blum K, Fisher JA, Adelman JA.: Effects of chromium picolinate supplementation on 
body composition: A randomized, double masked, placebo-controlled study. Current Therapeutic 
Research. 1996, 57:747-756. 
117.  Blum K, Cull JG, Chen JHT, Garcia-Swan  S, Holder  JM, Wood R, Braverman ER, Bucci, LR,  
Trachtenberg  MC: Clinical evidence For Effectiveness of Phencal 
TM in maintaining weight loss 
in an open-label, controlled, 2-year study. Current Therapeutic Research. 1997, 58: 745-763. 
118.  DeFrance JF, Hymel C, Trachtenberg MC, Ginsberg LD, Schweitzer FC, Estes S, Chen TJ, 
Braverman ER, Cull JG, Blum K.: Enhancement of attention processing by Kantroll in healthy 
humans: a pilot study. Clinical (EEG) Electroencephalography. 1997, 28(2):68-75. 
119.  Kaats GR, Blum K, Pullin D, Keith SC, Wood R.: A randomized, double-masked, placebo-
controlled study of the effects of chromium picolinate supplementation on body composition: A 
replication of a previous study. Current Therapeutic Research. 1998, 59:379-388. 
120.  Routtenberg, A.: The reward system of the brain. Scientific American. 1978, 239:154-165. Functional Foods in Health and Disease: 9:310-378                                                                         Page 368 of 378 
 
 
121.  Imperato  A,  Di  Chiara  G.:  Preferential  stimulation  of  dopamine  release  in  the  nucleus 
accumbens  of  freely  moving  rats  by  ethanol.  Journal  of  Pharmacology  and  Experimental 
Therapy. 1986, 239(1):219-28. 
122.  England JA, Gerhard DS, Pauls DL, Sussex JN, Kidd KK, Allen CR, Hostetter AM, Housmman 
DE.: Bipolar affective disorder linked to DNA markers on chromosome 11. Nature. 198. 325: 
783-787. 
123.  Cloninger  CR,  Bohman  M,  Sigvardsson  S.:  Inheritance  of  alcohol  abuse;  cross-fostering 
analysis of adopted men. Archives of General Psychiatry. 1981, 38:861-868. 
124.  Goodwin, DS.: Alcoholism and Heredity.  Archives of General Psychiatry. 1979, 36:57-61.  
125.  Neiswanger K, Hill SY, Kaplan RB.: Association between alcoholism and the Taq1 A RFLP of 
the  dopamine  D2  receptor  gene  in  samples  of  female  and  male  alcoholics.  Neuropsychiatric 
Genetics. 1995, 60:267-271.  
126. Bouchard C.: Genetics of obesity: an update on molecular markers.:  International Journal of 
Obesity. 1995, 19 (supple 3):S10-S13. 
127. Zhang X, Proenca R, Barone M, Leopold L, Freedman JM.: Positional cloning of the mouse 
obese gene and its human homologue. Nature. 1994, 372:425-32.  
128. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath 
MM,  Lambert  PD,  Wilding  JP,  Smith  DM,  Ghatei  MA,  Herbert  J,  Bloom  SR.:  A  role  for 
glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996, 379:60-72. 
129. Krahn,  D.:  The  relationship  of  eating  disorders  and  substance  abuse.  Journal  of  Studies  on 
Alcohol. 1991, 3:239-253. 
130. Newman MM, and Gold MS.: Preliminary findings of patterns of substance abuse in eating. 
American Journal of Drugs and Alcohol Abuse 1992, 18:207-211.  
131. Noble EP, Noble RE, Ritchie T, Syndulko K, St. jeor SC, Fitch RJ, Brunner RL, Sparkes RS.: D2 
dopamine receptor gene and obesity. International Journal of Eating Disorders. 1994, 15:205-
217.  
132. Comings DE, Gade R, MacMurray JP, Muhlleman D, Johnson P, Verde R, Peters WR.: Genetic 
variants of the human obesity (OB) gene: association with body mass index in young women 
psychiatric  symptoms,  and  interaction  with  the  dopamine  D2  receptor  gene.  Molecular 
Psychiatry. 1996, 1:325-335. 
133. Yasuno F, Suhara T, Yamamoto M, Inoue M, Okubo Y, Suzuki K.: Relation among dopamine 
D2 receptor binding, obesity and personality in normal human subjects. Neuroscience Letters. 
2001, 300(1): 59-61. 
134. Jenkinson CP, Hanson R, Cray K, Wiedrich C, Knowler WC, Bogardus C, Baier L.:  Association 
of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes 
mellitus in Pima Indians. International Journal of Obesity. 2000, 24:1233-1238. 
135. Wetterling,  T.:  Body  weight  gain  with  atypical  antipychotics.  A  comparative  review.  Drug 
Safety. 2001,   24(1):59-73.  
136. Thomas  GN,  Tomlinson  B,  Critchley  JA.:  Modulation  of  blood  pressure  and  obesity  with 
dopamine D2 receptor gene Taqi polymorphism. Hypertension. 2000, 369(2): 177-82.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 369 of 378 
 
 
137. Comings DE, Flanagan SD, Diez G, Muhlman D, Knell E, Gysin R.: The dopamine D2 receptor 
as a major gene in obesity and height. Biochemical Medicine and Metabolic Biology. 1993, 50: 
176-185. 
138. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS.: Brain 
dopamine and obesity. Lancet. 2001, 357( 9253):354-7.    
139. Volkow  ND,  Fowler  JS,  Wang  GJ,  Hitzman  R,  Logan  J,  Schlyer  D,  Dewey  S,  Wolf  AP.: 
Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in 
cocaine abusers. Synapse. 1993, 14:169-177. 
140. Ebstein RP, Novick O, Umansky R, Peil B, Osher Y, Blaine D, Bennett E, Nemanov L, Katz M,  
Belmaker  R.:  Dopamine  D4  receptor  exon  111  polymorphism  associated  with  the  human 
personality trait of novelty seeking. Nature Genetics. 1996, 12:78-80.  
141. Benjamin  J,  Lin  L,  Patterson  C,  Greenberg  BD,  Murphy  DL,  Hamer  DH.:  Population  and 
familial association between the D4 dopamine receptor gene and measures of novelty seeking. 
Nature Genetics. 1996, 12:81-84. 
142.  Poston WS 2nd, Ericsson M, Linder J, Haddock CK, Hanis CL, Nilsson T, Aström M, Foreyt 
JP.: D4 dopamine receptor gene exon III polymorphism and obesity risk. Eating and Weight 
Disorders. 1998, 3(2):71-7. 
143. Levin,  B.E.:  Glucose  –regulated  dopamine  release  from  substantia  nigra  neurons.  Brain 
Research. 2000, 874(2):158-64. 
144. Koshimura K, Tanala, J,  Murakami T, Kato,  T.:  Effect  of high concentration of glucose on 
dopamine release from Pheochromocytoma –12 cells. Metabolism. 2002, 52: 922-926.   
145.  Bello  NT,  Sweigart,  KM  Lakoski,  JM,  Norgren,  R,  Hajnal,  A.:  Restricted  feeding  with 
scheduled sucrose access results in an upregulation of the rat dopamine transporter. American 
Journal of Physiology:Regulatory, Integrative, and Comparative Physiology. 2000, 284: R1260-
R1268.  
146. Lee TL, Hsu SH, Yen SH, Lai CW. Cheng JT.: Activation of B3 – adrenoreceptors by exogenous 
dopamine to lower glucose uptake into rat adipocytes. Journal of Autonomic Nervous System. 
1998, 74: 86-90.   
147. Conti G, Blandini F, Tassorelli, Giubilei, F, Fornai, F, Zocchi, A, Orzi, F.: Intrastriatal injection 
of  D1  or  D2  dopamine  agonists  affects  glucose  utilization  in  both  the  direct  and  indirect 
pathways of the rat basal ganglia. Neuroscience Letters. 2001, 309:161-164.    
148. Umhau JC, Petrulis SG, Diaz R, Rawlings R, George DT.: Blood glucose is correlated with 
cerebrospinal fluid neurotransmitter metabolites. Neuroendocrinology. 2003, 78:339-43.    
149. Colantuoni C, Rada P, McCarthy J, Patten C, Avena NM, Chadeayne A, Hoebel BG.: Evidence 
that  intermittent,  excessive  sugar  intake  causes  endogenous  opioid  dependence.  Obesity 
Research. 2001, 10: 478-488. 
150. Kogan, HA, Marsden, CA, Fone CF.: DR4004, a putative 5-HT7 receptor antagonist, also has 
functional  activity  at  the  dopamine  D2  receptor.  European  Journal  of  Pharmacology.  2002, 
449:105-111.  
151. Hajnal A, Szekely M, Galosi, R, Lenard L.: Accumbens cholinergic interneurons play a role in 
the regulation of body weight and metabolism. Physiology and Behavior. 2000, 70:95-103.   Functional Foods in Health and Disease: 9:310-378                                                                         Page 370 of 378 
 
 
152. Adler CM, Elman I, Weisenfield N, Kestler L, Pickar D, Breier A.: Effects of acute metabolic 
stress  on  striatal  dopamine  release  in  healthy  volunteers.  Neuropsychopharmacolgy.  2000, 
22(5):545-50. 
153. Trugman JM,  and James CL.:  Dopamine agonist  and antagonist effects  on regional cerebral 
glucose utilization in rats with intact dopaminergic innervation. Brain Research. 1993, 607(1-
2):270-4.  
154. Shiroyama K, Moriwaki K and Yuge O.: The direct effect of dopamine on glucose release from 
primary cultured rat hepatocytes. In Vivo. 1998, 12(5):527-9.  
155. Collaku A, Rankinen T, Rice T, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C.: A 
genome-wide  linkage  scan  for  dietary  energy  and  nutrient  intakes:  the  health,  risk  factors. 
Exercise  training,  and  genetics  (HERITAGE)  family  study.  American  Journal  of  Clinical 
Nutrition. 2004, 79:881-886.      
156. Balcioglu  A.  and Wurtman RJ.: Sibutramine, serotonin  uptake inhibitor, increases  dopamine 
concentrations in rat striatal and hypothalamic extracellular fluid. Neuropharmacology. 2000, 
39(12) 2352-9.  
157.  Schaechter  JD,  Wurtman  RJ.:  Serotonin  release  varies  with  brain  tryptophan  levels.  Brain 
Research. 1990, 532(1-2):203-10. 
158. Cooper JR, Bloom FR, Roth RH.: The Biochemical Basis of Neuropharmacology. New York: 
Oxford University Press. 1996, pp 226-409. 
159. Milner  JD,  Irie  K  and  Wurtman  RJ.:  Effect  of  phenylalanine  on  the  release  of  endogenous 
dopamine from rat striatal slices. Journal of Neurochemistry. 1986, 47:1444-1448.  
160.  Downs BW, Chen AL, Chen TJ, Waite RL, Braverman ER, Kerner M, Braverman D, Rhoades 
P, Prihoda TJ, Palomo T, Oscar-Berman M, Reinking J, Blum SH, DiNubile NA, Liu HH, Blum 
K.:    Nutrigenomic  targeting  of  carbohydrate  craving  behavior:  can  we  manage  obesity  and 
aberrant  craving  behaviors  with  neurochemical  pathway  manipulation  by  Immunological 
Compatible Substances  (nutrients) using a Genetic Positioning System (GPS) Map? Medical 
Hypotheses. 2009, 73(3):427-34. 
161. Dziedzicka  –  Wasylewska  M,  Willner  P,  Papp  M.:  Changes  in  dopamine  receptor  mRNA 
expression following chronic and mild stress and chronic anti-depressant treatment. Behavioral 
Pharmacology. 1997,   8(6-7):607-18.   
162. Harris  GC,  and  Aston-Jones  G.:  Involvement  of  D2  dopamine  receptors  in  the  nucleus 
accumbens in the opiate withdrawal syndrome. Nature. 1994, 371: 155-157.  
163. Filtz TM, Artymyshyn RP, Guan W, Molinoff PB.: Paradoxical regulation of dopamine receptors 
in transfected HEK-293 cells. Journal of Molecular Pharmacology. 1993, 44:371-379. 
164. Filtz TM, Guan W, Artymyshyn RP, Pacheco M, Ford C, Molinoff  PB.: Mechanisms of up-
regulation  of  D2L  dopamine  receptors  by  agonists  antagonists  in  transfected  HEK-293  cells. 
Journal  of  the  American  Society  for  Pharmacology  and  Experimental  Therapeutics.  1994. 
271:1574-1582. 
165. Chen TJH, Blum K, Kaats, G , Braverman ER: Chromium Picolinate: a putative anti-obesity 
nutrient  induces  changes  inRu  body  composition  as  a  function  of  the  Taq  1  dopamine  D2 
receptor polymorphisms in a randomized double-blind placebo controlled study. Gene Therapy 
and Molecular Biology. 2007, 11: 161-170. Functional Foods in Health and Disease: 9:310-378                                                                         Page 371 of 378 
 
 
166.  Blum K, Chen ALC, and Che, TJH.: Putative targeting of dopamine D2 receptor function in 
reward deficiency syndrome (RDS) by Synaptamine Complex Variant (KB220): Clinical trial 
showing anti-anxiety effects. Gene Therapy & Molecular Biology. 2009, 13: 214-30.  
167. Fischer E, Heller B, Nachon M, Spatz H.: Therapy of depression by phenylalanine. Preliminary 
note. Arzneimittelforschung. 1975, 25(1):132. 
168. Royal Pharmaceutical Society. Oxedrine. In: Martindale. The Extra Pharmacopia. London: 1996, 
P 1584. 
169. Wagner H, Norr H, Winterhoff H.: Plant Adaptogens. Phytomedicine. 1994, 1: 63-76. 
170. Staneheva SL, and Mosharrof A.: Effect of the extract of Rhodiola rosea on the content of the 
brain biogenic monoamines. Comptes Rendus de l’ academie Bulgare des Sciences: 1987, 40: 
85-87.  
171. Germano C and Ramazanov Z.: Artic Root (Rhodiola rosea). New York: Kensington publishing 
Corp. 1999, pp 45-46.   
172. Blum K. Allison D, Trachtenberg MC, Williams RW, Loeblich LA.: Reduction of both drug 
hunger and withdrawal against advice rate of cocaine abusers in a 30-day inpatient treatment 
program by the neuronutrient Tropamine. Current Therapeutic Research. 1988, 43: 1204-1214.  
173.  Blum K, Noble EP, Sheridan PJ, Finley O, Montgomery A, Ritchie T, Ozkaragoz T, Fitch RJ, 
Sadlack F, Sheffield D, et al.: Association of the A1 allele of the D2 dopamine receptor gene 
with severe alcoholism. Alcohol. 1991, 8(5):409-16. 
174.  Kotler M, Cohen H, Segman R, Gritsenko I, Nemanov L, Lerer B, Kramer I, Zer-Zion M, Kletz 
I, Ebstein RP.: Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-
dependent subjects. Molecular Psychiatry. 1997, 2(3):251-4. 
175. Lee AM, Knoll JL, Suppes T.: The atyptical anti-psychotic sertindole: a case series. Journal Of 
Clinical Psychiatry. 1997, 58 (9): 410-6. 
176.  Duaux E, Gorwood P, Griffon N, Bourdel MC, Sautel F, Sokoloff  P, Schwartz JC, Ades J, Lôo 
H,  Poirier  MF.:  Homozygosity  at  the  dopamine  D3  receptor  gene  is  associated  with  opiate 
dependence. Molecular Psychiatry. 1998, 3(4):333-6. 
177. Xu K, Lichtermann D, Lipsky RH, Franke P, Liu X, Hu Y, Cao L, Schwab SG, Wildenauer DB, 
Bau CH, Ferro E, Astor W, Finch T, Terry J, Taubman J, Maier W, Goldman D.: Association of 
specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 
distinct populations. Archives of General Psychiatry. 2004. 61(6):597-606. 
178. Ross, Julia. The Diet Cure. USA: Viking Press, 1999. Print. 
179. Ross, J. Amino –acid precursor and enkephalinase inhibition therapy: evidence for effectiveness 
in  treatment  of  “Reward  Deficiency  Syndrome  (RDS)”,  with  particular  emphasis  on  eating 
disorders. Molecular Psychiatry.  2001, 6:(supple) S7. 
180.  Chen TJ, Blum K, Waite RL, Meshkin B, Schoolfield J, Downs BW, Braverman EE, Arcuri V, 
Varshavskiy  M,  Blum  SH,  Mengucci  J,  Reuben  C,  Palomo  T.  Gene  \Narcotic  Attenuation 
Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome. 
Adv Ther. 2007, 24(2):402-14. 
181. Bagchi, S.P. and Smith, T.M.: Synaptosomal dopamine from phenylalanine in brain: effects of 
some dopaminergic agents. Research Communications in Chemical Pathology & Pharmacology. 
1979, 26 (3): 447-58. Functional Foods in Health and Disease: 9:310-378                                                                         Page 372 of 378 
 
 
182. Gartside SE, Cowan PJ, Sharp T.: Effect of 5-hydroxy –l-tryptophan on the release of 5-HT in 
rat hypothalamus in vivo as measured by microdialysis. Neuropharmacology. 1992, 31(1): 9-14.   
183. Kaats GR, Wise JA, Blum K, Morin RA, Adelman JD, Craig J, Croft, HA.: The short-term 
therapeutic efficacy of treating obesity with a plan of improved nutrition and moderate caloric 
restriction. Current Therapeutic Research. 1992, 51:261-274, 9.  
184. Blum  K,  Chen  TJ,  Meshkin  B,  Waite  RL,  Downs  BW,  Blum  SH,  Mengucci  JF,  Arcuri  V, 
Braverman ER, Palomo T.: Manipulation of catechol-O-methyl-transferase (COMT) activity to 
influence  the  attenuation  of  substance  seeking  behavior,  a  subtype  of  Reward  Deficiency 
Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. Medical Hypotheses. 
2007, 69(5):1054-60.  
185.  Cifani  C,  Micioni  Di  B  MV,  Vitale  G,  Ruggieri  V,  Ciccocioppo  R,  Massi  M.:  Effect  of 
salidroside, active principle of Rhodiola rosea extract, on binge eating. Physiology & Behavior. 
2010, 101(5):555-62.  
186.  Maslova  LV,  Kondrat'ev  BIu,  Maslov  LN,  Lishmanov  IuB.:  The  cardioprotective  and 
antiadrenergic activity of an extract  of Rhodiola rosea in  stress. Eksp Klin  Farmakol. 1994, 
57(6):61-3.  
187.  Mattioli L, Funari C, Perfumi M.: Effects of Rhodiola rosea L. extract on behavioural and 
physiological  alterations  induced  by  chronic  mild  stress  in  female  rats.  Journal  of 
Psychopharmacology. 2009, 23(2):130-42 
188.  Perfumi M, Mattioli L.: Adaptogenic and central nervous system effects of single doses of 3% 
rosavin and 1% salidroside Rhodiola rosea L. extract in mice. Phytotherapy Research. 2007, 
21(1):37-43. 
189.  Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A.: Herbal medicine for depression, 
anxiety and insomnia: A review of psychopharmacology and clinical evidence. European Journal 
of Neuropsychopharmacology. 2011 May 20. (in press) 
190.  Hung SK, Perry R, Ernst E.: The effectiveness and efficacy of Rhodiola rosea L.: a systematic 
review of randomized clinical trials. Phytomedicine. 2011, 18(4):235-44. 
191.  Dwyer AV, Whitten DL, Hawrelak JA.: Herbal medicines, other than St. John's Wort, in the 
treatment of depression: a systematic review. Alternative Medicine Review. 2011, 16(1):40-9. 
192.  Azizov AP, Seĭfulla RD. The effect of elton, leveton, fitoton and adapton on the work capacity 
of experimental animals. Eksp Klin Farmakol. 1998, 61(3):61-3.  
193.  Preuss HG, Bagchi D, Bagchi M, Rao CV, Dey DK, Satyanarayana S.: Effects of a natural 
extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound 
chromium and Gymnema sylvestre extract on weight loss. Diabetes, Obesity, and Metabolism 
2004, 6(3):171-80. 
194. Davy BM and Melby CL.: The effect of fiber-rich carbohydrates on features of Syndrome X. 
Journal of the American Dietetic Association. 2003, 103: 86-96.   
195.  Leeds AT.: Glycemic index and heart disease.  American Journal of Clinical Nutrition. 2002, 
76: 286S-289S. 
196.  McCullough  ML,  Feskanich  D,  Rimm  EB,  Giovannucci  EL,  Ascherio  A,  Variyam  JN, 
Spiegelman D, Stampfer MJ, Willett WC.: Adherence to the Dietary Guidelines for Americans Functional Foods in Health and Disease: 9:310-378                                                                         Page 373 of 378 
 
 
and risk of major chronic disease in men. American Journal of Clinical Nutrition. 2000, 72:1223-
12231. 
197.  Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R, Papadopoulos 
NM, Chrousos GP.: Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared 
features with metabolic syndrome X and NIDDM. Endocrine Journal. 1996, 43:645-655. 
198.  Hansen AK, Escobar LK, Gilbert LE, Jansen RK.: Paternal, maternal, and biparental inheritance 
of the chloroplast genome in Passiflora (Passifloraceae): implications for phylogenetic studies. 
American Journal of Botany. 2007, 94(1):42-6. 
199. Dhawan K, Kumar S, Sharma A.: Suppression of alcohol –cessation –oriented hyper-anxiety by 
the  benzoflavone  moiety  of  Passiflora  incarnata  Linneaus  in  mice.    Journal  of 
Ethnopharmacology. 2002, 81: 239-244. 
200. Dhawan K, Dhawan S, Chhabra S.: Attenuation of benzoduazepine dependence in mice by a tri- 
substituted  benzoflavone  moiety  of  Passflora  incarnata  Linneaus:  A  non-habit  forming 
anxiolytic.  Journal of Pharmacy and Pharmaceutical Science. 2003, 6:215-222.  
201. Dhawan  K,  Kumar  S,  Sharma  A.:  Comparative  Anxiolytic  activity  profile  of  various 
preparations of Passiflora incarnate Linneaus: A comment on medicinal plants Standardization. 
The Journal of Alternative and Complementary Medicine. 2002, 8:283-291. 
202. Akhondzadeh  S,  Naghavi  HR,  Vazirian  M,  Shayeganpour  A,  Rashidi  H,  Khani  M.: 
Passionflower  in  the  treatment  of  generalized  anxiety:  A  pilot  double  –blind  randomized 
controlled reial with oxazepam. Journal of Clinical Pharmacy & Therapeutics. 2001, 26:363-367.  
203. Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M.: Passionflower in 
the  treatment  of  opiate  withdrawal:  a  double  –blind  randomized  controlled  trial.  Journal  of 
Clinical Pharmacy & Therapeutics. 2001, 26:369-373.   
204.  Krenn L.: Passion Flower (Passflora incarnata L.) – a reliable herbal sedative. Wiener Medozin. 
Woshenschrift. 2002, 152:404-406.   
205. Dhawan  K,  Kumar  S,  Sharma  A.:  Anxuilytic  activity  of  aerial  and  underground  parts  of 
Passflora incarnata.  Fitoterapia. 2001, 72: 922-926.  
206.  Geller, I. and Blum, K.: The effects of 5-HTP on para-chlorphenylalanine (p-CPA) attenuation 
of "conflict" behavior.   European Journal of Pharmacology. 1970, 9(3):319-24.  
207.  Srivastava  LM.:  Flow  of  couple  stress  fluid  through  stenotic  blood  vessels.  Journal  of 
Biomechanics. 1985, 18(7):479-85. 
208.  Nirmala  C,  Puvanakrishnan  R.:  Effect  of  curcumin  on  certain  lysosomal  hydrolases  in 
isoproterenol-induced myocardial infarction in rats. Biochemical Pharmacology. 1996, 51(1):47-
51. 
209.  Funk JL, Frye JB, Oyarzo JN, Kuscuoglu N, Wilson J, McCaffrey G, Stafford G, Chen G, Lantz 
RC, Jolad SD, Sólyom AM, Kiela PR, Timmermann BN.: Efficacy and mechanism of action of 
turmeric supplements in the treatment of experimental arthritis. Arthritis and Rheumatism. 2006. 
54(11):3452-64. 
210.  Deodhar SD, Sethi R, Srimal RC.: Preliminary study on antirheumatic activity of curcumin 
(diferuloyl methane). Indian Journal of Medical Research. 1980, 71:632-4.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 374 of 378 
 
 
211.  Holt HB, Wild SH, Wood PJ, Zhang J, Darekar AA, Dewbury K, Poole RB, Holt RI, Phillips 
DI,  Byrne  CD.:  Non-esterified  fatty  acid  concentrations  are  independently  associated  with 
hepatic steatosis in obese subjects. Diabetologia. 2006, 49(1):141-8.  
212.  Arun N, Nalini N.: Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino 
rats. Plant Foods for Human Nutrition. 2002, 57(1):41-52. 
213.  Aggarwal BB, Kumar A, Bharti AC.: Anticancer potential of curcumin: preclinical and clinical 
studies. Anticancer Research. 2003, 23(1A):363-98.  
214.  Aggarwal  BB.:  Prostate  cancer  and  curcumin:  add  spice  to  your  life.  Cancer  Biology  and 
Therapy. 2008. 7(9):1436-40.  
215.  Hsu CH, Cheng AL.:Clinical studies with curcumin. Advances in Experimental Medicine and 
Biology. 2007, 595:471-80.  
216.  Surh CD, Sprent J.: Regulation of mature T cell homeostasis. Seminars in Immunology. 2005, 
17(3):183-91. 
217.  Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, 
Glabe CG, Frautschy SA, Cole GM.: Curcumin inhibits formation of amyloid beta oligomers and 
fibrils,  binds  plaques,  and  reduces  amyloid  in  vivo.  Journal  of  Biological  Chemistry.  2005, 
280(7):5892-901.  
218.  El-Moselhy MA, Taye A, Sharkawi SS, El-Sisi SF, Ahmed AF.: The antihyperglycemic effect 
of curcumin in high fat diet fed rats. Role of TNF-α and free fatty acids. Food and Chemical 
Toxicology. 2011, 49(5):1129-40.  
219.  Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, 
Douste-Blazy P,  Luc G.:  A case-control  study  of lipoprotein particles  in  two populations  at 
contrasting risk for coronary heart disease. The ECTIM Study. Arteriosclerosisand Thrombosis 
1992. 12(6):701-7. 
220.  Boban  PT,  Nambisan  B,  Sudhakaran  PR.:  Hypolipidaemic  effect  of  chemically  different 
mucilages in rats: a comparative study. British Journal of Nutrition. 2006, 96(6):1021-9. 
221.  Izzat NN, Deshazer ME, Loose-Mitchell DS.: New molecular targets for cholesterol-lowering 
therapy. Journal of Pharmacology and Experimental Therapy. 2000, 293(2):315-20. 
222.  Brown  MS,  Goldstein  JL.:  Lipoprotein  receptors:  therapeutic  implications.  Journal  of 
Hypertension. Supplement 1990, 8(1):S33-5; discussion S35-6. 
223.  Yang Y, Ju D, Zhang M, Yang G.: Interleukin-6 stimulates lipolysis in porcine adipocytes. 
Endocrine. 2008. 33(3):261-9. 
224.  Rizzo  G,  Disante  M,  Mencarelli  A,  Renga  B,  Gioiello  A,  Pellicciari  R,  Fiorucci  S.:  The 
farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in 
vivo. Molecular Pharmacology. 2006, 70(4):1164-73.  
225.  Shishodia S, Harikumar KB, Dass S, Ramawat KG, Aggarwal BB.:  The guggul for chronic 
diseases: ancient medicine, modern targets. Anticancer Research. 2008, 28(6A):3647-64.  
226.  Gruzman A, Babai G, Sasson S.: Adenosine Monophosphate-Activated Protein Kinase (AMPK) 
as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical 
Considerations. Review of Diabetic Studies 2009, 6(1):13-36.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 375 of 378 
 
 
227.  Zhang CM, Qiu J, Chen XH, Wang B, Zhang M, Guo XR.: Effects of NYGGF4 gene over-
expression on the insulin sensitivity and secretory function of adipocytes. Zhongguo Dang Dai 
Er Ke Za Zhi. 2009, 11(10):846-9.  
228.  Claudel T, Staels B, Kuipers F.: The Farnesoid X receptor: a molecular link between bile acid 
and lipid and glucose metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005, 
25(10):2020-30.  
229.  Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris 
TP.: Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005, 
146(3):984-91. 
230.  Lage R, Diéguez C, Vidal-Puig A, López M.: AMPK: a metabolic gauge regulating whole-body 
energy homeostasis. Trends in Molecular Medicine. 2008, 14(12):539-49.  
231.   Long YC, Zierath JR.: AMP-activated protein kinase signaling in metabolic regulation. Journal 
of Clinical Investigation. 2006, 116(7):1776-83. 
232.  Cantó C, Pich S, Paz JC, Sanches R, Martínez V, Orpinell M, Palacín M, Zorzano A, Gumà A.: 
Neuregulins increase mitochondrial oxidative capacity and insulin sensitivity in skeletal muscle 
cells. Diabetes. 2007, 56(9):2185-93.  
233.  Steinberg  GR,  Kemp  BE.:  AMPK  in  Health  and  Disease.  Physiological  Reviews.  2009,  
89(3):1025-78.  
234.  Hardie DG, Sakamoto K.: AMPK: a key sensor of fuel and energy status in skeletal muscle. 
Physiology (Bethesda). 2006, 21:48-60.  
235.  Fogarty  S,  Hardie  DG.:  Development  of  protein  kinase  activators:  AMPK  as  a  target  in 
metabolic disorders and cancer. Biochimicaet Biophysica Acta. 2010, 1804(3):581-91.  
236.  Lim JG, Lee JJ, Park SH, Park JH, Kim SJ, Cho HC, Baek WK, Kim DK, Song DK.: Glucagon-
like  peptide-1  protects  NSC-34  motor  neurons  against  glucosamine  through  Epac-mediated 
glucose uptake enhancement. Neuroscience Letters. 2010, 479(1):13-7.  
237.  Lele RD.: Pro-insulin, C peptide, glucagon, adiponectin, TNF alpha, AMPK: neglected players 
in type 2 diabetes mellitus. Journal of the Association of Physicians of India. 2010, 58:30,35-40. 
238.  Lin SJ, Guarente L.: Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, 
longevity and disease. Current Opinion in Cell Biology. 2003, 15(2):241-6.  
239.  Wu A, Ying Z, Gomez-Pinilla F.: Oxidative stress modulates Sir2alpha in rat hippocampus and 
cerebral cortex. European Journal of Neuroscience. 2006, 23(10):2573-80. 
240.  Egawa M, Kamata H, Kushiyama A, Sakoda H, Fujishiro M, Horike N, Yoneda M, Nakatsu Y, 
Ying G, Jun Z, Tsuchiya Y, Takata K, Kurihara H, Asano T.: Long-term forskolin stimulation 
induces AMPK activation and thereby enhances tight junction formation in human placental 
trophoblast BeWo cells. Placenta. 2008, 29(12):1003-8.  
241.  Pugazhenthi  S,  Akhov L,  Selvaraj  G,  Wang  M,  Alam  J.:  Regulation  of  heme  oxygenase-1 
expression by demethoxy curcuminoids through Nrf2 by a PI3-kinase/Akt-mediated pathway in 
mouse  beta-cells.American  Journal  of  Physiology,  Endocrinology,  and  Metabolism.  2007, 
293(3):E645-55.  
242. Badmaev,  V.  and  Majeed,  M.:  Open  Field,  Physician  Controlled,  Clinical  Evaluation  of 
Botanical  Weight  Loss  Formula  Citrin.  [Abstract]  Nutriceuticals,  Dietary  Supplements  and 
Functional Foods. 1995, July, Las Vegas, NV. Functional Foods in Health and Disease: 9:310-378                                                                         Page 376 of 378 
 
 
243.  Shen  HQ,  Roth  MD,  Peterson  RG.:  The  effect  of  glucose  and  glucagon-like  peptide-1 
stimulation  on  insulin  release  in  the  perfused  pancreas  in  a  non-insulin-dependent  diabetes 
mellitus animal model. Metabolism. 1998, 47(9):1042-7. 
244.  Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, 
Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti 
A, Frega GN, Benedetti A, Gastaldelli A.: Glucagon-like peptide-1 receptor activation stimulates 
hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in 
nonalcoholic  steatohepatitis.  Liver  International.  2011  Feb  15.  Doi:  10.1111/j.1478-
3231.2011.02462.x.  
245.  Nisoli  E,  Clementi  E,  Moncada  S,  Carruba  MO.:  Mitochondrial  biogenesis  as  a  cellular 
signaling  framework.  Biochemical  Pharmacology.  2004,  67(1):1-15.  Review.  Erratum  in: 
Biochem Pharmacol. 2004, 67(4):803.  
246.  Wilson-Fritch L, Burkart A, Bell G, Mendelson K, Leszyk J, Nicoloro S, Czech M, Corvera S.: 
Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin 
sensitizer rosiglitazone. Molecular and Cellular Biology. 2003, 23(3):1085-94. 
247.  Kim  JA,  Wei  Y,  Sowers  JR.:  Role  of  mitochondrial  dysfunction  in  insulin  resistance. 
Circulation Research. 2008, 102(4):401-14.  
248.  Hardie DG.: Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular 
energy status. Endocrinology. 2003, 144(12):5179-83.  
249.  Carling D.: The AMP-activated protein kinase cascade--a unifying system for energy control. 
Trends in Biochemical Sciences. 2004, 29(1):18-24.  
250.  Roe  CR,  Mochel  F.;  Anaplerotic  diet  therapy  in  inherited  metabolic  disease:  therapeutic 
potential. Journal of Inherited Metabolic Disease. 2006, 29(2-3):332-40.  
251.  St-Onge  MP,  Bourque  C,  Jones  PJ,  Ross  R,  Parsons  WE.:  Medium-  versus  long-chain 
triglycerides for 27 days increases fat oxidation and  energy expenditure without resulting in 
changes in body composition in overweight women. International Journal of Obesity Relatated 
Metabolic Disorders. 2003, 27(1):95-102. 
252.  St-Onge  MP,  Ross  R,  Parsons  WD,  Jones  PJ.:  Medium-chain  triglycerides  increase  energy 
expenditure and decrease adiposity in overweight men. Obesity Research. 2003, 11(3):395-402. 
253.  St-Onge MP, Jones PJ.: Physiological effects of medium-chain triglycerides: potential agents in 
the prevention of obesity. Journal of Nutrition. 2002, 132(3):329-32.  
254.  Austin MA, Edwards KL, McNeely MJ, Chandler WL, Leonetti DL, Talmud PJ, Humphries 
SE, Fujimoto WY.: Heritability of multivariate factors of the metabolic syndrome in nondiabetic 
Japanese americans. Diabetes. 2004, 53(4):1166-9. 
255.  Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, Vincent J, Harwood HJ 
Jr.:  CP-346086:  an  MTP  inhibitor  that  lowers  plasma  cholesterol  and  triglycerides  in 
experimental animals and in humans. Journal of Lipid Research. 2003, 44(10):1887-901.  
256.  Mehra R, Raman R, Bayless ML, Sivitz WI.: Antecedent caloric intake and glucose excursion 
following a subsequent meal in Type 1 diabetes. Journal of Diabetes. 2009, 1(4):273-7. 
257.  Cernkovich ER, Deng J, Bond MC, Combs TP, Harp JB.: Adipose-specific disruption of signal 
transducer and activator of transcription 3 increases body weight and adiposity. Endocrinology. 
2008, 149(4):1581-90.  Functional Foods in Health and Disease: 9:310-378                                                                         Page 377 of 378 
 
 
258.  Rondanelli M, Opizzi A, Solerte SB, Trotti R, Klersy C, Cazzola R.: Administration of a dietary 
supplement  (N-oleyl-phosphatidylethanolamine  and  epigallocatechin-3-gallate  formula) 
enhances compliance with diet in healthy overweight subjects: a randomized controlled trial. 
British Journal of Nutrition. 2009, 101(3):457-64.  
259.  Parnetti  L,  Senin  U,  Carosi  M,  Baasch  H.:  Mental  deterioration  in  old  age:  results  of  two 
multicenter, clinical trials with nimodipine. The Nimodipine Study Group. Clinical Therapeutics. 
1993. 15(2):394-406. 
260.  Ceda GP, Ceresini G, Denti L, Marzani G, Piovani E, Banchini A, Tarditi E, Valenti G.: Alpha-
Glycerylphosphorylcholine administration increases the GH responses to GHRH of young and 
elderly subjects. Hormone and Metabolic Research. 1992, 24(3):119-21. 
261.  Miller DK, Bowirrat A, Manka M, Miller M, Stokes S, Manka D, Allen C, Gant C, Downs BW, 
Smolen A, Stevens E, Yeldandi S, Blum K.: Acute intravenous synaptamine complex variant 
KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from 
alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis 
for reward polymorphisms: part 1, pilot study with 2 case reports. Postgraduate Medicine. 2010,  
122(6):188-213. 
262.  Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, 
Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, 
Oscar-Berman M.: Activation instead of blocking mesolimbic dopaminergic reward circuitry is a 
preferred  modality  in  the  long  term  treatment  of  reward  deficiency  syndrome  (RDS):  a 
commentary. Theoretical Biology & Medical Modeling. 2008, 12; 5:24. 
263.  . Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, van 
den Brink W.: Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients 
using genetic indicators. Addiction Biology. 2009, 14(3):328-37. 
264.  Dackis CA, Gold MS.: New concepts in cocaine addiction: the dopamine depletion hypothesis. 
Neuroscience and Biobehavioral Reviews 1985, 9(3):469-77.  
265.  Bowirrat  A,  Oscar-Berman  M.:  Relationship  between  dopaminergic  neurotransmission, 
alcoholism, and Reward Deficiency syndrome. American Journal of Medical Genetics, Part B, 
Neuropsychiatric Genetics.  2005. 132B (1):29-37. 
266.  Blum K, Liu Y, Shriner R, Gold MS.:  Reward circuitry dopaminergic activation regulates food 
and drug craving behavior. Curr Pharm Des. 2011, 17(12):1158-67. 
267.  Blum K, Chen AL, Chen TJ, Rhoades P, Prihoda TJ, Downs BW, Waite RL, Williams L, 
Braverman ER, Braverman D, Arcuri V, Kerner M, Blum SH, Palomo T.: LG839: anti-obesity 
effects  and  polymorphic  gene  correlates  of  reward  deficiency  syndrome.  Adv  Ther.  2008, 
25(9):894-913. 
268.  Blum K, Chen TJH, Williams L, Chen ALCH, Downs BW, Waite RL, Huntington T, Sims S, 
Prioda T, Rhodes P, Reinking J, Braverman D, Kerner M, Blum SH, Quirk B, Braverman ER.: A 
short  term  pilot  open  label  study  to  evaluateefficacy  and  safety  of  LG839,  a  customized 
DNAdirected  nutraceutical  in  obesity:  Exploring  Nutrigenomics.  Gene  Ther  Mol  Biol  2008, 
12:371-382. 
269.  Blum K, Chen ALC, Chen TJH, Rhoades P, Prihoda TJ, Downs, BW, Bagchi, Bagchi M, Blum 
SH,  Williams  L,  Braverman,  ER,  Kerner  M,  Waite  RL,  Quirk  B,  White  L.:  Dopamine  D2 Functional Foods in Health and Disease: 9:310-378                                                                         Page 378 of 378 
 
 
Receptor Taq A1 allele predicts treatmentcompliance of LG839 in a subset analysis of a pilot 
study inthe Netherlands. Gene Ther Mol Biol.  2008, 12: 129-140. 
270.  Rivier  C,  Rivier  J,  Vale  W.:  Stress-induced  inhibition  of  reproductive  functions:  role  of 
endogenous corticotropin-releasing factor.  Science 1986 231(4738):607-9. 
271.  Ottosson M, Lönnroth P, Björntorp P, Edén S.: Effects of cortisol and growth hormone on 
lipolysis in human  adipose tissue. Journal of Clinical Endocrinololgy and Metabolism  2000. 
85(2):799-803. 
272. Large V, Hellström L, Reynisdottir S, Lönnqvist F, Eriksson P, Lannfelt L, Arner P.: Human 
Beta 2  adrenoreceptor gene poymorphisms are highly frequent in obesity and associate with 
altered Beta -2 adrenoreceptor function.  Journal of Clinical Investigation 1993, 100: 1057-1091.     
273. Clément K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, Silver KD, Shuldiner 
AR, Froguel P, Strosberg AD.: Genetic variation in the Beta 3 –adrenoreceptor and an increased 
capacity to gain weight in patients with morbid obesity. New England Journal of Medicine 1995, 
333: 352-354.    
274.  Dahlman I, Arner P.: Obesity and polymorphisms in genes regulating human adipose tissue. Int 
J Obes (Lond). 2007, 31(11):1629-41. 
275.  Chen, TJH, Blum K, Chen,LCH, Bowirrat A, Downs BW, Madigan MA, Waite RL, Bailey JA, 
Kerner  M,  Yelandi  S,  Giordano  J,  Morse  S, Miller  D,  Braverman  ER.  :  Neurogenetics  and 
clinical  evidence  for  the  putative  activation  of  the  brain  reward  circuitry  by  amino-acid 
precursor-catabolic  enzyme  inhibition  therapeutic  agent  (a  Neuroadaptagen):  Proposing  an 
addiction candidate gene panel map. Journal of Psychoactive Drugs 2011, 42(2):108-127. 
276.  Blum K (with James Payne).: Alcohol and the Addcitive Brain. Simon –Schuster; (The Free 
Press) New York, 1991.  
 
 
 